US20050256525A1 - Dilation introducer for orthopedic surgery - Google Patents
Dilation introducer for orthopedic surgery Download PDFInfo
- Publication number
- US20050256525A1 US20050256525A1 US11/038,784 US3878405A US2005256525A1 US 20050256525 A1 US20050256525 A1 US 20050256525A1 US 3878405 A US3878405 A US 3878405A US 2005256525 A1 US2005256525 A1 US 2005256525A1
- Authority
- US
- United States
- Prior art keywords
- dilator tube
- dilation introducer
- distal
- proximal
- dilation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
- C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Definitions
- This invention relates to bone fixation devices, and more particularly relates to a dilation introducer for introducing a bone fixation device for orthopedic surgery, such as for vertebral fusion.
- Fusion of two adjacent vertebrae is a common surgical treatment for back injuries due to damage or defects in a spinal disc between two adjacent vertebrae, such as conditions due to a herniated disc or disc degeneration.
- the entire disc may be removed by a discectomy procedure, and may be replaced with bone or a bone substitute and/or cage in order to prevent collapse of the disc space between the adjacent vertebrae.
- Early techniques for stabilizing the adjacent vertebrae included application of a plate or a rod in conjunction with screws across the adjacent vertebrae, after which the adjacent vertebrae would eventually fuse together. However, such techniques commonly required prolonged periods of recovery from the extensive surgery involved, and it would be desirable to provide an improved apparatus and method for providing a minimally invasive procedure that will result in less trauma and improvement in patient recovery.
- Bone fixation devices are known that are useful for connecting two or more bone segments for the healing of broken bones, typically including an elongate pin with a distal anchor and a proximal anchor movable on the pin to accommodate different bone dimensions, and to permit tensioning of the bone segments together.
- the surgical procedure of attaching two or more parts of a bone with a pin-like device commonly requires an initial incision into the tissue down to the bone, and the drilling of a hole through the bone parts to be joined.
- Such bone fixation devices can be useful for fusion of vertebrae together, because such a bone fixation device can be used to join adjacent bone segments through a single percutaneous incision or puncture, without the need to expose any other side of the bone segments to be joined.
- the invention provides for a telescoping dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration for dilating the patient's soft surrounding tissue to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue.
- each individual dilator tube is successively released and advanced to progressively expand the patient's soft tissue down to the tissue to be treated.
- the tissue to be treated is bone tissue which must be prepared prior to attachment of adjacent bone section in a fusion process.
- the invention is particularly applicable to fusion of bones in orthopedic surgery using minimally invasive technique, and will be described herein in particular applications of those procedures.
- the invention also concerns a minimally invasive procedure utilizing the telescoping dilation introducer to insert a bone fixation device into a patient's spine for posterior spine fusion. While posterior spine fusion currently takes up to two hours to complete, and requires a six inch incision, with the apparatus and method of the invention, comparable surgery can be completed in less than thirty minutes, with a dilation port 13 mm or less in diameter, thus lowering the chance of damage to the surrounding soft tissue.
- a telescoping dilation introducer is typically operated by pressing the introducer against a relatively hard surface, such as bone tissue being treated.
- the present invention provides for a guide wire assembly when such a telescoping dilation introducer is to used in treatment of soft tissue, such as an organ, to provide a surface against which the telescoping dilation introducer can be pushed during operation of the telescoping dilation introducer.
- a guide wire or K wire assembly is provided for use with a telescoping dilation introducer according to the invention.
- the guide wire assembly includes an elongated generally cylindrical first section, and an elongated tubular second section that receives the first section.
- the elongated generally cylindrical first section includes a proximal enlarged head or stop portion, and an elongated body portion with a proximal section and a relatively narrower diameter main section connected to the proximal section, and a pointed distal tip at the distal end of the narrow main section.
- the second section of the guide wire assembly includes an elongated tubular body with an internal bore adapted to receive the narrow main section, as is illustrated in FIG. 28 .
- the tubular second section advantageously includes a frustoconical distal tip with a narrowed portion at the distal end and an enlarged flat shoulder at the proximal end of the frustoconical distal tip.
- the assembly When the guide wire assembly is assembled, the assembly presents a pointed distal end with a proximal shoulder against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer.
- the main section thus adds a sharp point to the relatively blunt distal end of the tubular distal section, allowing the guide wire assembly to be inserted through soft tissue for placement in a soft tissue target of interest, such as an organ, and the first section can then be removed to allow a telescoping dilation introducer to be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer.
- the first section can be removed from the second section, leaving the blunt distal end in place at the desired location in the soft tissue, and the telescoping dilation introducer can be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer.
- the present invention provides for an improvement in a dilation introducer for orthopedic surgery, in which the dilation introducer includes one or more dilator tubes having a distal end and a proximal end, and the distal end of the one or more dilator tubes including a plurality of spikes for engaging bone tissue.
- the spikes may be formed of radiopaque material, for fluoroscopic imaging of the positioning of the one or more dilator tubes, and the spikes may be formed with a rounded shape so as to deflect soft tissue.
- the dilation introducer includes a parallel guide insert adapted to be received in the one or more dilator tubes.
- the parallel guide insert includes a main cylindrical shaft having a proximal end connected to a cylindrical head, and a plurality of longitudinal bores extending the length of the parallel guide insert through the main cylindrical shaft and cylindrical head.
- the distal tip of the parallel guide insert may be provided with a plurality of spikes for engaging bone tissue.
- the spikes of the parallel guide insert may be formed of radiopaque material, and may be formed with a rounded shape so as to deflect soft tissue.
- the present invention concerns a dilation introducer for orthopedic surgery having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue to be treated.
- the dilation introducer includes a first dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and a second dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and an inner lumen with a distal opening and a proximal opening.
- the first dilator tube is removably received in the second dilator tube for slidable telescoping movement within the second dilator tube.
- Means are provided for removably connecting the first and second dilator tubes together in a locked configuration.
- the means for removably connecting the first and second dilator tubes includes a first latching member disposed in the cylindrical head of the first dilator tube.
- the first latching member has a locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the first dilator tube toward the distal end of the first dilator tube, with the locking button extending transversely from the shaft through a side aperture in the cylindrical head of the first dilator tube.
- the locking button is biased outwardly from the cylindrical head, such as by a spring, and the first latching member is received in an upper aperture of the cylindrical head of an adjacent second dilator tube.
- the upper aperture of the cylindrical head of the second dilator tube includes a latching chamber for retaining the latching end of the latching member when the locking button is biased outwardly, to lock the cylindrical heads of the first and second dilator tubes together.
- the locking button is moveable inwardly to move the latching member inwardly and to move the latching end of the latching member inwardly out of the latching chamber, to unlock the first and second dilator tubes.
- the dilation introducer may include one or more additional dilator tubes, with the second dilator tube being removably received in the one or more additional dilator tubes for slidable telescoping movement within the one or more additional dilator tubes.
- the one or more additional dilator tubes likewise have a distal end and a proximal end with a cylindrical head, an inner lumen with a distal opening and a proximal opening, and the distal end having a tapered tip.
- the second dilator tube and the one or more additional dilator tubes having an unlocked configuration in which the one or more additional dilator tubes may slidably telescope over the second dilator tube to dilate the patient's soft tissue at the distal end of the dilation introducer.
- Means are provided for removably connecting the second dilator tube and the one or more additional dilator tubes together in a locked configuration.
- the means for removably connecting the second dilator tube and the one or more additional dilator tubes include a second latching member disposed in the cylindrical head of the second dilator tube.
- the second latching member has a locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the second dilator tube toward the distal end of the second dilator tube, and the locking button extends transversely from the shaft through a side aperture in the cylindrical head of the second dilator tube.
- the locking button is biased outwardly from the cylindrical head, such as by a spring, and the second latching member is received in an upper aperture of the cylindrical head of the additional dilator tube to be connected.
- the upper aperture of the cylindrical head of the additional dilator tubes include a latching chamber for retaining the latching end of the second latching member when the locking button is biased outwardly, to lock the cylindrical heads of the second and additional dilator tube together, and the locking button is moveable inwardly to move the second latching member inwardly and the latching end of the second latching member inwardly out of the latching chamber.
- the additional dilator tube comprises a handle connected to the proximal end of the additional dilator tube, and the cylindrical head of the additional dilator tube includes a plurality of the upper apertures, each including a latching chamber for receiving the second latching member.
- the present invention provides for an improvement in a dilation introducer for orthopedic surgery, in which the dilation introducer includes a dilator tube having a tubular shaft, a distal end and a proximal end, an inner lumen with a distal opening and a proximal opening, and a light emitter disposed in the dilator tube.
- the light emitter may be a light emitting diode, and the light emitting diode may be embedded in the tubular shaft of the dilator tube.
- the light emitter may include a fiber optic, and the fiber optic may be embedded in the tubular shaft of the dilator tube.
- the dilator tube includes a handle and a switch for controlling the light emitter, and at least one battery is disposed in the handle and is connected to the switch to power the light emitter.
- the light emitter includes one or more fiber optics
- the light emitter includes a light source providing light conducted to the one or more fiber optics.
- the light emitter may include one or more elongated energy conducting members disposed on an outer surface of the tubular shaft of the dilator tube, and the one or more elongated energy conducting members may be disposed in a groove on the exterior surface of the tubular shaft.
- the one or more elongated energy conducting members may be located on the inside of the dilator tube, or may extend through the wall of the dilator tube.
- the present invention also provides for a telescoping expander sleeve adapted to be slidably disposed over a shaft of a dilator tube for dilating a patient's soft tissue down to a bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue.
- the telescoping expander sleeve is moveable between an extended, unexpanded configuration and a collapsed, expanded configuration.
- the telescoping expander sleeve includes a first generally tubular section having a tubular proximal portion and a distal portion.
- the tubular proximal portion has an enlarged proximal head, and the distal portion includes two or more active spreader arms each having a proximal end and a distal tip.
- the tubular proximal portion may optionally be provided with a handle.
- the two or more active spreader arms are connected at their proximal ends to the tubular proximal portion, and the distal tips of the two or more active spreader arms are moveable radially between an unexpanded configuration and an expanded configuration.
- the telescoping expander sleeve also includes a second generally tubular section slidably disposed over the first generally tubular section.
- the second generally tubular section includes a tubular proximal portion and a distal portion including two or more passive spreader flaps each having a narrow proximal end and a wide distal tip.
- the proximal ends of the two or more passive spreader flaps are hingedly connected to the tubular proximal portion, and the distal tips of the two or more passive spreader flaps are moveable radially between an unexpanded configuration and an expanded configuration.
- the two or more active spreader arms slidably engage the two or more passive spreader flaps, so that as the telescoping expander sleeve telescopes from the extended, unexpanded configuration to the collapsed, expanded configuration, the two or more active spreader arms slide from the narrow proximal ends of the two or more passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of the two or more passive spreader flaps apart, and to spread the distal ends of the two or more active spreader arms apart.
- the distal tips of the two or more active spreader arms have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve
- the distal tips of the two or more passive spreader flaps have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve.
- the purpose of the active spreader arms and passive spreader flaps is to facilitate the creating of a larger working area adjacent to bone or bone tissues being treated.
- the spreader arms and flaps may optionally be covered by an expandable material, such as latex, for example, to prevent tissues from being pressed into cavities of the telescoping expander sleeve.
- the present invention is particularly useful for the purposes of orthopedic surgery, those skilled in the art will recognize that the invention can also be used for the treatment of a variety of internal organs or structures when it is desired to minimize the size of an opening in the patient's soft tissue and the resultant damage and trauma to tissue surrounding the operation site.
- FIG. 1 is a plan view of a first embodiment of a dilation introducer in a locked configuration, according to the present invention.
- FIG. 2 is a plan view of the dilation introducer of FIG. 1 shown in an unlocked, collapsed configuration.
- FIG. 3 is a plan view of the first or inner dilator tube of the dilation introducer of FIG. 1 .
- FIG. 4 is a plan view of the second or intermediate dilator tube of the dilation introducer of FIG. 1 .
- FIG. 5 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 1 .
- FIG. 6A is a top plan view of the first locking clip of the dilation introducer of FIG. 1 .
- FIG. 6B is an elevational view of the first locking clip of the dilation introducer of FIG. 1 .
- FIG. 6C is a bottom plan view of the first locking clip of the dilation introducer of FIG. 1 .
- FIG. 7A is a top plan view of the second locking clip of the dilation introducer of FIG. 1 .
- FIG. 7B is an elevational view of the second locking clip of the dilation introducer of FIG. 1 .
- FIG. 8 is a perspective view of a second embodiment of a dilation introducer in a locked configuration, according to the present invention.
- FIG. 9 is a perspective view of the dilation introducer of FIG. 8 shown in an unlocked, collapsed configuration.
- FIG. 10 is a perspective view of the first or inner dilator tube of the dilation introducer of FIG. 8 .
- FIG. 11 is a perspective view of the second or intermediate dilator tube of the dilation introducer of FIG. 8 .
- FIG. 12 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 8 .
- FIG. 13 is a plan view of a third embodiment of a dilation introducer in a locked configuration, according to the present invention.
- FIG. 14 is a plan view of the dilation introducer of FIG. 13 shown in an unlocked, collapsed configuration.
- FIG. 15 is a plan view of the first or inner dilator tube of the dilation introducer of FIG. 13 .
- FIG. 16 is a plan view of the second or intermediate dilator tube of the dilation introducer of FIG. 13 .
- FIG. 17 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 13 .
- FIG. 18 is a plan view of the plastic sleeve of the dilation introducer of FIG. 13 .
- FIG. 19 is a plan view of a fourth embodiment of a dilation introducer in a locked configuration, according to the present invention.
- FIG. 20 is a plan view of the dilation introducer of FIG. 19 shown in an unlocked, collapsed configuration.
- FIG. 21 is a plan view of the first or inner dilator tube of the dilation introducer of FIG. 19 .
- FIG. 22 is a plan view of the second or intermediate dilator tube of the dilation introducer of FIG. 19 .
- FIG. 23 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 19 .
- FIG. 24 is a schematic diagram illustrating location of a starting point for insertion of a bone fixation device according to the method of the invention.
- FIG. 25 is a schematic diagram of a lateral view illustrating location of a trajectory for insertion of a bone fixation device according to the method of the invention.
- FIG. 26 is a schematic diagram of an anterior view illustrating location of a trajectory for insertion of a bone fixation device according to the method of the invention.
- FIG. 27 is a plan view of a guide wire assembly for use with the various embodiments of the telescoping dilation introducer of the invention, shown disassembled.
- FIG. 28 is a plan view of the guide wire assembly of FIG. 27 , shown partially assembled.
- FIG. 29 is a plan view of the guide wire assembly of FIG. 27 , shown fully assembled.
- FIG. 30 is a perspective view of a variation of the outer dilator tube of the embodiment of FIGS. 8-12 , with a parallel guide.
- FIG. 31 is a perspective view of the parallel guide from FIG. 30 .
- FIG. 32 is a perspective view of a variation of the outer dilator tube of the embodiment of FIGS. 8-12 , with an angled tip and with a parallel guide.
- FIG. 33 is a perspective view of the parallel guide with an angled tip from FIG. 32 .
- FIG. 34 is a perspective of another variation of the outer dilator tube of the embodiment of FIGS. 8-12 , with an angled tip and spikes.
- FIG. 35 is a perspective view of the outer dilator tube of FIG. 34 , with a parallel guide with spikes.
- FIG. 36 is a perspective view of a fifth embodiment of a dilation introducer in an unlocked configuration, according to the present invention.
- FIG. 37 is a sectional view of a portion of the dilation introducer of FIG. 36 .
- FIG. 38 is a perspective view of a variation of the dilation introducer of FIG. 36 , shown in a locked configuration, according to the present invention.
- FIG. 39 is a sectional view of a portion of the dilation introducer of FIG. 36 taken along line 39 - 39 of FIG. 38 .
- FIG. 40 is a top perspective view of the head end of the handle of the dilation introducer of FIG. 36 , showing multiple locking locations.
- FIG. 41 is a schematic diagram of a variation of the dilation introducer of FIG. 36 , with a light emitter and switch for the light emitter.
- FIG. 42 is an enlarged view of the tip of the dilation introducer of FIG. 41 .
- FIG. 43 is a perspective view of another variation of the dilation introducer of FIG. 41 , with an exterior groove for one or more elongated energy conducting members.
- FIG. 44 is a side elevational view of a telescoping expander sleeve shown in an extended, unexpanded configuration.
- FIG. 45 is a side elevational view of the telescoping expander sleeve of FIG. 44 shown in an intermediate partially collapsed, partially expanded configuration.
- FIG. 46 is a side elevational view of the telescoping expander sleeve of FIG. 44 shown in a fully collapsed, fully expanded configuration.
- the present invention provides for a telescoping dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue to be treated.
- a dilation introducer 30 according to a first preferred embodiment is shown in a locked assembled configuration in FIG. 1 , and shown in an unlocked, collapsed configuration in FIG. 2 .
- the dilation introducer includes a first or inner dilator tube 32 having a distal end 34 with a tapered tip 36 , and a proximal end 38 with a head 40 including a pair of spaced part rings 42 .
- the first dilator tube has an inner lumen 44 with a distal opening 46 and a proximal opening 48 .
- the dilation introducer also includes a shorter second or intermediate dilator tube 52 having a distal end 54 with a tapered tip 56 , and a proximal end 58 with a head 60 including a pair of spaced apart rings 62 .
- the second dilator tube has an inner lumen 64 with a distal opening 66 and a proximal opening 68 .
- the dilation introducer also includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 72 having a distal end 74 with a tapered tip 76 , and a proximal end 78 with a handle 80 .
- the third dilator tube has an inner lumen 82 with a distal opening 84 and a proximal opening 86 .
- the means for removably connecting the first and second dilator tubes together in a locked configuration includes a first locking clip 88 .
- a means for removably connecting the second and third dilator tubes together in a locked configuration may also be provided, and may include a second locking clip 90 .
- the first locking clip includes a first portion 92 and a second portion 94 , and a cross-piece or handle 96 having a first end 98 and a second end 100 connected at right angles between the first and second portions.
- the first portion includes pair of resilient arms 102 each having a proximal narrow neck portion 104 connected to the cross-piece, and a distal gripping portion 106 extending from the narrow neck portion.
- the resilient arms have an inner rounded surface 108 adapted to snap over the first dilator tube between the spaced apart rings of the first dilator tube.
- the second portion currently preferably includes a single arm 112 having a proximal narrow neck portion 114 , and a distal gripping portion 116 extending from the narrow neck portion.
- the gripping portion has an inner rounded surface 118 adapted to fit over the outer surface of the second dilator tube between the spaced apart rings of the second dilator tube, to connect the first and second dilator tubes. Removing the first locking clip allows the second or intermediate dilator tube to slidably telescope over the first inner dilator tube to dilate tissue at the distal end of the dilation introducer.
- the second locking clip includes a first portion 122 and a second portion 124 , and a cross-piece or handle 126 having a first end 128 and a second end 130 connected between the first portion and the second portion at right angles.
- the first portion includes a pair of resilient arms 132 each having a proximal narrow neck portion 134 connected to the cross-piece, and a distal gripping portion 136 extending from the narrow neck portion.
- the pair of resilient arms have an inner rounded surface 138 adapted to snap over the outer surface of the second dilator tube between the spaced apart rings of the second dilator tube.
- the second portion of the second locking clip includes a pair of resilient arms 142 each having a proximal narrow neck portion (not shown) connected to the cross-piece and a distal gripping portion 146 extending from the narrow neck portion, the pair of resilient arms having an inner rounded surface (not shown) adapted to fit over the outer surface of the third dilator tube to connect the second and third dilator tubes. Removing the second locking clip allows the third or outer dilator tube to slidably telescope over the second inner dilator tube to further dilate tissue at the distal end of the dilation introducer.
- a tubular bone drill or tap 150 can be inserted through an intermediate or outer dilator tube, and the tubular bone drill or tap can be passed or threaded over a guide wire or K wire 151 to contact the surface of the vertebra or bone to be treated, as will be further described below.
- the inner dilator tube, the tubular bone drill, and the intermediate dilator tube can be withdrawn and removed to leave the outer dilator tube in place to permit further surgical procedures.
- the invention provides for a second presently preferred embodiment of a dilation introducer 160 shown in a locked assembled configuration in FIG. 8 , and shown in an unlocked, collapsed configuration in FIG. 9 .
- the dilation introducer includes a first or inner dilator tube 162 having a distal end 164 with a tapered tip 166 , and a proximal end 168 with a cylindrical head 170 .
- the means for removably connecting the first and second dilator tubes together in a locked configuration includes a latching member 172 , such as a hook, projecting from the cylindrical head toward the distal end, receiving a locking pin 216 , although other latching members, such as a projection with aperture for receiving a locking pin may also be suitable, as will be apparent from the explanation below.
- the first dilator tube has an inner lumen 174 with a distal opening 176 and a proximal opening 178 .
- the dilation introducer includes a shorter second or intermediate dilator tube 182 having a distal end 184 with a tapered tip 186 , and a proximal end 188 having a cylindrical head 190 .
- the means for removably connecting the second and third dilator tubes together in a locked configuration includes a latching member 192 , such as a hook, projecting from the cylindrical head toward the distal end, receiving a locking pin 218 , although other latching members, such as a projection with aperture for receiving a locking pin may also be suitable, as noted above.
- the second dilator tube has an inner lumen 194 with a distal opening 196 , and a proximal opening 198 .
- the cylindrical head includes a first radial aperture 200 for receiving the locking pin 216 , and a second longitudinal aperture 201 for receiving the distally projecting latching member of the cylindrical head of the first or inner dilator tube.
- the dilation introducer includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 202 having a distal end 204 with a tapered tip 206 , and a proximal end 208 to which a handle 210 is connected at its head end 212 .
- the head end of the handle includes a radial aperture 214 for receiving the locking pin 218 , and a longitudinal aperture 215 for receiving the distally projecting latching member of the cylindrical head of the second or intermediate dilator tube.
- the first locking pin 216 is substantially the same as the second locking pin 218 .
- the third dilator tube has an inner lumen 219 with proximal and distal openings.
- a tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above.
- the invention provides for a third presently preferred embodiment of a dilation introducer 220 , shown in a locked assembled configuration in FIG. 13 , and shown in an unlocked, collapsed configuration in FIG. 14 .
- the dilation introducer includes a first or inner dilator tube 222 having a distal end 224 with a tapered, beveled tip 226 , and a proximal end 228 with a cylindrical head 230 .
- the means for removably connecting the first and second dilator tubes together in a locked configuration includes a pair of opposing bayonet pins 232 extending from the proximal end of the first dilator tube.
- the first dilator tube has an inner lumen 234 with a distal opening 236 and a proximal opening 238 .
- the dilation introducer includes a shorter second or intermediate dilator tube 242 having a distal end 244 with a tapered, beveled tip 246 , and a proximal end 248 with a cylindrical head 250 .
- a means for removably connecting the second and third dilator tubes together in a locked configuration includes a pair of opposing bayonet pins 252 .
- the second dilator tube has an inner lumen 254 with a distal opening 256 and a proximal opening 258 , and as part of the means for removably connecting the second and third dilator tubes together, interior opposing bayonet slots 260 for receiving the pair of opposing bayonet pins of the first or inner dilator tube.
- the dilation introducer includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 262 having a distal end 264 with a tapered tip 266 , and a proximal end 268 having a pair of opposing handles 270 .
- the third dilator tube has an inner lumen 271 , with proximal and distal openings.
- a plastic sleeve 272 is slidably disposed over the shaft of the third or outer dilator tube, and the plastic sleeve preferably has a distal tapered, beveled end 274 .
- a proximal sleeve ring 276 may also be slidably disposed over the shaft of the third or outer dilator tube between the plastic sleeve 272 and the opposing handles.
- the tapered tips of the dilator tubes and plastic sleeve are beveled or angled at a common angle with respect to the longitudinal axis of the dilation introducer, so that the beveled edges of the tapered tips of the dilator tubes and plastic sleeve can be aligned together generally parallel to the surface of the soft tissue to be dilated, so that the bore and dilation passage of the dilation introducer may be aligned at a predetermined desired angle with respect to the soft tissue to be dilated and the bone tissue to be treated.
- the third dilator tube includes interior opposing bayonet slots 278 for receiving the pair of opposing bayonet pins of the second or intermediate dilator tube.
- a tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above.
- the invention provides for a fourth embodiment of a dilation introducer 280 shown in a locked assembled configuration in FIG. 19 , and shown in an unlocked, collapsed configuration in FIG. 20 .
- the dilation introducer includes a first or inner dilator tube 282 having a distal end 284 with a tapered tip 286 , and a proximal end 288 having a generally spherical handle or head 290 .
- the proximal end of the first dilator tube near the handle includes a bayonet pin 292 .
- the first dilator tube has an inner lumen 294 with a distal opening 296 , and a proximal opening 298 .
- the dilation introducer includes a shorter second or intermediate dilator tube 302 having a distal end 304 with a tapered tip 306 , and a proximal end 308 having a generally cylindrical head 310 and a pair of opposing handles 312 .
- the second dilator tube has an inner lumen 314 with a distal opening 316 and a proximal opening 318 .
- the proximal end of the second dilator tube includes a bayonet slot 320 formed in the cylindrical head for receiving the bayonet pin of the first or inner dilator tube.
- the dilation introducer includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 322 , currently preferably formed of plastic, having a distal end 324 with a tapered tip 326 , and a proximal end 328 with a generally cylindrical head end or handle 330 .
- the third dilator tube has an inner lumen 332 , with proximal and distal openings.
- a tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above.
- a surgical method for spinal fusion utilizing the dilation introducer apparatus and a bone fixation device such as a bone fixation device available under the trade name BONE-LOK from Triage Medical, Inc. of Irvine, Calif., is described.
- a bone fixation device available under the trade name BONE-LOK from Triage Medical, Inc. of Irvine, Calif.
- Other types of bone screws or fixation devices may also be suitable.
- the method of the invention involves dilating a patient's soft tissue down to bone tissue to be treated in orthopedic surgery, and necessarily entails an incision and fluoroscopy to locate an entry point on the bone tissue to be treated.
- An entry point is located on the bone tissue to be treated, and the tip of a guide wire or K-wire 151 is placed at the entry point on the bone tissue to be treated shown in FIG. 25 , and driven into the soft tissue of the patient to the target point of the inferior articular facet.
- a vertical midline incision to a desired depth, such as approximately 17 mm, is made in the skin and fascia of the patient, using the entry point as the middle of the incision.
- a first dilator tube of the dilation introducer is then passed over the guide wire until the tip of the dilation introducer reaches the target point of the bone.
- the guide wire is then driven into the facet joint and into the pedicle of the patient, with verification of the trajectory and depth by fluoroscopy.
- the second dilator tube of the dilation introducer is then released and passed over the first dilator tube to allow it to progress to the bone, allowing removal of the first dilator tube. This is repeated for the remaining, progressively wider telescoping dilator tubes, to progressively expand the patient's soft tissue down to the entry point on the bone tissue to be treated, and leaving an outer dilator tube port in place.
- a depth gauge is then used to verify that the appropriate depth has been reached.
- a pre-drill is advanced to the desired location, which is then also verified by fluoroscopy.
- a cortex drill is advanced until its positive stop engages, and the distal tip of a tap is driven into the bone until it reaches the appropriate depth, which is then also verified by fluoroscopy.
- the drill can be connected through an AO style quick connect, or a Jacobs chuck, as long as they are fully cannulated, to a ratcheting handle which is also preferably cannulated.
- a bone fixation device is then driven into the bone until it reaches the appropriate depth, which is then also verified by fluoroscopy.
- the bone fixation device is compressed to achieve appropriate stabilization, which is then also verified by fluoroscopy. Once compression of the bone fixation device has been achieved, the pull pin is removed, the guide wire is removed, and the remaining outer dilator tube port is removed, and the incision can be closed normally.
- a guide wire or K wire assembly 340 for use with the telescoping dilation introducer of the invention includes an elongated, generally cylindrical first section 342 and an elongated, tubular second section 344 that is adapted to receive the first section.
- the first section includes a proximal enlarged head or stop portion 346 , and a relatively narrow elongated body portion 348 .
- the elongated body portion is preferably formed with a proximal section 350 having a relatively larger diameter to provide relatively greater strength, rigidity and torquability for manipulation of the guide wire, and a relatively narrower diameter main section 352 connected to the proximal section, and a pointed distal tip 354 at the distal end 358 of the main section.
- the elongated tubular second section has a relatively larger diameter than the main section and an internal bore slightly larger in diameter than the main section for receiving the main section, as is illustrated in FIG. 28 .
- the tubular second section advantageously also includes a frustoconical distal tip 362 with a narrowed portion 364 at the distal end 366 of the tubular distal section, and presenting an enlarged flat shoulder 368 at the proximal end of the frustoconical distal tip, so that when the guide wire assembly is assembled as shown in FIG.
- the elongated main section is received in the internal bore of the elongated tubular section, and the proximal section of the elongated body portion of the elongated generally cylindrical section is seated against said proximal end of said elongated tubular section, the pointed distal tip extends out of said frustoconical distal tip of said elongated tubular section so that the assembly presents a pointed distal end, with a proximal shoulder against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer.
- the elongated generally cylindrical first section thus adds a sharp point to the relatively blunt distal end of the elongated tubular second section, allowing the guide wire assembly to be inserted through soft tissue for placement in a soft tissue target of interest, such as an organ. Since the soft tissue present no hard surface against which the telescoping dilation introducer can be pushed, after the sharp point of the guide wire is placed in the desired location in the soft tissue, the first section can be removed from the second section, leaving the blunt distal end in place at the desired location in the soft tissue, and the telescoping dilation introducer can be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer.
- the outer dilator tube 400 includes a parallel guide insert 402 , shown in FIG. 31 .
- the outer dilator tube has a distal end 404 with a tapered tip 406 , and a proximal portion 408 to which a handle 410 is connected at the extreme proximal or head end 412 of the outer dilator tube.
- the head end of the outer dilator tube includes a radial aperture 414 for receiving the locking pin 416 , and a longitudinal aperture 418 for receiving a distally projecting latching member 420 of the cylindrical head 422 of the parallel guide insert.
- the outer dilator tube has an inner bore 424 with proximal and distal openings.
- the parallel guide insert includes a main cylindrical shaft 425 connected at a proximal end 426 to the cylindrical head of the parallel guide insert.
- the parallel guide insert includes a plurality of longitudinal bores 428 extending the length of the parallel guide insert from the distal end 430 , with distal openings visible in FIG. 31 , to proximal openings (not shown) in the cylindrical head of the parallel guide insert.
- a single guide wire or K wire or other device may be passed through one or more of the bores of the parallel guide insert, or multiple guide wires or K wires or other devices may be passed through a plurality of the bores simultaneously, as desired.
- the parallel guide insert may be provided without a latching member, in order to allow the parallel guide member to be rotated freely to allow alignment of the desired locations of the guide wires through the holes in the parallel guide insert.
- the outer dilator tube 440 includes a parallel guide insert 442 , shown in FIG. 33 .
- the outer dilator tube has a distal end 444 with an angled tip 446 , and a proximal end 448 to which a handle 450 is connected at the extreme proximal or head end 452 of the outer dilator tube.
- the head end of the outer dilator tube includes a radial aperture 454 for receiving the locking pin 456 , and a longitudinal aperture 458 for receiving a distally projecting latching member 460 of the cylindrical head 462 of the parallel guide insert.
- the outer dilator tube has an inner bore 464 with proximal and distal openings.
- the parallel guide insert includes a main cylindrical shaft 465 connected at a proximal end 466 to the cylindrical head of the parallel guide insert.
- the parallel guide insert includes a plurality of longitudinal bores 468 extending the length of the parallel guide insert from the angled distal end 470 , with distal openings visible in FIG. 33 , to proximal openings (not shown) in the cylindrical head of the parallel guide insert.
- the angled tips of the outer dilator tube and the parallel guide insert are beveled or angled at a common angle with respect to the longitudinal axis of the dilation introducer, so that the angled tips of the outer dilator tube and the parallel guide insert can be aligned together generally parallel to the surface of the soft tissue to be dilated, with the bore and dilation passage of the dilation introducer aligned at a predetermined desired angle with respect to the soft tissue to be dilated and the bone tissue to be treated.
- a single guide wire or K wire or other device may be passed through one or more of the bores of the parallel guide insert, or multiple guide wires or K wires or other devices may be passed through a plurality of the bores simultaneously, as desired.
- the distal tip 480 of an outer dilator tube 482 may be angled or beveled, and may include a plurality of spikes 484 to provide for increased traction of the tip of the outer dilator tube on bone tissue.
- the spikes may be formed of radiopaque material, such as gold, platinum, tantalum or the like, for use with fluoroscopy.
- a parallel guide 486 disposed in the outer dilator tube has a distal tip 488 that may optionally also be provided with a plurality of embedded spikes 490 for increased traction on bone tissue.
- the spikes of the outer dilator tube and parallel guide may formed with a rounded shape so as to deflect soft tissue during dilation, and to provide increased traction with bone upon completion of the insertion of the dilator.
- the invention provides for a fifth presently preferred embodiment of a dilation introducer 500 , which is similar to the embodiment illustrated in FIGS. 8-12 , and which is shown in an unlocked configuration in FIG. 36 .
- the dilation introducer includes a first or inner dilator tube 502 having distal end (not shown) and a proximal end 504 with a cylindrical head 506 .
- the means for removably connecting the first and second dilator tubes together in a locked configuration includes a first latching member 508 , having a shaft 510 and a latching end 512 , such as a hook, projecting from the cylindrical head toward the distal end, and connected to a locking button 514 , which extends transversely out through a side aperture 516 in the cylindrical head.
- the locking button includes a shaft 518 and an enlarged head 520 connected to the shaft, and the locking button is biased outwardly from the cylindrical head by a spring 522 .
- the latching member is received in an upper aperture 524 of the adjacent cylindrical head of a second or intermediate dilator tube 526 , having a side opening latching chamber 528 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the first and second dilator tubes together.
- the cylindrical heads of the first and second dilator tubes can be unlocked and separated by manually depressing the locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber.
- the first dilator tube is essentially the same as the first dilator tube of the embodiment of FIGS. 8-12 .
- the second or intermediate dilator tube 526 of the dilation introducer has a distal end (not shown) and a proximal end 530 with a cylindrical head 532 .
- the means for removably connecting the second and third dilator tubes together in a locked configuration includes a second latching member 534 , having a shaft 536 and a latching end 538 , such as a hook, projecting from the cylindrical head toward the distal end, and connected to a second locking button 540 , which extends transversely out through a side aperture 542 in the cylindrical head.
- the locking button includes a shaft 544 and an enlarged head 546 connected to the shaft, and the locking button is biased outwardly from the cylindrical head by a spring 548 .
- the latching member is received in an upper aperture 550 of the adjacent cylindrical head of a third or second intermediate dilator tube 552 , having a side opening latching chamber 554 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the second and third dilator tubes together.
- the cylindrical heads of the second and third dilator tubes can be unlocked and separated by manually depressing the second locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber.
- the second dilator tube is essentially the same as the second dilator tube of the embodiment of FIGS. 8-12 .
- the third, or second intermediate, dilator tube 552 of the dilation introducer has a distal end (not shown) and a proximal end 556 with a cylindrical head 558 .
- the means for removably connecting the third dilator tube and the outer dilator tube 560 together in a locked configuration includes a third latching member 562 , having a shaft 564 and a latching end 566 , such as a hook, projecting from the cylindrical head toward the distal end, and connected to a third locking button 568 , which extends transversely out through a side aperture 570 in the cylindrical head.
- the third locking button includes a shaft 572 and an enlarged head 574 connected to the shaft, and the third locking button is biased outwardly from the cylindrical head by a spring 576 .
- the latching member is received in an upper aperture 578 of the adjacent cylindrical head 580 of the outer dilator tube, having a side opening latching chamber 582 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the third and outer dilator tubes together.
- the cylindrical heads of the third and outer dilator tubes can be unlocked and separated by manually depressing the third locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber.
- the third dilator tube is essentially the same as the second dilator tube of the embodiment of FIGS. 8-12 .
- the outer dilator tube includes a distal end (not shown) and a proximal end 584 to which a handle 586 is connected at its cylindrical head end.
- the head end of the handle preferably includes a plurality of the upper apertures 578 connected to corresponding side opening latching apertures 582 for receiving the latching member of the adjacent dilator tube cylindrical head, as is illustrated in FIG. 40 .
- the outer dilator tube is essentially the same as the outer dilator tube of the embodiment of FIGS. 8-12 .
- the side opening latching chambers of the cylindrical heads of the dilator tubes may be closed so as to form covered latching chambers 590 a, b, c for the latching members.
- the variation shown in FIGS. 38 and 39 is essentially the same as in FIGS. 36 and 37 .
- an outer dilation tube 600 may be provided with a light emitter 602 , such as one or more light emitting diodes (LEDs) or the end of a fiber optic, connected to or embedded in the tubular shaft 604 of the outer dilation tube, and preferably near the distal end 606 of the tubular shaft.
- the light emitter may be an LED embedded in the wall 608 of the tubular shaft, with the LED directed to illuminate the interior, exterior, or distal edge of the tubular shaft of the outer dilation tube. As is shown in FIG.
- one or more elongated energy conducting members 610 may be embedded in the tubular shaft, for conducting electricity or light to the light emitter.
- the handle 612 of the outer dilator tube preferably contains one or more batteries 614 connected to a switch 616 which is in turn connected to power the light emitter.
- the handle may be provided with a battery or batteries, which may be disposable, a switch, resistor and other associated electronics, so that the handle is disposable, or alternatively the handle may be provided with a connector for connection to an external power source.
- the switch is a thumb switch conveniently located on the handle adjacent to the cylindrical head 618 of the outer dilation tube.
- the handle, cylindrical head, and tubular shaft of the outer dilation tube preferably includes one or more channels 620 for the electrical wires connecting the one or more batteries to the switch and to the light emitter.
- a light source 622 such as one or more LEDs providing light to be conducted through the one or more fiber optics may be placed adjacent to the switch in the handle, with the one or more fiber optics extending through the wall of the tubular shaft of the outer dilator tube.
- the one or more elongated energy conducting members such as one or more wires or one or more fiber optics, may be disposed on the outer surface of the tubular shaft of the outer dilation tube.
- the tubular shaft of the outer dilation tube may be formed with a groove 620 running longitudinally on the exterior surface of the tubular shaft, parallel to the longitudinal axis of the outer dilation tube, to accommodate one or more wires or one or more fiber optics.
- the one or more elongated energy conducting members may be located on the inside of the dilator tube, or may extend through the wall of the dilator tube.
- the present invention also provides for a telescoping expander sleeve 630 that is adapted to be slidably disposed over the shaft of an outer dilator tube of any of the foregoing embodiments for expanding the patient's soft tissue down to the entry point on the bone tissue to be treated, while leaving the outer dilator tube in place, or allowing for replacement of the outer dilator tube with other equipment for treatment of the bone tissue.
- the tubular proximal portion may optionally be provided with a handle.
- the expander sleeve may be pre-assembled in combination with one or more of the dilation introducers, adapted to be ready for use.
- the telescoping expander sleeve has a first or inner generally tubular section 632 , having a tubular proximal portion 634 with an enlarged proximal head 636 , and a distal portion 638 with at least two substantially identical opposing active spreader arms 640 (one of which is not visible in FIGS. 44-46 ) connected at one end to the tubular proximal portion and moveable radially at their distal tips 642 .
- the distal tips of the active spreader arms preferably have beveled edges 644 to deflect soft tissue during insertion of the telescoping expander sleeve.
- a second or outer generally tubular section 646 is slidably disposed over the first or inner generally tubular section, and includes a tubular proximal portion 648 and a distal portion 650 with at least two substantial identical opposing passive spreader flaps 652 interposed between the active spreader arms, hingedly connected to the tubular proximal portion at proximal ends 654 , and moveable radially at their distal tips 656 .
- the distal tips of the passive spreader flaps preferably also have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve.
- the distal tips of the passive spreader flaps when placed together in an unexpanded configuration have a generally circular configuration, so that the distal tips of two passive spreader flaps, for example, have a semi-circular configuration.
- the passive spreader flaps taper progressively toward their narrowed proximal ends connected to the tubular proximal portion of the outer tubular section.
- the passive spreader flaps are connected to the tubular proximal portion of the outer generally tubular section by rings 656 passing through apertures 658 and 660 in the adjacent ends of the tubular proximal portion and the passive spreader flaps, respectively.
- the active spreader arms are slidably interposed between and engage the passive spreader flaps, so that as the telescoping expander sleeve telescopes from an extended, unexpanded configuration to a collapsed, expanded configuration, as shown in FIG. 44 , the active spreader arms slide from the narrow proximal ends of the passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of the passive spreader flaps apart, which also forces the distal ends of the active spreader arms apart, as shown in FIG. 46 .
- the distal ends of the active spreader arms are slidably connected to slots 662 extending along the inner edges 664 of the passive spreader flaps by loops or rings 666 , such as loops of nylon filament or metal rings, for example, which pass through apertures 668 in the distal ends of the active spreader arms.
- Telescoping of expander sleeve from a collapsed, expanded configuration to an extended, unexpanded configuration thus slides the distal ends of the active spreader arms of the inner tubular section from the wide distal ends of the passive spreader flaps along the inner edges of the passive spreader flaps to the narrowed proximal ends of the passive spreader flaps, to bring the passive spreader flaps together.
- the purpose of the active spreader arms and passive spreader flaps is to facilitate the creating of a larger working area adjacent to bone or bone tissues being treated.
- the spreader arms and flaps may optionally be covered by an expandable material, such as latex, for example, with a central through hole permitting operation of the device, to cover the spreader arms and flaps to prevent tissues from being pressed into cavities of the telescoping expander sleeve.
- the components of the dilation introducer may be formed from plastic, stainless steel, or similar materials or combinations thereof, that can be readily sterilized and packaged ready for use, after which the dilation introducer may be disposed of or resterilized for subsequent use, as desired.
- the dilator tubes may be radioluscent, with radiopaque markers located on the tips of one or more of the dilator tubes.
- the tip of the first dilator may also be scored, grooved, or otherwise be provided with a rough surface, to prevent migration.
- the dilation introducer may also have curved or otherwise non-linear dilator tubes, and the dilation introducer may also have a non-cylindrical shape, such as an oval shape, for example, to allow the dilation introducer to be inserted around objects or a patient's organs.
- one or more devices can be inserted through the same dilation introducer, and that the dilation introducer can be repositioned within the same incision for fixation of multiple devices.
- fiber optic devices may be inserted through or integrated with the dilation introducer for visual inspection of the target area. While particular locking features have been described for the different embodiments of the dilation introducer, any combination of locking features or alternate locking features may be utilized.
- the outer dilator tube may not be locked, and a handle on the outer dilator tube may simply be used as a stop.
- the dilation introducer of the invention can also be useful in dilation of soft tissue for percutaneous, minimally invasive surgical procedures such as nephrostomy, neurosurgery, heart valve repair or replacement, gastrointestinal surgery such as for gall bladder or gall stone surgery, hernia removal, transjugular intrahepatic portal-systemic shunt (TIPS) procedures for treatment of the liver, and the like.
- percutaneous, minimally invasive surgical procedures such as nephrostomy, neurosurgery, heart valve repair or replacement
- gastrointestinal surgery such as for gall bladder or gall stone surgery
- hernia removal such as for gall bladder or gall stone surgery
- TIPS transjugular intrahepatic portal-systemic shunt
Abstract
The dilation introducer has a locked assembled configuration for placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration for dilating the patient's soft tissue down to tissue to be treated. Dilator tubes are successively released and advanced to progressively expand the patient's soft tissue down to the bone tissue to be treated. The dilator tubes and a guide insert may include spikes for engaging bone tissue. The dilation introducer may include a light emitter disposed in a dilator tube. A telescoping expander sleeve is also provided.
Description
- This is a continuation-in-part of Ser. No. 10/911,215, filed Aug. 3, 2004.
- 1. Field of the Invention
- This invention relates to bone fixation devices, and more particularly relates to a dilation introducer for introducing a bone fixation device for orthopedic surgery, such as for vertebral fusion.
- 2. General Background and State of the Art
- Fusion of two adjacent vertebrae is a common surgical treatment for back injuries due to damage or defects in a spinal disc between two adjacent vertebrae, such as conditions due to a herniated disc or disc degeneration. The entire disc may be removed by a discectomy procedure, and may be replaced with bone or a bone substitute and/or cage in order to prevent collapse of the disc space between the adjacent vertebrae. Early techniques for stabilizing the adjacent vertebrae included application of a plate or a rod in conjunction with screws across the adjacent vertebrae, after which the adjacent vertebrae would eventually fuse together. However, such techniques commonly required prolonged periods of recovery from the extensive surgery involved, and it would be desirable to provide an improved apparatus and method for providing a minimally invasive procedure that will result in less trauma and improvement in patient recovery.
- Bone fixation devices are known that are useful for connecting two or more bone segments for the healing of broken bones, typically including an elongate pin with a distal anchor and a proximal anchor movable on the pin to accommodate different bone dimensions, and to permit tensioning of the bone segments together. The surgical procedure of attaching two or more parts of a bone with a pin-like device commonly requires an initial incision into the tissue down to the bone, and the drilling of a hole through the bone parts to be joined. Such bone fixation devices can be useful for fusion of vertebrae together, because such a bone fixation device can be used to join adjacent bone segments through a single percutaneous incision or puncture, without the need to expose any other side of the bone segments to be joined. In either type of procedure, there is substantial trauma to the surrounding tissue if a large incision is required. Thus, it would be desirable to provide a minimally invasive dilation introducer to allow the penetration and spreading of soft tissues down to vertebrae to be fused, for use of such a bone fixation device to join adjacent vertebrae, and to allow for more easily performing the delicate maneuvering of drilling adjacent vertebrae and application of one or more bone fixation devices to join the vertebrae to be fused. The present invention satisfies these and other needs.
- Briefly, and in general terms, the invention provides for a telescoping dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration for dilating the patient's soft surrounding tissue to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue. As the telescoping dilation introducer is inserted, each individual dilator tube is successively released and advanced to progressively expand the patient's soft tissue down to the tissue to be treated. In a particularly useful aspect of the invention, the tissue to be treated is bone tissue which must be prepared prior to attachment of adjacent bone section in a fusion process. While there are many applications of the dilation introducer of the invention, the invention is particularly applicable to fusion of bones in orthopedic surgery using minimally invasive technique, and will be described herein in particular applications of those procedures. The invention also concerns a minimally invasive procedure utilizing the telescoping dilation introducer to insert a bone fixation device into a patient's spine for posterior spine fusion. While posterior spine fusion currently takes up to two hours to complete, and requires a six inch incision, with the apparatus and method of the invention, comparable surgery can be completed in less than thirty minutes, with a dilation port 13 mm or less in diameter, thus lowering the chance of damage to the surrounding soft tissue.
- A telescoping dilation introducer is typically operated by pressing the introducer against a relatively hard surface, such as bone tissue being treated. The present invention provides for a guide wire assembly when such a telescoping dilation introducer is to used in treatment of soft tissue, such as an organ, to provide a surface against which the telescoping dilation introducer can be pushed during operation of the telescoping dilation introducer. In a presently preferred embodiment, a guide wire or K wire assembly is provided for use with a telescoping dilation introducer according to the invention. The guide wire assembly includes an elongated generally cylindrical first section, and an elongated tubular second section that receives the first section. The elongated generally cylindrical first section includes a proximal enlarged head or stop portion, and an elongated body portion with a proximal section and a relatively narrower diameter main section connected to the proximal section, and a pointed distal tip at the distal end of the narrow main section. The second section of the guide wire assembly includes an elongated tubular body with an internal bore adapted to receive the narrow main section, as is illustrated in
FIG. 28 . The tubular second section advantageously includes a frustoconical distal tip with a narrowed portion at the distal end and an enlarged flat shoulder at the proximal end of the frustoconical distal tip. When the guide wire assembly is assembled, the assembly presents a pointed distal end with a proximal shoulder against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer. The main section thus adds a sharp point to the relatively blunt distal end of the tubular distal section, allowing the guide wire assembly to be inserted through soft tissue for placement in a soft tissue target of interest, such as an organ, and the first section can then be removed to allow a telescoping dilation introducer to be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer. After the sharp point of the guide wire is placed in the desired location in the soft tissue, the first section can be removed from the second section, leaving the blunt distal end in place at the desired location in the soft tissue, and the telescoping dilation introducer can be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer. - In one presently preferred embodiment, the present invention provides for an improvement in a dilation introducer for orthopedic surgery, in which the dilation introducer includes one or more dilator tubes having a distal end and a proximal end, and the distal end of the one or more dilator tubes including a plurality of spikes for engaging bone tissue. In one presently preferred aspect, the spikes may be formed of radiopaque material, for fluoroscopic imaging of the positioning of the one or more dilator tubes, and the spikes may be formed with a rounded shape so as to deflect soft tissue.
- In another presently preferred aspect, the dilation introducer includes a parallel guide insert adapted to be received in the one or more dilator tubes. The parallel guide insert includes a main cylindrical shaft having a proximal end connected to a cylindrical head, and a plurality of longitudinal bores extending the length of the parallel guide insert through the main cylindrical shaft and cylindrical head. The distal tip of the parallel guide insert may be provided with a plurality of spikes for engaging bone tissue. The spikes of the parallel guide insert may be formed of radiopaque material, and may be formed with a rounded shape so as to deflect soft tissue.
- In another presently preferred embodiment, the present invention concerns a dilation introducer for orthopedic surgery having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue to be treated. The dilation introducer includes a first dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and a second dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and an inner lumen with a distal opening and a proximal opening. The first dilator tube is removably received in the second dilator tube for slidable telescoping movement within the second dilator tube. Means are provided for removably connecting the first and second dilator tubes together in a locked configuration. The means for removably connecting the first and second dilator tubes includes a first latching member disposed in the cylindrical head of the first dilator tube. The first latching member has a locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the first dilator tube toward the distal end of the first dilator tube, with the locking button extending transversely from the shaft through a side aperture in the cylindrical head of the first dilator tube. The locking button is biased outwardly from the cylindrical head, such as by a spring, and the first latching member is received in an upper aperture of the cylindrical head of an adjacent second dilator tube. The upper aperture of the cylindrical head of the second dilator tube includes a latching chamber for retaining the latching end of the latching member when the locking button is biased outwardly, to lock the cylindrical heads of the first and second dilator tubes together. The locking button is moveable inwardly to move the latching member inwardly and to move the latching end of the latching member inwardly out of the latching chamber, to unlock the first and second dilator tubes.
- The dilation introducer may include one or more additional dilator tubes, with the second dilator tube being removably received in the one or more additional dilator tubes for slidable telescoping movement within the one or more additional dilator tubes. The one or more additional dilator tubes likewise have a distal end and a proximal end with a cylindrical head, an inner lumen with a distal opening and a proximal opening, and the distal end having a tapered tip. The second dilator tube and the one or more additional dilator tubes having an unlocked configuration in which the one or more additional dilator tubes may slidably telescope over the second dilator tube to dilate the patient's soft tissue at the distal end of the dilation introducer. Means are provided for removably connecting the second dilator tube and the one or more additional dilator tubes together in a locked configuration. The means for removably connecting the second dilator tube and the one or more additional dilator tubes include a second latching member disposed in the cylindrical head of the second dilator tube. The second latching member has a locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the second dilator tube toward the distal end of the second dilator tube, and the locking button extends transversely from the shaft through a side aperture in the cylindrical head of the second dilator tube. The locking button is biased outwardly from the cylindrical head, such as by a spring, and the second latching member is received in an upper aperture of the cylindrical head of the additional dilator tube to be connected. The upper aperture of the cylindrical head of the additional dilator tubes include a latching chamber for retaining the latching end of the second latching member when the locking button is biased outwardly, to lock the cylindrical heads of the second and additional dilator tube together, and the locking button is moveable inwardly to move the second latching member inwardly and the latching end of the second latching member inwardly out of the latching chamber.
- In a presently preferred aspect, the additional dilator tube comprises a handle connected to the proximal end of the additional dilator tube, and the cylindrical head of the additional dilator tube includes a plurality of the upper apertures, each including a latching chamber for receiving the second latching member.
- In another presently preferred embodiment, the present invention provides for an improvement in a dilation introducer for orthopedic surgery, in which the dilation introducer includes a dilator tube having a tubular shaft, a distal end and a proximal end, an inner lumen with a distal opening and a proximal opening, and a light emitter disposed in the dilator tube. In one aspect, the light emitter may be a light emitting diode, and the light emitting diode may be embedded in the tubular shaft of the dilator tube. In another aspect, the light emitter may include a fiber optic, and the fiber optic may be embedded in the tubular shaft of the dilator tube.
- In a presently preferred aspect, the dilator tube includes a handle and a switch for controlling the light emitter, and at least one battery is disposed in the handle and is connected to the switch to power the light emitter. Where the light emitter includes one or more fiber optics, the light emitter includes a light source providing light conducted to the one or more fiber optics. The light emitter may include one or more elongated energy conducting members disposed on an outer surface of the tubular shaft of the dilator tube, and the one or more elongated energy conducting members may be disposed in a groove on the exterior surface of the tubular shaft. Alternatively, the one or more elongated energy conducting members may be located on the inside of the dilator tube, or may extend through the wall of the dilator tube.
- The present invention also provides for a telescoping expander sleeve adapted to be slidably disposed over a shaft of a dilator tube for dilating a patient's soft tissue down to a bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue. The telescoping expander sleeve is moveable between an extended, unexpanded configuration and a collapsed, expanded configuration. The telescoping expander sleeve includes a first generally tubular section having a tubular proximal portion and a distal portion. The tubular proximal portion has an enlarged proximal head, and the distal portion includes two or more active spreader arms each having a proximal end and a distal tip. The tubular proximal portion may optionally be provided with a handle. The two or more active spreader arms are connected at their proximal ends to the tubular proximal portion, and the distal tips of the two or more active spreader arms are moveable radially between an unexpanded configuration and an expanded configuration.
- The telescoping expander sleeve also includes a second generally tubular section slidably disposed over the first generally tubular section. The second generally tubular section includes a tubular proximal portion and a distal portion including two or more passive spreader flaps each having a narrow proximal end and a wide distal tip. The proximal ends of the two or more passive spreader flaps are hingedly connected to the tubular proximal portion, and the distal tips of the two or more passive spreader flaps are moveable radially between an unexpanded configuration and an expanded configuration. The two or more active spreader arms slidably engage the two or more passive spreader flaps, so that as the telescoping expander sleeve telescopes from the extended, unexpanded configuration to the collapsed, expanded configuration, the two or more active spreader arms slide from the narrow proximal ends of the two or more passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of the two or more passive spreader flaps apart, and to spread the distal ends of the two or more active spreader arms apart.
- In a presently preferred aspect, the distal tips of the two or more active spreader arms have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve, and the distal tips of the two or more passive spreader flaps have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve. The purpose of the active spreader arms and passive spreader flaps is to facilitate the creating of a larger working area adjacent to bone or bone tissues being treated. The spreader arms and flaps may optionally be covered by an expandable material, such as latex, for example, to prevent tissues from being pressed into cavities of the telescoping expander sleeve.
- While the present invention is particularly useful for the purposes of orthopedic surgery, those skilled in the art will recognize that the invention can also be used for the treatment of a variety of internal organs or structures when it is desired to minimize the size of an opening in the patient's soft tissue and the resultant damage and trauma to tissue surrounding the operation site.
- Other features and advantages of the present invention will become more apparent from the following detailed description of the preferred embodiments in conjunction with the accompanying drawings, which illustrate, by way of example, the operation of the invention.
-
FIG. 1 is a plan view of a first embodiment of a dilation introducer in a locked configuration, according to the present invention. -
FIG. 2 is a plan view of the dilation introducer ofFIG. 1 shown in an unlocked, collapsed configuration. -
FIG. 3 is a plan view of the first or inner dilator tube of the dilation introducer ofFIG. 1 . -
FIG. 4 is a plan view of the second or intermediate dilator tube of the dilation introducer ofFIG. 1 . -
FIG. 5 is a plan view of the third or outer dilator tube of the dilation introducer ofFIG. 1 . -
FIG. 6A is a top plan view of the first locking clip of the dilation introducer ofFIG. 1 . -
FIG. 6B is an elevational view of the first locking clip of the dilation introducer ofFIG. 1 . -
FIG. 6C is a bottom plan view of the first locking clip of the dilation introducer ofFIG. 1 . -
FIG. 7A is a top plan view of the second locking clip of the dilation introducer ofFIG. 1 . -
FIG. 7B is an elevational view of the second locking clip of the dilation introducer ofFIG. 1 . -
FIG. 8 is a perspective view of a second embodiment of a dilation introducer in a locked configuration, according to the present invention. -
FIG. 9 is a perspective view of the dilation introducer ofFIG. 8 shown in an unlocked, collapsed configuration. -
FIG. 10 is a perspective view of the first or inner dilator tube of the dilation introducer ofFIG. 8 . -
FIG. 11 is a perspective view of the second or intermediate dilator tube of the dilation introducer ofFIG. 8 . -
FIG. 12 is a plan view of the third or outer dilator tube of the dilation introducer ofFIG. 8 . -
FIG. 13 is a plan view of a third embodiment of a dilation introducer in a locked configuration, according to the present invention. -
FIG. 14 is a plan view of the dilation introducer ofFIG. 13 shown in an unlocked, collapsed configuration. -
FIG. 15 is a plan view of the first or inner dilator tube of the dilation introducer ofFIG. 13 . -
FIG. 16 is a plan view of the second or intermediate dilator tube of the dilation introducer ofFIG. 13 . -
FIG. 17 is a plan view of the third or outer dilator tube of the dilation introducer ofFIG. 13 . -
FIG. 18 is a plan view of the plastic sleeve of the dilation introducer ofFIG. 13 . -
FIG. 19 is a plan view of a fourth embodiment of a dilation introducer in a locked configuration, according to the present invention. -
FIG. 20 is a plan view of the dilation introducer ofFIG. 19 shown in an unlocked, collapsed configuration. -
FIG. 21 is a plan view of the first or inner dilator tube of the dilation introducer ofFIG. 19 . -
FIG. 22 is a plan view of the second or intermediate dilator tube of the dilation introducer ofFIG. 19 . -
FIG. 23 is a plan view of the third or outer dilator tube of the dilation introducer ofFIG. 19 . -
FIG. 24 is a schematic diagram illustrating location of a starting point for insertion of a bone fixation device according to the method of the invention. -
FIG. 25 is a schematic diagram of a lateral view illustrating location of a trajectory for insertion of a bone fixation device according to the method of the invention. -
FIG. 26 is a schematic diagram of an anterior view illustrating location of a trajectory for insertion of a bone fixation device according to the method of the invention. -
FIG. 27 is a plan view of a guide wire assembly for use with the various embodiments of the telescoping dilation introducer of the invention, shown disassembled. -
FIG. 28 is a plan view of the guide wire assembly ofFIG. 27 , shown partially assembled. -
FIG. 29 is a plan view of the guide wire assembly ofFIG. 27 , shown fully assembled. -
FIG. 30 is a perspective view of a variation of the outer dilator tube of the embodiment ofFIGS. 8-12 , with a parallel guide. -
FIG. 31 is a perspective view of the parallel guide fromFIG. 30 . -
FIG. 32 is a perspective view of a variation of the outer dilator tube of the embodiment ofFIGS. 8-12 , with an angled tip and with a parallel guide. -
FIG. 33 is a perspective view of the parallel guide with an angled tip fromFIG. 32 . -
FIG. 34 is a perspective of another variation of the outer dilator tube of the embodiment ofFIGS. 8-12 , with an angled tip and spikes. -
FIG. 35 is a perspective view of the outer dilator tube ofFIG. 34 , with a parallel guide with spikes. -
FIG. 36 is a perspective view of a fifth embodiment of a dilation introducer in an unlocked configuration, according to the present invention. -
FIG. 37 is a sectional view of a portion of the dilation introducer ofFIG. 36 . -
FIG. 38 is a perspective view of a variation of the dilation introducer ofFIG. 36 , shown in a locked configuration, according to the present invention. -
FIG. 39 is a sectional view of a portion of the dilation introducer ofFIG. 36 taken along line 39-39 ofFIG. 38 . -
FIG. 40 is a top perspective view of the head end of the handle of the dilation introducer ofFIG. 36 , showing multiple locking locations. -
FIG. 41 is a schematic diagram of a variation of the dilation introducer ofFIG. 36 , with a light emitter and switch for the light emitter. -
FIG. 42 is an enlarged view of the tip of the dilation introducer ofFIG. 41 . -
FIG. 43 is a perspective view of another variation of the dilation introducer ofFIG. 41 , with an exterior groove for one or more elongated energy conducting members. -
FIG. 44 is a side elevational view of a telescoping expander sleeve shown in an extended, unexpanded configuration. -
FIG. 45 is a side elevational view of the telescoping expander sleeve ofFIG. 44 shown in an intermediate partially collapsed, partially expanded configuration. -
FIG. 46 is a side elevational view of the telescoping expander sleeve ofFIG. 44 shown in a fully collapsed, fully expanded configuration. - Referring to the drawings, which are provided for purposes of illustration and by way of example, the present invention provides for a telescoping dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue to be treated.
- While the invention will be described with specificity to a spinal fusion procedure, those skilled in the art will recognize that the apparatus and method of the art will recognize that the apparatus and method of the invention can also be advantageously used for procedures in which the dilation introducer can be brought up against other firm or solid structures in the body or introduced into the body to thereby gain the advantages of the invention for other minimally invasive procedures.
- A
dilation introducer 30 according to a first preferred embodiment is shown in a locked assembled configuration inFIG. 1 , and shown in an unlocked, collapsed configuration inFIG. 2 . Referring toFIG. 3 , the dilation introducer includes a first orinner dilator tube 32 having adistal end 34 with a taperedtip 36, and aproximal end 38 with ahead 40 including a pair of spaced part rings 42. The first dilator tube has aninner lumen 44 with adistal opening 46 and aproximal opening 48. - Referring to
FIG. 4 , the dilation introducer also includes a shorter second orintermediate dilator tube 52 having adistal end 54 with a taperedtip 56, and aproximal end 58 with ahead 60 including a pair of spaced apart rings 62. The second dilator tube has aninner lumen 64 with adistal opening 66 and aproximal opening 68. - Referring to
FIG. 5 , in a presently preferred aspect, the dilation introducer also includes at least one additional dilator tube, such as a still shorter third orouter dilator tube 72 having adistal end 74 with a taperedtip 76, and aproximal end 78 with ahandle 80. The third dilator tube has aninner lumen 82 with adistal opening 84 and aproximal opening 86. - Referring to
FIGS. 6A, 6B and 6C, the means for removably connecting the first and second dilator tubes together in a locked configuration includes afirst locking clip 88. As is shown inFIGS. 7A and 7B , a means for removably connecting the second and third dilator tubes together in a locked configuration may also be provided, and may include asecond locking clip 90. The first locking clip includes afirst portion 92 and asecond portion 94, and a cross-piece or handle 96 having afirst end 98 and asecond end 100 connected at right angles between the first and second portions. The first portion includes pair ofresilient arms 102 each having a proximalnarrow neck portion 104 connected to the cross-piece, and a distalgripping portion 106 extending from the narrow neck portion. The resilient arms have an innerrounded surface 108 adapted to snap over the first dilator tube between the spaced apart rings of the first dilator tube. The second portion currently preferably includes asingle arm 112 having a proximalnarrow neck portion 114, and a distalgripping portion 116 extending from the narrow neck portion. The gripping portion has an innerrounded surface 118 adapted to fit over the outer surface of the second dilator tube between the spaced apart rings of the second dilator tube, to connect the first and second dilator tubes. Removing the first locking clip allows the second or intermediate dilator tube to slidably telescope over the first inner dilator tube to dilate tissue at the distal end of the dilation introducer. - The second locking clip includes a
first portion 122 and asecond portion 124, and a cross-piece or handle 126 having afirst end 128 and asecond end 130 connected between the first portion and the second portion at right angles. The first portion includes a pair ofresilient arms 132 each having a proximalnarrow neck portion 134 connected to the cross-piece, and a distalgripping portion 136 extending from the narrow neck portion. The pair of resilient arms have an innerrounded surface 138 adapted to snap over the outer surface of the second dilator tube between the spaced apart rings of the second dilator tube. The second portion of the second locking clip includes a pair ofresilient arms 142 each having a proximal narrow neck portion (not shown) connected to the cross-piece and a distalgripping portion 146 extending from the narrow neck portion, the pair of resilient arms having an inner rounded surface (not shown) adapted to fit over the outer surface of the third dilator tube to connect the second and third dilator tubes. Removing the second locking clip allows the third or outer dilator tube to slidably telescope over the second inner dilator tube to further dilate tissue at the distal end of the dilation introducer. - As is shown in
FIG. 1 , a tubular bone drill or tap 150 can be inserted through an intermediate or outer dilator tube, and the tubular bone drill or tap can be passed or threaded over a guide wire orK wire 151 to contact the surface of the vertebra or bone to be treated, as will be further described below. Once the outer dilator tube has been moved to the distal end of the dilation introducer into position against the vertebra or bone to be treated to fully dilate the soft tissue, the inner dilator tube, the tubular bone drill, and the intermediate dilator tube can be withdrawn and removed to leave the outer dilator tube in place to permit further surgical procedures. - Referring to
FIGS. 8-12 , the invention provides for a second presently preferred embodiment of adilation introducer 160 shown in a locked assembled configuration inFIG. 8 , and shown in an unlocked, collapsed configuration inFIG. 9 . Referring toFIG. 10 , the dilation introducer includes a first orinner dilator tube 162 having adistal end 164 with a taperedtip 166, and aproximal end 168 with acylindrical head 170. The means for removably connecting the first and second dilator tubes together in a locked configuration includes a latchingmember 172, such as a hook, projecting from the cylindrical head toward the distal end, receiving alocking pin 216, although other latching members, such as a projection with aperture for receiving a locking pin may also be suitable, as will be apparent from the explanation below. The first dilator tube has aninner lumen 174 with adistal opening 176 and aproximal opening 178. - Referring to
FIG. 11 , the dilation introducer includes a shorter second orintermediate dilator tube 182 having adistal end 184 with a taperedtip 186, and aproximal end 188 having acylindrical head 190. The means for removably connecting the second and third dilator tubes together in a locked configuration includes a latchingmember 192, such as a hook, projecting from the cylindrical head toward the distal end, receiving alocking pin 218, although other latching members, such as a projection with aperture for receiving a locking pin may also be suitable, as noted above. The second dilator tube has aninner lumen 194 with adistal opening 196, and aproximal opening 198. The cylindrical head includes a firstradial aperture 200 for receiving thelocking pin 216, and a secondlongitudinal aperture 201 for receiving the distally projecting latching member of the cylindrical head of the first or inner dilator tube. - Referring to
FIG. 12 , in a preferred aspect, the dilation introducer includes at least one additional dilator tube, such as a still shorter third orouter dilator tube 202 having adistal end 204 with a taperedtip 206, and aproximal end 208 to which ahandle 210 is connected at itshead end 212. The head end of the handle includes aradial aperture 214 for receiving thelocking pin 218, and alongitudinal aperture 215 for receiving the distally projecting latching member of the cylindrical head of the second or intermediate dilator tube. Thefirst locking pin 216 is substantially the same as thesecond locking pin 218. The third dilator tube has aninner lumen 219 with proximal and distal openings. A tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above. - With reference to
FIGS. 13-18 , the invention provides for a third presently preferred embodiment of adilation introducer 220, shown in a locked assembled configuration inFIG. 13 , and shown in an unlocked, collapsed configuration inFIG. 14 . As is illustrated inFIG. 15 , the dilation introducer includes a first orinner dilator tube 222 having adistal end 224 with a tapered,beveled tip 226, and aproximal end 228 with acylindrical head 230. The means for removably connecting the first and second dilator tubes together in a locked configuration includes a pair of opposing bayonet pins 232 extending from the proximal end of the first dilator tube. The first dilator tube has aninner lumen 234 with adistal opening 236 and aproximal opening 238. - As is shown in
FIG. 16 , the dilation introducer includes a shorter second orintermediate dilator tube 242 having adistal end 244 with a tapered,beveled tip 246, and aproximal end 248 with acylindrical head 250. In a preferred aspect, a means for removably connecting the second and third dilator tubes together in a locked configuration includes a pair of opposing bayonet pins 252. The second dilator tube has aninner lumen 254 with adistal opening 256 and aproximal opening 258, and as part of the means for removably connecting the second and third dilator tubes together, interior opposingbayonet slots 260 for receiving the pair of opposing bayonet pins of the first or inner dilator tube. - Referring to
FIG. 17 , in a preferred aspect, the dilation introducer includes at least one additional dilator tube, such as a still shorter third orouter dilator tube 262 having adistal end 264 with a taperedtip 266, and aproximal end 268 having a pair of opposing handles 270. The third dilator tube has aninner lumen 271, with proximal and distal openings. In another presently preferred aspect, aplastic sleeve 272 is slidably disposed over the shaft of the third or outer dilator tube, and the plastic sleeve preferably has a distal tapered,beveled end 274. Aproximal sleeve ring 276 may also be slidably disposed over the shaft of the third or outer dilator tube between theplastic sleeve 272 and the opposing handles. - As is illustrated in
FIGS. 13 and 14 , in this embodiment the tapered tips of the dilator tubes and plastic sleeve are beveled or angled at a common angle with respect to the longitudinal axis of the dilation introducer, so that the beveled edges of the tapered tips of the dilator tubes and plastic sleeve can be aligned together generally parallel to the surface of the soft tissue to be dilated, so that the bore and dilation passage of the dilation introducer may be aligned at a predetermined desired angle with respect to the soft tissue to be dilated and the bone tissue to be treated. - As part of the means for removably connecting the second and third dilator tubes together, the third dilator tube includes interior opposing
bayonet slots 278 for receiving the pair of opposing bayonet pins of the second or intermediate dilator tube. A tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above. - With reference to
FIGS. 19-23 , the invention provides for a fourth embodiment of adilation introducer 280 shown in a locked assembled configuration inFIG. 19 , and shown in an unlocked, collapsed configuration inFIG. 20 . Referring toFIG. 21 , the dilation introducer includes a first orinner dilator tube 282 having adistal end 284 with a taperedtip 286, and aproximal end 288 having a generally spherical handle orhead 290. As part of a means for removably connecting first and second dilator tubes together in a locked configuration, the proximal end of the first dilator tube near the handle includes abayonet pin 292. The first dilator tube has aninner lumen 294 with adistal opening 296, and aproximal opening 298. - Referring to
FIG. 22 , the dilation introducer includes a shorter second orintermediate dilator tube 302 having adistal end 304 with a taperedtip 306, and aproximal end 308 having a generallycylindrical head 310 and a pair of opposing handles 312. The second dilator tube has aninner lumen 314 with adistal opening 316 and aproximal opening 318. As part of the means for removably connecting first and second dilator tubes together in a locked configuration, the proximal end of the second dilator tube includes abayonet slot 320 formed in the cylindrical head for receiving the bayonet pin of the first or inner dilator tube. - Referring to
FIG. 23 , in a preferred aspect, the dilation introducer includes at least one additional dilator tube, such as a still shorter third orouter dilator tube 322, currently preferably formed of plastic, having adistal end 324 with a taperedtip 326, and aproximal end 328 with a generally cylindrical head end or handle 330. The third dilator tube has aninner lumen 332, with proximal and distal openings. A tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above. - Facet Screw Surgical Technique:
- Referring to
FIGS. 24-26 , a surgical method for spinal fusion utilizing the dilation introducer apparatus and a bone fixation device such as a bone fixation device available under the trade name BONE-LOK from Triage Medical, Inc. of Irvine, Calif., is described. Alternatively, other types of bone screws or fixation devices may also be suitable. The method of the invention involves dilating a patient's soft tissue down to bone tissue to be treated in orthopedic surgery, and necessarily entails an incision and fluoroscopy to locate an entry point on the bone tissue to be treated. - An entry point is located on the bone tissue to be treated, and the tip of a guide wire or K-
wire 151 is placed at the entry point on the bone tissue to be treated shown inFIG. 25 , and driven into the soft tissue of the patient to the target point of the inferior articular facet. A vertical midline incision to a desired depth, such as approximately 17 mm, is made in the skin and fascia of the patient, using the entry point as the middle of the incision. A first dilator tube of the dilation introducer is then passed over the guide wire until the tip of the dilation introducer reaches the target point of the bone. The guide wire is then driven into the facet joint and into the pedicle of the patient, with verification of the trajectory and depth by fluoroscopy. The second dilator tube of the dilation introducer is then released and passed over the first dilator tube to allow it to progress to the bone, allowing removal of the first dilator tube. This is repeated for the remaining, progressively wider telescoping dilator tubes, to progressively expand the patient's soft tissue down to the entry point on the bone tissue to be treated, and leaving an outer dilator tube port in place. A depth gauge is then used to verify that the appropriate depth has been reached. A pre-drill is advanced to the desired location, which is then also verified by fluoroscopy. A cortex drill is advanced until its positive stop engages, and the distal tip of a tap is driven into the bone until it reaches the appropriate depth, which is then also verified by fluoroscopy. The drill can be connected through an AO style quick connect, or a Jacobs chuck, as long as they are fully cannulated, to a ratcheting handle which is also preferably cannulated. A bone fixation device is then driven into the bone until it reaches the appropriate depth, which is then also verified by fluoroscopy. The bone fixation device is compressed to achieve appropriate stabilization, which is then also verified by fluoroscopy. Once compression of the bone fixation device has been achieved, the pull pin is removed, the guide wire is removed, and the remaining outer dilator tube port is removed, and the incision can be closed normally. - Referring to
FIGS. 27-29 , in one presently preferred embodiment, a guide wire orK wire assembly 340 for use with the telescoping dilation introducer of the invention includes an elongated, generally cylindricalfirst section 342 and an elongated, tubularsecond section 344 that is adapted to receive the first section. The first section includes a proximal enlarged head or stopportion 346, and a relatively narrowelongated body portion 348. The elongated body portion is preferably formed with aproximal section 350 having a relatively larger diameter to provide relatively greater strength, rigidity and torquability for manipulation of the guide wire, and a relatively narrower diametermain section 352 connected to the proximal section, and a pointeddistal tip 354 at thedistal end 358 of the main section. The elongated tubular second section has a relatively larger diameter than the main section and an internal bore slightly larger in diameter than the main section for receiving the main section, as is illustrated inFIG. 28 . The tubular second section advantageously also includes a frustoconicaldistal tip 362 with a narrowedportion 364 at thedistal end 366 of the tubular distal section, and presenting an enlargedflat shoulder 368 at the proximal end of the frustoconical distal tip, so that when the guide wire assembly is assembled as shown inFIG. 29 , and the elongated main section is received in the internal bore of the elongated tubular section, and the proximal section of the elongated body portion of the elongated generally cylindrical section is seated against said proximal end of said elongated tubular section, the pointed distal tip extends out of said frustoconical distal tip of said elongated tubular section so that the assembly presents a pointed distal end, with a proximal shoulder against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer. The elongated generally cylindrical first section thus adds a sharp point to the relatively blunt distal end of the elongated tubular second section, allowing the guide wire assembly to be inserted through soft tissue for placement in a soft tissue target of interest, such as an organ. Since the soft tissue present no hard surface against which the telescoping dilation introducer can be pushed, after the sharp point of the guide wire is placed in the desired location in the soft tissue, the first section can be removed from the second section, leaving the blunt distal end in place at the desired location in the soft tissue, and the telescoping dilation introducer can be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer. - As is shown in
FIG. 30 , in one presently preferred variation of the at least one additional or outer dilator tube, such as in the embodiment ofFIGS. 8-12 for example, theouter dilator tube 400 includes aparallel guide insert 402, shown inFIG. 31 . The outer dilator tube has adistal end 404 with a taperedtip 406, and aproximal portion 408 to which ahandle 410 is connected at the extreme proximal orhead end 412 of the outer dilator tube. The head end of the outer dilator tube includes aradial aperture 414 for receiving thelocking pin 416, and alongitudinal aperture 418 for receiving a distally projecting latchingmember 420 of thecylindrical head 422 of the parallel guide insert. The outer dilator tube has aninner bore 424 with proximal and distal openings. - The parallel guide insert includes a main
cylindrical shaft 425 connected at aproximal end 426 to the cylindrical head of the parallel guide insert. The parallel guide insert includes a plurality oflongitudinal bores 428 extending the length of the parallel guide insert from the distal end 430, with distal openings visible inFIG. 31 , to proximal openings (not shown) in the cylindrical head of the parallel guide insert. The insertion of the distally projecting latching member of the cylindrical head of the parallel guide insert in the longitudinal aperture of the head end of the handle of the outer dilator tube insures that the parallel guide insert remains in a fixed position in the outer dilator tube when the parallel guide insert is secured with the locking pin. A single guide wire or K wire or other device may be passed through one or more of the bores of the parallel guide insert, or multiple guide wires or K wires or other devices may be passed through a plurality of the bores simultaneously, as desired. However, the parallel guide insert may be provided without a latching member, in order to allow the parallel guide member to be rotated freely to allow alignment of the desired locations of the guide wires through the holes in the parallel guide insert. - Referring to
FIG. 32 , in another presently preferred variation of the at least one additional or outer dilator tube, such as in the embodiment ofFIGS. 13-18 for example, theouter dilator tube 440 includes aparallel guide insert 442, shown inFIG. 33 . The outer dilator tube has adistal end 444 with anangled tip 446, and aproximal end 448 to which ahandle 450 is connected at the extreme proximal orhead end 452 of the outer dilator tube. The head end of the outer dilator tube includes aradial aperture 454 for receiving thelocking pin 456, and alongitudinal aperture 458 for receiving a distally projecting latchingmember 460 of thecylindrical head 462 of the parallel guide insert. The outer dilator tube has aninner bore 464 with proximal and distal openings. - The parallel guide insert includes a main
cylindrical shaft 465 connected at aproximal end 466 to the cylindrical head of the parallel guide insert. The parallel guide insert includes a plurality oflongitudinal bores 468 extending the length of the parallel guide insert from the angleddistal end 470, with distal openings visible inFIG. 33 , to proximal openings (not shown) in the cylindrical head of the parallel guide insert. The insertion of the distally projecting latching member of the cylindrical head of the parallel guide insert in the longitudinal aperture of the head end of the handle of the outer dilator tube insures that the parallel guide insert remains in a fixed position in the outer dilator tube when the parallel guide insert is secured with the locking pin. The angled tips of the outer dilator tube and the parallel guide insert are beveled or angled at a common angle with respect to the longitudinal axis of the dilation introducer, so that the angled tips of the outer dilator tube and the parallel guide insert can be aligned together generally parallel to the surface of the soft tissue to be dilated, with the bore and dilation passage of the dilation introducer aligned at a predetermined desired angle with respect to the soft tissue to be dilated and the bone tissue to be treated. A single guide wire or K wire or other device may be passed through one or more of the bores of the parallel guide insert, or multiple guide wires or K wires or other devices may be passed through a plurality of the bores simultaneously, as desired. - Referring to
FIG. 34 , in a variation of the outer dilator tube of the embodiment ofFIGS. 32-33 , thedistal tip 480 of anouter dilator tube 482 may be angled or beveled, and may include a plurality ofspikes 484 to provide for increased traction of the tip of the outer dilator tube on bone tissue. The spikes may be formed of radiopaque material, such as gold, platinum, tantalum or the like, for use with fluoroscopy. As is illustrated inFIG. 35 , aparallel guide 486 disposed in the outer dilator tube has a distal tip 488 that may optionally also be provided with a plurality of embeddedspikes 490 for increased traction on bone tissue. The spikes of the outer dilator tube and parallel guide may formed with a rounded shape so as to deflect soft tissue during dilation, and to provide increased traction with bone upon completion of the insertion of the dilator. - Referring to
FIGS. 36-43 , the invention provides for a fifth presently preferred embodiment of adilation introducer 500, which is similar to the embodiment illustrated inFIGS. 8-12 , and which is shown in an unlocked configuration inFIG. 36 . Referring toFIGS. 36-37 , the dilation introducer includes a first orinner dilator tube 502 having distal end (not shown) and aproximal end 504 with acylindrical head 506. The means for removably connecting the first and second dilator tubes together in a locked configuration includes afirst latching member 508, having ashaft 510 and alatching end 512, such as a hook, projecting from the cylindrical head toward the distal end, and connected to alocking button 514, which extends transversely out through aside aperture 516 in the cylindrical head. The locking button includes ashaft 518 and anenlarged head 520 connected to the shaft, and the locking button is biased outwardly from the cylindrical head by aspring 522. The latching member is received in anupper aperture 524 of the adjacent cylindrical head of a second orintermediate dilator tube 526, having a sideopening latching chamber 528 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the first and second dilator tubes together. The cylindrical heads of the first and second dilator tubes can be unlocked and separated by manually depressing the locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber. In all other aspects, the first dilator tube is essentially the same as the first dilator tube of the embodiment ofFIGS. 8-12 . - The second or
intermediate dilator tube 526 of the dilation introducer has a distal end (not shown) and aproximal end 530 with acylindrical head 532. The means for removably connecting the second and third dilator tubes together in a locked configuration includes asecond latching member 534, having ashaft 536 and alatching end 538, such as a hook, projecting from the cylindrical head toward the distal end, and connected to asecond locking button 540, which extends transversely out through aside aperture 542 in the cylindrical head. The locking button includes ashaft 544 and anenlarged head 546 connected to the shaft, and the locking button is biased outwardly from the cylindrical head by aspring 548. The latching member is received in anupper aperture 550 of the adjacent cylindrical head of a third or secondintermediate dilator tube 552, having a sideopening latching chamber 554 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the second and third dilator tubes together. The cylindrical heads of the second and third dilator tubes can be unlocked and separated by manually depressing the second locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber. In all other aspects, the second dilator tube is essentially the same as the second dilator tube of the embodiment ofFIGS. 8-12 . - The third, or second intermediate,
dilator tube 552 of the dilation introducer has a distal end (not shown) and aproximal end 556 with acylindrical head 558. The means for removably connecting the third dilator tube and theouter dilator tube 560 together in a locked configuration includes athird latching member 562, having ashaft 564 and alatching end 566, such as a hook, projecting from the cylindrical head toward the distal end, and connected to athird locking button 568, which extends transversely out through a side aperture 570 in the cylindrical head. The third locking button includes ashaft 572 and anenlarged head 574 connected to the shaft, and the third locking button is biased outwardly from the cylindrical head by aspring 576. The latching member is received in anupper aperture 578 of the adjacentcylindrical head 580 of the outer dilator tube, having a sideopening latching chamber 582 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the third and outer dilator tubes together. The cylindrical heads of the third and outer dilator tubes can be unlocked and separated by manually depressing the third locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber. In all other aspects, the third dilator tube is essentially the same as the second dilator tube of the embodiment ofFIGS. 8-12 . - Referring to
FIG. 36 , the outer dilator tube includes a distal end (not shown) and aproximal end 584 to which ahandle 586 is connected at its cylindrical head end. The head end of the handle preferably includes a plurality of theupper apertures 578 connected to corresponding sideopening latching apertures 582 for receiving the latching member of the adjacent dilator tube cylindrical head, as is illustrated inFIG. 40 . Although three lockinglocations 588 of the upper apertures and corresponding side opening latching apertures in the cylindrical head of the outer dilator tube are shown, more or fewer locking locations may be provided, and the locking locations may be provided at various positions, to aid in user flexibility as to which hand to use during the dilation procedure, as well as varying the position of the inner dilator tubes and optionally a parallel guide member during use or guide pin placement. In all other aspects, the outer dilator tube is essentially the same as the outer dilator tube of the embodiment ofFIGS. 8-12 . - Referring to
FIGS. 38 and 39 , in a variation of the embodiment shown inFIGS. 36 and 37 , the side opening latching chambers of the cylindrical heads of the dilator tubes may be closed so as to form covered latching chambers 590 a, b, c for the latching members. In all other aspects, the variation shown inFIGS. 38 and 39 is essentially the same as inFIGS. 36 and 37 . - Referring to
FIGS. 41-43 , in another variation, anouter dilation tube 600 may be provided with alight emitter 602, such as one or more light emitting diodes (LEDs) or the end of a fiber optic, connected to or embedded in thetubular shaft 604 of the outer dilation tube, and preferably near thedistal end 606 of the tubular shaft. As is illustrated inFIGS. 41 and 42 , the light emitter may be an LED embedded in thewall 608 of the tubular shaft, with the LED directed to illuminate the interior, exterior, or distal edge of the tubular shaft of the outer dilation tube. As is shown inFIG. 42 , one or more elongatedenergy conducting members 610, such as electrically conductive wires or fiber optics, for example, may be embedded in the tubular shaft, for conducting electricity or light to the light emitter. Referring toFIG. 41 , thehandle 612 of the outer dilator tube preferably contains one ormore batteries 614 connected to aswitch 616 which is in turn connected to power the light emitter. The handle may be provided with a battery or batteries, which may be disposable, a switch, resistor and other associated electronics, so that the handle is disposable, or alternatively the handle may be provided with a connector for connection to an external power source. In a presently preferred aspect, the switch is a thumb switch conveniently located on the handle adjacent to thecylindrical head 618 of the outer dilation tube. The handle, cylindrical head, and tubular shaft of the outer dilation tube preferably includes one ormore channels 620 for the electrical wires connecting the one or more batteries to the switch and to the light emitter. When the light emitter includes one or more fiber optics, alight source 622 such as one or more LEDs providing light to be conducted through the one or more fiber optics may be placed adjacent to the switch in the handle, with the one or more fiber optics extending through the wall of the tubular shaft of the outer dilator tube. - Referring to
FIG. 43 , in another variation of the dilation introducer ofFIG. 41 , the one or more elongated energy conducting members, such as one or more wires or one or more fiber optics, may be disposed on the outer surface of the tubular shaft of the outer dilation tube. In a presently preferred aspect, the tubular shaft of the outer dilation tube may be formed with agroove 620 running longitudinally on the exterior surface of the tubular shaft, parallel to the longitudinal axis of the outer dilation tube, to accommodate one or more wires or one or more fiber optics. Alternatively, the one or more elongated energy conducting members may be located on the inside of the dilator tube, or may extend through the wall of the dilator tube. - Referring to
FIGS. 44-46 , the present invention also provides for atelescoping expander sleeve 630 that is adapted to be slidably disposed over the shaft of an outer dilator tube of any of the foregoing embodiments for expanding the patient's soft tissue down to the entry point on the bone tissue to be treated, while leaving the outer dilator tube in place, or allowing for replacement of the outer dilator tube with other equipment for treatment of the bone tissue. The tubular proximal portion may optionally be provided with a handle. The expander sleeve may be pre-assembled in combination with one or more of the dilation introducers, adapted to be ready for use. The telescoping expander sleeve has a first or inner generallytubular section 632, having a tubularproximal portion 634 with an enlargedproximal head 636, and adistal portion 638 with at least two substantially identical opposing active spreader arms 640 (one of which is not visible inFIGS. 44-46 ) connected at one end to the tubular proximal portion and moveable radially at theirdistal tips 642. The distal tips of the active spreader arms preferably have bevelededges 644 to deflect soft tissue during insertion of the telescoping expander sleeve. - A second or outer generally
tubular section 646 is slidably disposed over the first or inner generally tubular section, and includes a tubularproximal portion 648 and adistal portion 650 with at least two substantial identical opposing passive spreader flaps 652 interposed between the active spreader arms, hingedly connected to the tubular proximal portion at proximal ends 654, and moveable radially at theirdistal tips 656. The distal tips of the passive spreader flaps preferably also have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve. The distal tips of the passive spreader flaps when placed together in an unexpanded configuration have a generally circular configuration, so that the distal tips of two passive spreader flaps, for example, have a semi-circular configuration. The passive spreader flaps taper progressively toward their narrowed proximal ends connected to the tubular proximal portion of the outer tubular section. In a presently preferred aspect, the passive spreader flaps are connected to the tubular proximal portion of the outer generally tubular section byrings 656 passing throughapertures - The active spreader arms are slidably interposed between and engage the passive spreader flaps, so that as the telescoping expander sleeve telescopes from an extended, unexpanded configuration to a collapsed, expanded configuration, as shown in
FIG. 44 , the active spreader arms slide from the narrow proximal ends of the passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of the passive spreader flaps apart, which also forces the distal ends of the active spreader arms apart, as shown inFIG. 46 . In a presently preferred aspect, the distal ends of the active spreader arms are slidably connected toslots 662 extending along theinner edges 664 of the passive spreader flaps by loops or rings 666, such as loops of nylon filament or metal rings, for example, which pass throughapertures 668 in the distal ends of the active spreader arms. Telescoping of expander sleeve from a collapsed, expanded configuration to an extended, unexpanded configuration thus slides the distal ends of the active spreader arms of the inner tubular section from the wide distal ends of the passive spreader flaps along the inner edges of the passive spreader flaps to the narrowed proximal ends of the passive spreader flaps, to bring the passive spreader flaps together. The purpose of the active spreader arms and passive spreader flaps is to facilitate the creating of a larger working area adjacent to bone or bone tissues being treated. The spreader arms and flaps may optionally be covered by an expandable material, such as latex, for example, with a central through hole permitting operation of the device, to cover the spreader arms and flaps to prevent tissues from being pressed into cavities of the telescoping expander sleeve. - In the foregoing embodiments, the components of the dilation introducer may be formed from plastic, stainless steel, or similar materials or combinations thereof, that can be readily sterilized and packaged ready for use, after which the dilation introducer may be disposed of or resterilized for subsequent use, as desired. The dilator tubes may be radioluscent, with radiopaque markers located on the tips of one or more of the dilator tubes. The tip of the first dilator may also be scored, grooved, or otherwise be provided with a rough surface, to prevent migration. The dilation introducer may also have curved or otherwise non-linear dilator tubes, and the dilation introducer may also have a non-cylindrical shape, such as an oval shape, for example, to allow the dilation introducer to be inserted around objects or a patient's organs.
- It should also be appreciated that one or more devices can be inserted through the same dilation introducer, and that the dilation introducer can be repositioned within the same incision for fixation of multiple devices. In addition, fiber optic devices may be inserted through or integrated with the dilation introducer for visual inspection of the target area. While particular locking features have been described for the different embodiments of the dilation introducer, any combination of locking features or alternate locking features may be utilized. The outer dilator tube may not be locked, and a handle on the outer dilator tube may simply be used as a stop. It should also be appreciated that while the invention has been described as being used in the context of orthopedic surgery, and more particularly for implantation of bone fixation devices, the dilation introducer of the invention can also be useful in dilation of soft tissue for percutaneous, minimally invasive surgical procedures such as nephrostomy, neurosurgery, heart valve repair or replacement, gastrointestinal surgery such as for gall bladder or gall stone surgery, hernia removal, transjugular intrahepatic portal-systemic shunt (TIPS) procedures for treatment of the liver, and the like.
- It will be apparent from the foregoing that, while particular forms of the invention have been illustrated and described, various modifications can be made without departing from the spirit and scope of the invention. Accordingly, it is not intended that the invention be limited, except as by the appended claims.
Claims (23)
1. In a dilation introducer for surgery on an internal body structure, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue to be treated, the improvement in the dilation introducer comprising:
at least one dilator tube having a distal end and a proximal end, the distal end of the at least one dilator tube including a plurality of spikes.
2. The dilation introducer of claim 1 , wherein said spikes are formed of radiopaque material.
3. The dilation introducer of claim 1 , wherein said spikes are formed are formed with a rounded shape so as to deflect soft tissue.
4. The dilation introducer of claim 1 , further comprising a parallel guide insert adapted to be received in said at least one additional dilator tube, said parallel guide insert including a main cylindrical shaft having a proximal end connected to a cylindrical head, and a plurality of longitudinal bores extending the length of the parallel guide insert through the main cylindrical shaft and cylindrical head, and wherein parallel guide insert has a distal tip with a plurality of spikes.
5. The dilation introducer of claim 4 , wherein said spikes are formed of radiopaque material.
6. The dilation introducer of claim 4 , wherein said spikes are formed are formed with a rounded shape so as to deflect soft tissue.
7. A dilation introducer for surgery on an internal structure to be treated, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue to be treated, comprising:
a first dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head;
a second dilator tube, the first dilator tube being removably received in the second dilator tube for slidable telescoping movement within the second dilator tube, the second dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and an inner lumen with a distal opening and a proximal opening; and
means for removably connecting the first and second dilator tubes together in a locked configuration including a first latching member disposed in the cylindrical head of the first dilator tube, the first latching member having locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the first dilator tube toward the distal end of the first dilator tube, the locking button extending transversely from the shaft through a side aperture in the cylindrical head of the first dilator tube, the locking button being biased outwardly from the cylindrical head, the first latching member being received in an upper aperture of the cylindrical head of the second dilator tube, the upper aperture of the cylindrical head of the second dilator tube having a latching chamber for retaining the latching end of the latching member when the locking button is biased outwardly, to lock the cylindrical heads of the first and second dilator tubes together, the locking button being moveable inwardly to move the latching member inwardly and the latching end of the latching member inwardly out of the latching chamber.
8. The dilation introducer of claim 7 , further comprising at least one additional dilator tube, the second dilator tube being removably received in the at least one additional dilator tube for slidable telescoping movement within the at least one additional dilator tube, the at least one additional dilator tube having a distal end and a proximal end with a cylindrical head, an inner lumen with a distal opening and a proximal opening, the distal end having a tapered tip, the second dilator tube and the at least one additional dilator tube having an unlocked configuration in which the at least one additional dilator tube is permitted to slidably telescope over the second dilator tube to dilate the patient's soft tissue at the distal end of the dilation introducer; and
means for removably connecting the second dilator tube and the at least one additional dilator tube together in a locked configuration including a second latching member disposed in the cylindrical head of the second dilator tube, the second latching member having locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the second dilator tube toward the distal end of the second dilator tube, the locking button extending transversely from the shaft through a side aperture in the cylindrical head of the second dilator tube, the locking button being biased outwardly from the cylindrical head, the second latching member being received in an upper aperture of the cylindrical head of the at least one additional dilator tube, the upper aperture of the cylindrical head of the at least one additional dilator tube having a latching chamber for retaining the latching end of the second latching member when the locking button is biased outwardly, to lock the cylindrical heads of the second and at least one additional dilator tubes together, the locking button being moveable inwardly to move the second latching member inwardly and the latching end of the second latching member inwardly out of the latching chamber.
9. The dilation introducer of claim 8 , wherein said at least one additional dilator tube comprises a handle connected to the proximal end of said at least one additional dilator tube, and the cylindrical head of said at least one additional dilator tube including a plurality of said upper apertures each including one said latching chamber for receiving the second latching member.
10. In a dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue to be treated, the improvement in the dilation introducer comprising:
at least one dilator tube having a tubular shaft, a distal end and a proximal end, an inner lumen with a distal opening and a proximal opening; and
a light emitter disposed in said at least one additional dilator tube.
11. The dilation introducer of claim 10 , wherein said light emitter comprises a light emitting diode.
12. The dilation introducer of claim 11 , wherein said light emitting diode is embedded in said tubular shaft of said at least one dilator tube.
13. The dilation introducer of claim 10 , wherein said light emitter comprises a fiber optic.
14. The dilation introducer of claim 13 , wherein said fiber optic is embedded in said tubular shaft of said at least one dilator tube.
15. The dilation introducer of claim 10 , wherein said at least one dilator tube comprises a handle and a switch for controlling said light emitter, and at least one battery is disposed in said handle, said at least one battery being connected to said switch to power said light emitter.
16. The dilation introducer of claim 13 , wherein said light emitter further comprises a light source providing light conducted to said at least one fiber optic.
17. The dilation introducer of claim 10 , wherein said light emitter comprises at least one elongated energy conducting member disposed on an outer surface of the tubular shaft of said at least one dilator tube.
18. The dilation introducer of claim 17 , wherein said at least one elongated energy conducting member is disposed in a groove on the exterior surface of the tubular shaft.
19. A telescoping expander sleeve adapted to be slidably disposed over a shaft of a dilator tube for dilating a patient's soft tissue down to tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue to be treated, the telescoping expander sleeve being moveable between an extended, unexpanded configuration and a collapsed, expanded configuration, the telescoping expander sleeve comprising:
a first generally tubular section having a tubular proximal portion and a distal portion, the tubular proximal portion having an enlarged proximal head, and the distal portion including at least two active spreader arms each having a proximal end and a distal tip, said at least two active spreader arms being connected at the proximal end, respectively, to the tubular proximal portion, said distal tips of said at least two active spreader arms being moveable radially between an unexpanded configuration and an expanded configuration;
a second generally tubular section slidably disposed over the first generally tubular section, said second generally tubular section including a tubular proximal portion and a distal portion including at least two passive spreader flaps each having a narrow proximal end and a wide distal tip, said proximal ends of said at least two passive spreader flaps being hingedly connected to said tubular proximal portion, said distal tips of said at least two passive spreader flaps being moveable radially between an unexpanded configuration and an expanded configuration, said at least two active spreader arms slidably engaging said at least two passive spreader flaps, so that as the telescoping expander sleeve telescopes from the extended, unexpanded configuration to a collapsed, expanded configuration, said at least two active spreader arms slide from the narrow proximal ends of said at least two passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of said at least two passive spreader flaps apart and to spread the distal ends of said at least two active spreader arms apart.
20. The telescoping expander sleeve of claim 19 , wherein the distal tips of said at least two active spreader arms have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve.
21. The telescoping expander sleeve of claim 19 , wherein the distal tips of said at least two passive spreader flaps have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve.
22. A guide wire assembly for use with a telescoping dilation introducer in treatment of soft tissue, to provide a surface against which the telescoping dilation introducer can be pushed during operation of the telescoping dilation introducer, comprising:
an elongated tubular section having a proximal end, a distal end, an internal bore, and a frustoconical distal tip with a narrowed portion at the distal end and an enlarged flat shoulder at a proximal portion of the frustoconical distal tip; and
an elongated generally cylindrical section removably received in said internal bore of said elongated tubular section, the elongated generally cylindrical section having a proximal enlarged head and an elongated body portion, said elongated body portion having a proximal end and a distal end, said distal end having a pointed distal tip, such that when said elongated generally cylindrical section is received in said elongated tubular section, said pointed distal tip extends out of the distal end of said frustoconical distal tip to present a sharp point that can be positioned in soft tissue, and such that when said elongated generally cylindrical section is thereafter removed, said enlarged flat shoulder of said frustoconical distal tip provides a surface against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer in treatment of soft tissue.
23. The guide wire assembly of claim 22 , wherein said elongated body portion of said elongated generally cylindrical section includes a proximal section adjacent to said proximal enlarged head and an elongated main section connected to the proximal section, said proximal section having a diameter larger than an outer diameter of said elongated tubular section, and said elongated main section having a diameter narrower than the diameter of said internal bore of said elongated tubular section so as to be receivable in said internal bore of said elongated tubular section, such that when said elongated main section is received in said internal bore of said elongated tubular section and said proximal section of the elongated body portion of the elongated generally cylindrical section is seated against said proximal end of said elongated tubular section, said pointed distal tip extends out of said frustoconical distal tip of said elongated tubular section so that said guide wire assembly presents a pointed distal end.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/659,025 US9387313B2 (en) | 2004-08-03 | 2005-08-02 | Telescopic percutaneous tissue dilation systems and related methods |
EP05777628.8A EP1773438B1 (en) | 2004-08-03 | 2005-08-02 | Telescopic percutaneous tissue dilation systems |
PCT/US2005/027431 WO2006017507A2 (en) | 2004-08-03 | 2005-08-02 | Telescopic percutaneous tissue dilation systems and related methods |
EP16207090.8A EP3205371B1 (en) | 2004-08-03 | 2005-08-02 | Telescopic percutaneous tissue dilation systems and related methods of producing |
JP2007524917A JP5164571B2 (en) | 2004-08-03 | 2005-08-02 | Percutaneous tissue expansion system and related methods |
US15/186,963 US10293147B2 (en) | 2004-08-03 | 2016-06-20 | Telescopic percutaneous tissue dilation systems and related methods |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42613702P | 2002-11-14 | 2002-11-14 | |
US50205003P | 2003-09-10 | 2003-09-10 | |
US10/714,333 US8090542B2 (en) | 2002-11-14 | 2003-11-14 | Functional and hyperfunctional siRNA |
US11/083,784 US7820809B2 (en) | 2002-11-14 | 2005-03-18 | Functional and hyperfunctional siRNA directed against Bcl-2 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/714,333 Continuation US8090542B2 (en) | 2002-11-14 | 2003-11-14 | Functional and hyperfunctional siRNA |
US10/911,215 Continuation-In-Part US20060030872A1 (en) | 2004-08-03 | 2004-08-03 | Dilation introducer for orthopedic surgery |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/911,215 Continuation-In-Part US20060030872A1 (en) | 2004-08-03 | 2004-08-03 | Dilation introducer for orthopedic surgery |
US11/659,025 Continuation-In-Part US9387313B2 (en) | 2004-08-03 | 2005-08-02 | Telescopic percutaneous tissue dilation systems and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050256525A1 true US20050256525A1 (en) | 2005-11-17 |
Family
ID=32329096
Family Applications (52)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/714,333 Expired - Fee Related US8090542B2 (en) | 2002-11-14 | 2003-11-14 | Functional and hyperfunctional siRNA |
US10/940,892 Abandoned US20120052487A9 (en) | 2002-11-14 | 2004-09-14 | Methods and compositions for selecting sirna of improved functionality |
US11/038,784 Abandoned US20050256525A1 (en) | 2002-11-14 | 2005-01-19 | Dilation introducer for orthopedic surgery |
US11/083,784 Expired - Fee Related US7820809B2 (en) | 2002-11-14 | 2005-03-18 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/093,832 Abandoned US20070039072A1 (en) | 2002-11-14 | 2005-03-29 | Functional and hyperfunctional siRNA |
US11/095,383 Active 2027-05-09 US7834170B2 (en) | 2002-11-14 | 2005-03-30 | Functional and hyperfunctional siRNA |
US11/101,244 Active 2026-02-28 US7691997B2 (en) | 2002-11-14 | 2005-04-07 | Functional and hyperfunctional siRNA |
US11/633,342 Expired - Fee Related US7608707B2 (en) | 2002-11-14 | 2006-12-04 | siRNA targeting survivin |
US11/633,404 Abandoned US20070093653A1 (en) | 2002-11-14 | 2006-12-04 | siRNA targeting MCL1 |
US11/633,383 Expired - Lifetime US7645869B2 (en) | 2002-11-14 | 2006-12-04 | siRNA targeting spleen tyrosine kinase |
US11/633,306 Expired - Lifetime US7507811B2 (en) | 2002-11-14 | 2006-12-04 | siRNA targeting KRAS |
US11/635,330 Expired - Lifetime US7696344B2 (en) | 2002-11-14 | 2006-12-07 | siRNA targeting complement factor B |
US11/635,618 Expired - Fee Related US7579457B2 (en) | 2002-11-14 | 2006-12-07 | siRNA targeting carbonic anhydrase II |
US11/635,478 Abandoned US20070088155A1 (en) | 2002-11-14 | 2006-12-07 | siRNA targeting tumor necrosis factor superfamily member 1A |
US11/635,329 Expired - Fee Related US7674896B2 (en) | 2002-11-14 | 2006-12-07 | siRNA targeting BCL2L1 |
US11/880,628 Expired - Fee Related US7595389B2 (en) | 2002-11-14 | 2007-07-23 | siRNA targeting casitas B cell lymphoma-B (CBL-B) |
US11/880,855 Abandoned US20080300395A1 (en) | 2002-11-14 | 2007-07-24 | siRNA targeting vascular endothelial growth factor receptor 1 (VEGFR1) |
US11/880,755 Abandoned US20080293595A1 (en) | 2002-11-14 | 2007-07-24 | siRNA targeting protein tyrosine phosphatase-1B (PTP1B) |
US11/880,777 Abandoned US20080188648A1 (en) | 2002-11-14 | 2007-07-24 | siRNA targeting human hairless protein (HR) |
US11/880,775 Expired - Lifetime US7655788B2 (en) | 2002-11-14 | 2007-07-24 | siRNA targeting DNA-damage-inducible transcript 4 (DDIT4) |
US11/881,385 Abandoned US20080306015A1 (en) | 2002-11-14 | 2007-07-25 | siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) |
US11/881,386 Abandoned US20080221317A1 (en) | 2002-11-14 | 2007-07-25 | siRNA targeting cystic fibrosis transmembrane conductance regulator (CFTR) |
US11/903,001 Expired - Lifetime US7514550B2 (en) | 2002-11-14 | 2007-09-20 | siRNA targeting myeloid cell leukemia sequence 1 |
US11/974,610 Abandoned US20080091001A1 (en) | 2002-11-14 | 2007-10-15 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/974,865 Abandoned US20080091002A1 (en) | 2002-11-14 | 2007-10-16 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/974,885 Expired - Lifetime US7511132B2 (en) | 2002-11-14 | 2007-10-16 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/974,878 Abandoned US20080114162A1 (en) | 2002-11-14 | 2007-10-16 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/974,880 Abandoned US20080091003A1 (en) | 2002-11-14 | 2007-10-16 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/975,152 Expired - Fee Related US7795420B2 (en) | 2002-11-14 | 2007-10-17 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/975,331 Abandoned US20080091004A1 (en) | 2002-11-14 | 2007-10-18 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/975,661 Abandoned US20080108803A1 (en) | 2002-11-14 | 2007-10-19 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US12/157,137 Expired - Lifetime US7642349B2 (en) | 2002-11-14 | 2008-06-06 | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US12/287,757 Expired - Fee Related US7576196B2 (en) | 2002-11-14 | 2008-10-14 | siRNA targeting transducin (beta)-like 3 (TBL3) |
US12/330,981 Expired - Fee Related US7576197B2 (en) | 2002-11-14 | 2008-12-09 | SiRNA targeting KRAS |
US12/322,980 Abandoned US20090163701A1 (en) | 2002-11-14 | 2009-02-10 | siRNA targeting tumor necrosis factor receptor superfamily member 1A |
US12/378,164 Expired - Fee Related US7592444B2 (en) | 2002-11-14 | 2009-02-11 | siRNA targeting myeloid cell leukemia sequence 1 |
US12/384,768 Active 2024-05-21 US8030474B2 (en) | 2002-11-14 | 2009-04-08 | siRNA targeting cyclin-dependent kinase 4 (CDK4) |
US12/459,489 Abandoned US20090291497A1 (en) | 2002-11-14 | 2009-07-01 | siRNA targeting transducin (beta)-like 3 (TBL3) |
US12/459,670 Expired - Fee Related US7745611B2 (en) | 2002-11-14 | 2009-07-06 | siRNA targeting KRAS |
US12/463,000 Abandoned US20100004142A1 (en) | 2002-11-14 | 2009-08-12 | siRNA targeting myeloid cell Leukemia sequence 1 |
US12/584,705 Expired - Fee Related US7807819B2 (en) | 2002-11-14 | 2009-09-10 | siRNA targeting survivin |
US12/590,707 Expired - Lifetime US7803933B2 (en) | 2002-11-14 | 2009-11-12 | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US12/592,335 Expired - Lifetime US7893247B2 (en) | 2002-11-14 | 2009-11-23 | siRNA targeting spleen tyrosine kinase |
US12/657,263 Abandoned US20100152064A1 (en) | 2002-11-14 | 2010-01-15 | siRNA targeting BCL2L1 |
US12/799,844 Expired - Fee Related US8008474B2 (en) | 2002-11-14 | 2010-05-03 | siRNA targeting KRAS |
US12/802,647 Active US8000902B2 (en) | 2002-11-14 | 2010-06-11 | Methods and compositions for selecting siRNA of improved functionality |
US12/806,320 Expired - Lifetime US7985854B2 (en) | 2002-11-14 | 2010-08-10 | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US12/806,513 Abandoned US20100331214A1 (en) | 2002-11-14 | 2010-08-13 | siRNA Targeting Survivin |
US12/928,190 Expired - Fee Related US8093370B2 (en) | 2002-11-14 | 2010-12-06 | siRNA targeting spleen tyrosine kinase |
US13/199,001 Abandoned US20110319474A1 (en) | 2002-11-14 | 2011-08-17 | siRNA targeting cyclin-dependent kinase 4 (CDK4) |
US13/373,956 Abandoned US20120135892A1 (en) | 2002-11-14 | 2011-12-06 | siRNA targeting spleen tyrosine kinase |
US16/292,513 Abandoned US20190345573A1 (en) | 2002-11-14 | 2019-03-05 | Methods and Compositions for Selecting siRNA of Improved Functionality |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/714,333 Expired - Fee Related US8090542B2 (en) | 2002-11-14 | 2003-11-14 | Functional and hyperfunctional siRNA |
US10/940,892 Abandoned US20120052487A9 (en) | 2002-11-14 | 2004-09-14 | Methods and compositions for selecting sirna of improved functionality |
Family Applications After (49)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/083,784 Expired - Fee Related US7820809B2 (en) | 2002-11-14 | 2005-03-18 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/093,832 Abandoned US20070039072A1 (en) | 2002-11-14 | 2005-03-29 | Functional and hyperfunctional siRNA |
US11/095,383 Active 2027-05-09 US7834170B2 (en) | 2002-11-14 | 2005-03-30 | Functional and hyperfunctional siRNA |
US11/101,244 Active 2026-02-28 US7691997B2 (en) | 2002-11-14 | 2005-04-07 | Functional and hyperfunctional siRNA |
US11/633,342 Expired - Fee Related US7608707B2 (en) | 2002-11-14 | 2006-12-04 | siRNA targeting survivin |
US11/633,404 Abandoned US20070093653A1 (en) | 2002-11-14 | 2006-12-04 | siRNA targeting MCL1 |
US11/633,383 Expired - Lifetime US7645869B2 (en) | 2002-11-14 | 2006-12-04 | siRNA targeting spleen tyrosine kinase |
US11/633,306 Expired - Lifetime US7507811B2 (en) | 2002-11-14 | 2006-12-04 | siRNA targeting KRAS |
US11/635,330 Expired - Lifetime US7696344B2 (en) | 2002-11-14 | 2006-12-07 | siRNA targeting complement factor B |
US11/635,618 Expired - Fee Related US7579457B2 (en) | 2002-11-14 | 2006-12-07 | siRNA targeting carbonic anhydrase II |
US11/635,478 Abandoned US20070088155A1 (en) | 2002-11-14 | 2006-12-07 | siRNA targeting tumor necrosis factor superfamily member 1A |
US11/635,329 Expired - Fee Related US7674896B2 (en) | 2002-11-14 | 2006-12-07 | siRNA targeting BCL2L1 |
US11/880,628 Expired - Fee Related US7595389B2 (en) | 2002-11-14 | 2007-07-23 | siRNA targeting casitas B cell lymphoma-B (CBL-B) |
US11/880,855 Abandoned US20080300395A1 (en) | 2002-11-14 | 2007-07-24 | siRNA targeting vascular endothelial growth factor receptor 1 (VEGFR1) |
US11/880,755 Abandoned US20080293595A1 (en) | 2002-11-14 | 2007-07-24 | siRNA targeting protein tyrosine phosphatase-1B (PTP1B) |
US11/880,777 Abandoned US20080188648A1 (en) | 2002-11-14 | 2007-07-24 | siRNA targeting human hairless protein (HR) |
US11/880,775 Expired - Lifetime US7655788B2 (en) | 2002-11-14 | 2007-07-24 | siRNA targeting DNA-damage-inducible transcript 4 (DDIT4) |
US11/881,385 Abandoned US20080306015A1 (en) | 2002-11-14 | 2007-07-25 | siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) |
US11/881,386 Abandoned US20080221317A1 (en) | 2002-11-14 | 2007-07-25 | siRNA targeting cystic fibrosis transmembrane conductance regulator (CFTR) |
US11/903,001 Expired - Lifetime US7514550B2 (en) | 2002-11-14 | 2007-09-20 | siRNA targeting myeloid cell leukemia sequence 1 |
US11/974,610 Abandoned US20080091001A1 (en) | 2002-11-14 | 2007-10-15 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/974,865 Abandoned US20080091002A1 (en) | 2002-11-14 | 2007-10-16 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/974,885 Expired - Lifetime US7511132B2 (en) | 2002-11-14 | 2007-10-16 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/974,878 Abandoned US20080114162A1 (en) | 2002-11-14 | 2007-10-16 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/974,880 Abandoned US20080091003A1 (en) | 2002-11-14 | 2007-10-16 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/975,152 Expired - Fee Related US7795420B2 (en) | 2002-11-14 | 2007-10-17 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/975,331 Abandoned US20080091004A1 (en) | 2002-11-14 | 2007-10-18 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US11/975,661 Abandoned US20080108803A1 (en) | 2002-11-14 | 2007-10-19 | Functional and hyperfunctional siRNA directed against Bcl-2 |
US12/157,137 Expired - Lifetime US7642349B2 (en) | 2002-11-14 | 2008-06-06 | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US12/287,757 Expired - Fee Related US7576196B2 (en) | 2002-11-14 | 2008-10-14 | siRNA targeting transducin (beta)-like 3 (TBL3) |
US12/330,981 Expired - Fee Related US7576197B2 (en) | 2002-11-14 | 2008-12-09 | SiRNA targeting KRAS |
US12/322,980 Abandoned US20090163701A1 (en) | 2002-11-14 | 2009-02-10 | siRNA targeting tumor necrosis factor receptor superfamily member 1A |
US12/378,164 Expired - Fee Related US7592444B2 (en) | 2002-11-14 | 2009-02-11 | siRNA targeting myeloid cell leukemia sequence 1 |
US12/384,768 Active 2024-05-21 US8030474B2 (en) | 2002-11-14 | 2009-04-08 | siRNA targeting cyclin-dependent kinase 4 (CDK4) |
US12/459,489 Abandoned US20090291497A1 (en) | 2002-11-14 | 2009-07-01 | siRNA targeting transducin (beta)-like 3 (TBL3) |
US12/459,670 Expired - Fee Related US7745611B2 (en) | 2002-11-14 | 2009-07-06 | siRNA targeting KRAS |
US12/463,000 Abandoned US20100004142A1 (en) | 2002-11-14 | 2009-08-12 | siRNA targeting myeloid cell Leukemia sequence 1 |
US12/584,705 Expired - Fee Related US7807819B2 (en) | 2002-11-14 | 2009-09-10 | siRNA targeting survivin |
US12/590,707 Expired - Lifetime US7803933B2 (en) | 2002-11-14 | 2009-11-12 | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US12/592,335 Expired - Lifetime US7893247B2 (en) | 2002-11-14 | 2009-11-23 | siRNA targeting spleen tyrosine kinase |
US12/657,263 Abandoned US20100152064A1 (en) | 2002-11-14 | 2010-01-15 | siRNA targeting BCL2L1 |
US12/799,844 Expired - Fee Related US8008474B2 (en) | 2002-11-14 | 2010-05-03 | siRNA targeting KRAS |
US12/802,647 Active US8000902B2 (en) | 2002-11-14 | 2010-06-11 | Methods and compositions for selecting siRNA of improved functionality |
US12/806,320 Expired - Lifetime US7985854B2 (en) | 2002-11-14 | 2010-08-10 | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US12/806,513 Abandoned US20100331214A1 (en) | 2002-11-14 | 2010-08-13 | siRNA Targeting Survivin |
US12/928,190 Expired - Fee Related US8093370B2 (en) | 2002-11-14 | 2010-12-06 | siRNA targeting spleen tyrosine kinase |
US13/199,001 Abandoned US20110319474A1 (en) | 2002-11-14 | 2011-08-17 | siRNA targeting cyclin-dependent kinase 4 (CDK4) |
US13/373,956 Abandoned US20120135892A1 (en) | 2002-11-14 | 2011-12-06 | siRNA targeting spleen tyrosine kinase |
US16/292,513 Abandoned US20190345573A1 (en) | 2002-11-14 | 2019-03-05 | Methods and Compositions for Selecting siRNA of Improved Functionality |
Country Status (9)
Country | Link |
---|---|
US (52) | US8090542B2 (en) |
EP (7) | EP2284266B1 (en) |
JP (2) | JP2006507841A (en) |
AT (1) | ATE517992T1 (en) |
AU (1) | AU2003295600A1 (en) |
DK (1) | DK2284266T3 (en) |
ES (1) | ES2440284T3 (en) |
PT (1) | PT2284266E (en) |
WO (1) | WO2004045543A2 (en) |
Cited By (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060004398A1 (en) * | 2004-07-02 | 2006-01-05 | Binder Lawrence J Jr | Sequential dilator system |
US20060069384A1 (en) * | 2004-09-21 | 2006-03-30 | Daniel Wallaker | Instrument for use in a medical simulator |
US20070129747A1 (en) * | 2005-11-14 | 2007-06-07 | Scapa Flow, Llc | Medical dilator system or dilator device |
US20080097436A1 (en) * | 2006-04-21 | 2008-04-24 | Culbert Brad S | Method and apparatus for spinal fixation |
US20080294172A1 (en) * | 2007-05-23 | 2008-11-27 | Rainer Baumgart | Instrument set for minimally invasive preparation for bone nailing |
WO2009147527A2 (en) | 2008-05-26 | 2009-12-10 | Rudolf Morgernstern Lopez | Intervertebral implant and installation tool |
US20110004222A1 (en) * | 2009-04-07 | 2011-01-06 | Lutz Biedermann | Tool for Use with a Bone Anchor, in Particular for Spinal Surgery |
US20110144687A1 (en) * | 2009-12-10 | 2011-06-16 | Kleiner Jeffrey | Lateral Based Retractor System |
US8043343B2 (en) | 2007-06-28 | 2011-10-25 | Zimmer Spine, Inc. | Stabilization system and method |
US8109977B2 (en) | 2002-07-19 | 2012-02-07 | Interventional Spine, Inc. | Method and apparatus for spinal fixation |
US8221396B2 (en) | 2009-08-27 | 2012-07-17 | Silver Bullet Therapeutics, Inc. | Bone implants for the treatment of infection |
WO2012102842A1 (en) * | 2011-01-28 | 2012-08-02 | Laser Spine Surgical Center, LLC | Foraminoplasty device |
USD666292S1 (en) * | 2002-06-26 | 2012-08-28 | Nuvasive, Inc. | Dilator |
US8430813B2 (en) | 2006-05-26 | 2013-04-30 | Depuy Spine, Inc. | Illuminated surgical access system including a surgical access device and integrated light emitter |
US20140171946A1 (en) * | 2012-12-14 | 2014-06-19 | Warsaw Orthopedic, Inc. | Surgical instrument and method |
US8771323B2 (en) | 2010-11-12 | 2014-07-08 | Silver Bullet Therapeutics, Inc. | Bone implant and systems that controllably releases silver |
US8927004B1 (en) | 2014-06-11 | 2015-01-06 | Silver Bullet Therapeutics, Inc. | Bioabsorbable substrates and systems that controllably release antimicrobial metal ions |
US20150094610A1 (en) * | 2011-03-10 | 2015-04-02 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US20150112398A1 (en) * | 2011-03-10 | 2015-04-23 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US9114197B1 (en) | 2014-06-11 | 2015-08-25 | Silver Bullett Therapeutics, Inc. | Coatings for the controllable release of antimicrobial metal ions |
US9277928B2 (en) | 2013-03-11 | 2016-03-08 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US9387009B2 (en) | 2007-10-05 | 2016-07-12 | DePuy Synthes Products, Inc. | Dilation system and method of using the same |
US9452242B2 (en) | 2014-06-11 | 2016-09-27 | Silver Bullet Therapeutics, Inc. | Enhancement of antimicrobial silver, silver coatings, or silver platings |
US9522028B2 (en) | 2013-07-03 | 2016-12-20 | Interventional Spine, Inc. | Method and apparatus for sacroiliac joint fixation |
US9522070B2 (en) | 2013-03-07 | 2016-12-20 | Interventional Spine, Inc. | Intervertebral implant |
US20170000627A1 (en) * | 2015-06-30 | 2017-01-05 | Mark M Levy | Tool for intervertebral cage |
US9821094B2 (en) | 2014-06-11 | 2017-11-21 | Silver Bullet Therapeutics, Inc. | Coatings for the controllable release of antimicrobial metal ions |
US9839530B2 (en) | 2007-06-26 | 2017-12-12 | DePuy Synthes Products, Inc. | Highly lordosed fusion cage |
US9883951B2 (en) | 2012-08-30 | 2018-02-06 | Interventional Spine, Inc. | Artificial disc |
US9895236B2 (en) | 2010-06-24 | 2018-02-20 | DePuy Synthes Products, Inc. | Enhanced cage insertion assembly |
US9913727B2 (en) | 2015-07-02 | 2018-03-13 | Medos International Sarl | Expandable implant |
US9924979B2 (en) | 2014-09-09 | 2018-03-27 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US9931223B2 (en) | 2008-04-05 | 2018-04-03 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
US9980737B2 (en) | 2014-08-04 | 2018-05-29 | Medos International Sarl | Flexible transport auger |
US9993349B2 (en) | 2002-06-27 | 2018-06-12 | DePuy Synthes Products, Inc. | Intervertebral disc |
US9993353B2 (en) | 2013-03-14 | 2018-06-12 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10058433B2 (en) | 2012-07-26 | 2018-08-28 | DePuy Synthes Products, Inc. | Expandable implant |
US20180271574A1 (en) * | 2017-03-22 | 2018-09-27 | Benvenue Medical, Inc. | Minimal Impact Access System To Disc Space |
US10111712B2 (en) | 2014-09-09 | 2018-10-30 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US10265435B2 (en) | 2009-08-27 | 2019-04-23 | Silver Bullet Therapeutics, Inc. | Bone implant and systems and coatings for the controllable release of antimicrobial metal ions |
US10264959B2 (en) | 2014-09-09 | 2019-04-23 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US10299838B2 (en) | 2016-02-05 | 2019-05-28 | Medos International Sarl | Method and instruments for interbody fusion and posterior fixation through a single incision |
US10390963B2 (en) | 2006-12-07 | 2019-08-27 | DePuy Synthes Products, Inc. | Intervertebral implant |
US10398563B2 (en) | 2017-05-08 | 2019-09-03 | Medos International Sarl | Expandable cage |
US10433977B2 (en) | 2008-01-17 | 2019-10-08 | DePuy Synthes Products, Inc. | Expandable intervertebral implant and associated method of manufacturing the same |
US10500062B2 (en) | 2009-12-10 | 2019-12-10 | DePuy Synthes Products, Inc. | Bellows-like expandable interbody fusion cage |
US10537436B2 (en) | 2016-11-01 | 2020-01-21 | DePuy Synthes Products, Inc. | Curved expandable cage |
US10548741B2 (en) | 2010-06-29 | 2020-02-04 | DePuy Synthes Products, Inc. | Distractible intervertebral implant |
US10682130B2 (en) | 2015-09-04 | 2020-06-16 | Medos International Sarl | Surgical access port stabilization |
US10786264B2 (en) | 2015-03-31 | 2020-09-29 | Medos International Sarl | Percutaneous disc clearing device |
US10888433B2 (en) | 2016-12-14 | 2021-01-12 | DePuy Synthes Products, Inc. | Intervertebral implant inserter and related methods |
US10940016B2 (en) | 2017-07-05 | 2021-03-09 | Medos International Sarl | Expandable intervertebral fusion cage |
USRE48534E1 (en) | 2012-04-16 | 2021-04-27 | DePuy Synthes Products, Inc. | Detachable dilator blade |
US11013530B2 (en) | 2019-03-08 | 2021-05-25 | Medos International Sarl | Surface features for device retention |
US11045324B2 (en) | 2006-12-08 | 2021-06-29 | DePuy Synthes Products, Inc. | Method of implanting a curable implant material |
US11051862B2 (en) | 2001-11-03 | 2021-07-06 | DePuy Synthes Products, Inc. | Device for straightening and stabilizing the vertebral column |
US11129727B2 (en) | 2019-03-29 | 2021-09-28 | Medos International Sari | Inflatable non-distracting intervertebral implants and related methods |
US11134987B2 (en) | 2011-10-27 | 2021-10-05 | DePuy Synthes Products, Inc. | Method and devices for a sub-splenius/supra-levator scapulae surgical access technique |
US11219439B2 (en) | 2012-09-26 | 2022-01-11 | DePuy Synthes Products, Inc. | NIR/RED light for lateral neuroprotection |
US11224453B2 (en) | 2014-07-08 | 2022-01-18 | Spinal Elements, Inc. | Apparatus and methods for disrupting intervertebral disc tissue |
US11241252B2 (en) | 2019-03-22 | 2022-02-08 | Medos International Sarl | Skin foundation access portal |
US11344424B2 (en) | 2017-06-14 | 2022-05-31 | Medos International Sarl | Expandable intervertebral implant and related methods |
US11426290B2 (en) | 2015-03-06 | 2022-08-30 | DePuy Synthes Products, Inc. | Expandable intervertebral implant, system, kit and method |
US11426286B2 (en) | 2020-03-06 | 2022-08-30 | Eit Emerging Implant Technologies Gmbh | Expandable intervertebral implant |
US11439380B2 (en) | 2015-09-04 | 2022-09-13 | Medos International Sarl | Surgical instrument connectors and related methods |
US11446156B2 (en) | 2018-10-25 | 2022-09-20 | Medos International Sarl | Expandable intervertebral implant, inserter instrument, and related methods |
US11452607B2 (en) | 2010-10-11 | 2022-09-27 | DePuy Synthes Products, Inc. | Expandable interspinous process spacer implant |
US11471145B2 (en) | 2018-03-16 | 2022-10-18 | Spinal Elements, Inc. | Articulated instrumentation and methods of using the same |
US11510788B2 (en) | 2016-06-28 | 2022-11-29 | Eit Emerging Implant Technologies Gmbh | Expandable, angularly adjustable intervertebral cages |
US11559328B2 (en) | 2015-09-04 | 2023-01-24 | Medos International Sarl | Multi-shield spinal access system |
US11564811B2 (en) | 2015-02-06 | 2023-01-31 | Spinal Elements, Inc. | Graft material injector system and method |
US11583327B2 (en) | 2018-01-29 | 2023-02-21 | Spinal Elements, Inc. | Minimally invasive interbody fusion |
US11596522B2 (en) | 2016-06-28 | 2023-03-07 | Eit Emerging Implant Technologies Gmbh | Expandable and angularly adjustable intervertebral cages with articulating joint |
US11612491B2 (en) | 2009-03-30 | 2023-03-28 | DePuy Synthes Products, Inc. | Zero profile spinal fusion cage |
US11660082B2 (en) | 2011-11-01 | 2023-05-30 | DePuy Synthes Products, Inc. | Dilation system |
US11672562B2 (en) | 2015-09-04 | 2023-06-13 | Medos International Sarl | Multi-shield spinal access system |
US11744447B2 (en) | 2015-09-04 | 2023-09-05 | Medos International | Surgical visualization systems and related methods |
US11752009B2 (en) | 2021-04-06 | 2023-09-12 | Medos International Sarl | Expandable intervertebral fusion cage |
US11771517B2 (en) | 2021-03-12 | 2023-10-03 | Medos International Sarl | Camera position indication systems and methods |
US11813026B2 (en) | 2019-04-05 | 2023-11-14 | Medos International Sarl | Systems, devices, and methods for providing surgical trajectory guidance |
US11850160B2 (en) | 2021-03-26 | 2023-12-26 | Medos International Sarl | Expandable lordotic intervertebral fusion cage |
US11911287B2 (en) | 2010-06-24 | 2024-02-27 | DePuy Synthes Products, Inc. | Lateral spondylolisthesis reduction cage |
Families Citing this family (1251)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20050053976A1 (en) * | 1996-06-06 | 2005-03-10 | Baker Brenda F. | Chimeric oligomeric compounds and their use in gene modulation |
EP1080226A4 (en) * | 1998-05-21 | 2004-04-21 | Isis Pharmaceuticals Inc | Compositions and methods for topical delivery of oligonucleotides |
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
US7098192B2 (en) * | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
EP2270148A3 (en) * | 1999-04-09 | 2011-06-08 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US20040157327A1 (en) * | 1999-10-22 | 2004-08-12 | Wyeth | Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto |
CA2404890C (en) | 2000-03-30 | 2013-11-19 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
BRPI0115814B8 (en) | 2000-12-01 | 2021-05-25 | Europaeisches Laboratorium Fuer Molekularbiologie Embl | double-stranded RNA molecules, their method of preparation and pharmaceutical composition comprising them |
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US20030176379A1 (en) * | 2001-05-11 | 2003-09-18 | Raoof Araz A. | Antisense permeation enhancers |
US20050164968A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA) |
US20070173473A1 (en) * | 2001-05-18 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
US20050119212A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA) |
WO2008030239A1 (en) * | 2006-09-05 | 2008-03-13 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HISTONE DEACETYLASE (HDAC) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050196767A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA) |
US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
US20030144221A1 (en) * | 2001-07-17 | 2003-07-31 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL2-associated X protein expression |
US7425545B2 (en) * | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US20050043256A1 (en) * | 2001-07-30 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
AU2002330724A1 (en) * | 2001-08-16 | 2003-03-10 | Bar Ilan University | Diagnosis, prevention and treatment of cancer |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
WO2003064621A2 (en) * | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
EP3415625A1 (en) | 2002-02-01 | 2018-12-19 | Life Technologies Corporation | Double-stranded oligonucleotides |
US7405292B2 (en) * | 2002-02-19 | 2008-07-29 | The Children's Hospital Of Philadelphia | Cellular genes regulated by HIV-1 infection and methods of use thereof |
US7662952B2 (en) * | 2002-02-20 | 2010-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) |
US8067575B2 (en) * | 2002-02-20 | 2011-11-29 | Merck, Sharp & Dohme Corp. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
MXPA04010283A (en) * | 2002-04-18 | 2005-08-18 | Acuity Pharmaceuticals Inc | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification. |
US7199107B2 (en) * | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
ATE427352T1 (en) | 2002-07-26 | 2009-04-15 | Novartis Vaccines & Diagnostic | MODIFIED SMALL IRNS MOLECULES AND METHODS OF THEREOF APPLICATION |
US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
US8729036B2 (en) | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
WO2004018676A2 (en) * | 2002-08-21 | 2004-03-04 | The University Of British Columbia | Rnai probes targeting cancer-related proteins |
CA2497792C (en) | 2002-09-06 | 2014-08-05 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
EP2272958A1 (en) | 2002-09-26 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
US20060160759A1 (en) * | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
US20050259483A1 (en) * | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
US9827263B2 (en) | 2002-11-05 | 2017-11-28 | Ionis Pharmaceuticals, Inc. | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
US7405289B2 (en) * | 2002-11-13 | 2008-07-29 | Metabolex, Inc. | Pancreatic islet transcription factor and uses thereof |
US20060009410A1 (en) * | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
US7635770B2 (en) * | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
US7977471B2 (en) * | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
US7592442B2 (en) * | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
JP2006507841A (en) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | Functional and ultrafunctional siRNA |
US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
US20080268457A1 (en) * | 2002-11-14 | 2008-10-30 | Dharmacon, Inc. | siRNA targeting forkhead box P3 (FOXP3) |
US20090227780A1 (en) * | 2002-11-14 | 2009-09-10 | Dharmacon, Inc. | siRNA targeting connexin 43 |
US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7691998B2 (en) * | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
US7619081B2 (en) * | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
CN1742086B (en) * | 2002-11-22 | 2010-05-12 | 生物智囊团株式会社 | Method for searching RNA interfered target basic group sequence |
US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7618948B2 (en) * | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20060257851A1 (en) * | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
JP3792655B2 (en) * | 2003-01-20 | 2006-07-05 | 日本電気株式会社 | Novel oncogene, recombinant protein derived from the oncogene, and uses thereof |
US7732591B2 (en) * | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
US7994149B2 (en) | 2003-02-03 | 2011-08-09 | Medtronic, Inc. | Method for treatment of Huntington's disease through intracranial delivery of sirna |
US8084432B2 (en) | 2003-02-13 | 2011-12-27 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of pouchitis |
WO2004076664A2 (en) * | 2003-02-21 | 2004-09-10 | University Of South Florida | Vectors for regulating gene expression |
JP2006520611A (en) * | 2003-03-05 | 2006-09-14 | セネスコ テクノロジーズ,インコーポレイティド | Use of antisense oligonucleotides or siRNA to suppress the expression of eIF-5A1 |
AU2004220525B2 (en) * | 2003-03-12 | 2011-03-31 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
US20040185559A1 (en) * | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
WO2004100977A1 (en) * | 2003-03-25 | 2004-11-25 | The Board Of Trustees Of The University Of Illinois | Inhibition of tumor cell proliferation by foxm1b inhibitors |
EP1469070A1 (en) * | 2003-04-15 | 2004-10-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Livin-specific siRNAs for the treatment of therapy-resistant tumors |
AU2004233043A1 (en) * | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2 |
JP4505749B2 (en) * | 2003-05-30 | 2010-07-21 | 日本新薬株式会社 | Oligo double-stranded RNA that suppresses expression of Bcl-2 and pharmaceutical composition containing the same |
WO2004105774A1 (en) * | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
WO2005001043A2 (en) * | 2003-06-02 | 2005-01-06 | University Of Massachusetts | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
DK1633767T3 (en) | 2003-06-02 | 2019-03-25 | Univ Massachusetts | METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING |
EP2508608A1 (en) * | 2003-06-09 | 2012-10-10 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
US7595306B2 (en) | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US7479546B2 (en) * | 2003-06-27 | 2009-01-20 | Diadexus, Inc. | Pro104 antibody compositions and methods of use |
US20060280725A1 (en) * | 2003-07-02 | 2006-12-14 | Barrie Bode | Compositions and methods of treating and diagnosing hepatoma |
FR2857013B1 (en) * | 2003-07-02 | 2005-09-30 | Commissariat Energie Atomique | SMALL INTERFERING RNA SPECIFIC OF ALPHA, ALPHA PRIME AND BETA SUBUNITS OF PROTEIN KINASE CK2 AND THEIR APPLICATIONS |
AU2004257167B2 (en) * | 2003-07-03 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
EP1664274A4 (en) * | 2003-08-13 | 2010-06-30 | Univ Illinois | Silencing of tgf-beta receptor type ii expression by sirna |
US7888497B2 (en) * | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
WO2005017154A1 (en) * | 2003-08-18 | 2005-02-24 | Japan Health Sciences Foundation | IMPROVED siRNA MOLECULE AND METHOD OF INHIBITING GENE EXPRESSION WITH THE USE OF THE SAME |
WO2005026344A1 (en) * | 2003-09-11 | 2005-03-24 | Hubit Genomix, Inc. | Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in preventing and/or treating proliferative diseases causing sclerosis |
US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
EP3760234B1 (en) | 2003-09-12 | 2023-11-01 | University of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
EP2256201A3 (en) | 2003-09-18 | 2012-07-04 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E expression |
WO2005037303A1 (en) * | 2003-09-22 | 2005-04-28 | Board Of Trustees Of The University Of Illinois | Methods and compositions of ig20 and denn-sv splice variants |
US20070054849A1 (en) * | 2003-09-24 | 2007-03-08 | Oncotherapy Science, Inc. | Method for diagnosing hepatocellular carcinomas |
AR041407A1 (en) * | 2003-09-26 | 2005-05-18 | Nestor Alberto Kerner | OLIGONUCLEOTIDOS ANTIANDROGENOS USABLE IN THE TREATMENT OF DERMATOLOGICAL PATHOLOGIES RELATED TO THE ANDROGEN METABOLISM, ITS PHARMACEUTICAL COMPOSITIONS AND THEIR USES AND METHODS OF TREATMENT |
EP1687410A4 (en) | 2003-10-07 | 2008-04-09 | Isis Pharmaceuticals Inc | Antisense oligonucleotides optimized for kidney targeting |
JP4486928B2 (en) * | 2003-10-09 | 2010-06-23 | タカラバイオ株式会社 | Composition for suppressing the function of human Flt3 |
US20080227733A1 (en) * | 2003-10-30 | 2008-09-18 | Immune Disease Institute, Inc. | Method for Treating and Preventing Ischemia-Reperfusion Injury Using Rna Interfering Agent |
US20050191653A1 (en) * | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
EP1689414A4 (en) | 2003-12-04 | 2009-04-08 | Univ South Florida Res Foundat | Polynucleotides for reducing respiratory syncytial virus gene expression |
SE0303397D0 (en) * | 2003-12-17 | 2003-12-17 | Index Pharmaceuticals Ab | Compounds and method for RNA interference |
US20060134787A1 (en) | 2004-12-22 | 2006-06-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
WO2005065719A1 (en) * | 2004-01-12 | 2005-07-21 | Genesense Technologies Inc. | Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer |
WO2005069872A2 (en) * | 2004-01-15 | 2005-08-04 | Washington University | High throughput pharmaceutical screening using drosophila |
US20070161586A1 (en) * | 2004-01-16 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Drug for preventing and treating atherosclerosis |
JP2007520222A (en) * | 2004-01-20 | 2007-07-26 | アイシス ファーマシューティカルズ インコーポレイテッド | Regulation of glucocorticoid receptor expression |
US8778900B2 (en) * | 2004-01-22 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP1 expression |
US7468431B2 (en) * | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US20050203043A1 (en) * | 2004-01-23 | 2005-09-15 | Dharmacon, Inc. | Identification of toxic nucleotide sequences |
CA2556435C (en) * | 2004-02-13 | 2014-08-12 | The Rockefeller University | Anti-microrna oligonucleotide molecules |
US8491914B2 (en) * | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
GB0404209D0 (en) * | 2004-02-25 | 2004-03-31 | Uws Ventures Ltd | Materials and methods for treatment of allergic disease |
WO2005085443A2 (en) * | 2004-03-01 | 2005-09-15 | Massachusetts Institute Of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
DE102004010547A1 (en) * | 2004-03-03 | 2005-11-17 | Beiersdorf Ag | Oligoribonucleotides for the treatment of irritative and / or inflammatory skin conditions by RNA interference |
EP1735009A4 (en) | 2004-03-12 | 2011-03-30 | Alnylam Pharmaceuticals Inc | iRNA AGENTS TARGETING VEGF |
WO2005089287A2 (en) * | 2004-03-15 | 2005-09-29 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
BRPI0508970A (en) * | 2004-03-19 | 2007-08-21 | Penn State Res Found | combinatorial methods and compositions for the treatment of melanoma |
EP2343384A3 (en) * | 2004-03-23 | 2012-01-04 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancer |
JP2005312428A (en) * | 2004-03-31 | 2005-11-10 | Keio Gijuku | Treatment of cancer by utilizing skp-2 expression inhibition |
KR101147147B1 (en) * | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Modified polynucleotides for reducing off-target effects in rna interference |
US8088902B2 (en) * | 2004-04-05 | 2012-01-03 | The Rockefeller University | DNA virus microRNA and methods for inhibiting same |
US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
AU2005230684B2 (en) | 2004-04-05 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Process and reagents for oligonucleotide synthesis and purification |
US7416842B2 (en) * | 2004-04-05 | 2008-08-26 | The Rockefeller University | DNA virus microRNA |
US8193332B2 (en) * | 2004-04-09 | 2012-06-05 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
WO2005117938A2 (en) * | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
US20050261233A1 (en) * | 2004-04-21 | 2005-11-24 | Sanjay Bhanot | Modulation of glucose-6-phosphatase translocase expression |
EP1737957A1 (en) * | 2004-04-22 | 2007-01-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING |
AU2005325262B2 (en) | 2004-04-27 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
MXPA06012162A (en) * | 2004-04-27 | 2007-03-30 | Galapagos Nv | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. |
JP4584987B2 (en) | 2004-04-30 | 2010-11-24 | アルニラム ファーマスーティカルズ インコーポレイテッド | Oligonucleotides containing C5-modified pyrimidines |
US20050287558A1 (en) | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
US7605250B2 (en) * | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
EP1784501B1 (en) * | 2004-05-14 | 2015-11-18 | Rosetta Genomics Ltd | VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF |
EP1747784A4 (en) * | 2004-05-18 | 2008-03-26 | Univ Kurume | Target gene mimitin of myc |
US20100152280A1 (en) * | 2004-05-24 | 2010-06-17 | Isis Pharmaceuticals, Inc. | Modulation of sid-1 expression |
US7563885B1 (en) * | 2004-05-24 | 2009-07-21 | Isis Pharmaceuticals, Inc. | Modulation of Tudor-SN expression |
US8101350B1 (en) * | 2004-05-24 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Modulation of exportin 5 expression |
US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
US7575863B2 (en) * | 2004-05-28 | 2009-08-18 | Applied Biosystems, Llc | Methods, compositions, and kits comprising linker probes for quantifying polynucleotides |
US20060015264A1 (en) * | 2004-06-02 | 2006-01-19 | Mcshea Andrew | Interfering stem-loop sequences and method for identifying |
US8394947B2 (en) * | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
EP1765416A4 (en) * | 2004-06-03 | 2010-03-24 | Isis Pharmaceuticals Inc | Double strand compositions comprising differentially modified strands for use in gene modulation |
EP1602926A1 (en) * | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
US20060156421A1 (en) * | 2004-06-18 | 2006-07-13 | Cagan Ross L | High throughput screening methods for anti-metastatic compounds |
DE602005026811D1 (en) * | 2004-06-22 | 2011-04-21 | Univ Illinois | PROCESS FOR INHIBITING TUMOR CELL GROWTH WITH FOXM1 SIRNS |
US20060051815A1 (en) * | 2004-06-25 | 2006-03-09 | The J. David Gladstone Institutes | Methods of treating smooth muscle cell disorders |
PL2206781T3 (en) | 2004-06-28 | 2016-06-30 | Univ Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
JP2008504840A (en) | 2004-06-30 | 2008-02-21 | アルニラム ファーマスーティカルズ インコーポレイテッド | Oligonucleotides containing non-phosphate backbone bonds |
JP2006031308A (en) * | 2004-07-15 | 2006-02-02 | Mitsubishi Space Software Kk | Apparatus, method, and program for designing nucleic acid array, apparatus, method, and program for calculating function impediment effect, and apparatus, method, and program for calculating degree of function impediment effect |
EP1778310A2 (en) * | 2004-07-21 | 2007-05-02 | Medtronic, Inc. | Medical devices and methods for reducing localized fibrosis |
EP1828215A2 (en) | 2004-07-21 | 2007-09-05 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
WO2006017556A1 (en) * | 2004-08-02 | 2006-02-16 | University Of Iowa Research Foundation | Methods of inhibiting cox-2 |
US7632932B2 (en) | 2004-08-04 | 2009-12-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
US20060223147A1 (en) * | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
CN101123994B (en) | 2004-08-16 | 2012-11-14 | 夸克医药公司 | Therapeutic uses of inhibitors of rtp801 |
EP1786905B1 (en) * | 2004-08-18 | 2011-08-03 | Lorus Therapeutics Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
US20110313024A1 (en) * | 2004-08-20 | 2011-12-22 | Leonid Beigelman | RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CN105251024A (en) * | 2004-08-23 | 2016-01-20 | 西伦蒂斯私人股份公司 | Treatment of eye disorders |
CN100410373C (en) * | 2004-08-24 | 2008-08-13 | 暨南大学 | siRNA double-chain for suppressing bc1-2 gene expression |
CN100395335C (en) * | 2004-08-24 | 2008-06-18 | 暨南大学 | siRNA double-chain for suppressing bc1-2 gene expression |
CN1324136C (en) * | 2004-08-24 | 2007-07-04 | 暨南大学 | SiRNA double chain for inhibiting bc 1-2 gen expression and use |
RU2410430C2 (en) * | 2004-08-31 | 2011-01-27 | Силентис С.А.У. | Methods and compositions for inhibiting expression of p2x7 receptor |
WO2006032039A2 (en) | 2004-09-17 | 2006-03-23 | University Of Massachusetts | Compositions and their uses for lysosomal enzyme deficiencies |
WO2006034456A2 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
CA2580707C (en) | 2004-09-24 | 2014-07-08 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of apob and uses thereof |
CN101291948B (en) * | 2004-09-28 | 2012-05-30 | 夸克医药公司 | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
MX2007003795A (en) * | 2004-09-28 | 2007-07-11 | Quark Biotech Inc | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases. |
ATE439440T1 (en) * | 2004-09-29 | 2009-08-15 | Childrens Memorial Hospital | SIRNA-MEDIATED GENE SILENCING OF ALPHA-SYNUKLEIN |
US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
ES2441791T3 (en) * | 2004-10-01 | 2014-02-06 | Novartis Vaccines And Diagnostics, Inc. | Modified small interference RNA molecules and methods of use |
US7825229B2 (en) * | 2005-03-25 | 2010-11-02 | Rosetta Genomics Ltd. | Lung cancer-related nucleic acids |
US20090186353A1 (en) * | 2004-10-04 | 2009-07-23 | Rosetta Genomics Ltd. | Cancer-related nucleic acids |
WO2006044531A2 (en) * | 2004-10-13 | 2006-04-27 | Isis Parmaceuticals, Inc. | Antisense modulation of ptp1b expression |
US8080420B2 (en) | 2004-10-22 | 2011-12-20 | University Of Central Florida Research Foundation, Inc. | Methods and products for biasing cellular development |
US20060110440A1 (en) * | 2004-10-22 | 2006-05-25 | Kiminobu Sugaya | Method and system for biasing cellular development |
US7790878B2 (en) * | 2004-10-22 | 2010-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US8440610B2 (en) * | 2004-11-12 | 2013-05-14 | Massachusetts Institute Of Technology | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells |
CA2586987A1 (en) * | 2004-11-12 | 2006-05-18 | Massachusetts Institute Of Technology | Methods and compositions for treating cellular proliferative diseases |
WO2006053430A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
KR101330229B1 (en) * | 2004-11-19 | 2013-11-15 | 가부시키가이샤 진케어켄큐쇼 | Cancer cell-specific cell proliferation inhibitors |
US7923206B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Method of determining a cellular response to a biological agent |
US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
US9944713B2 (en) | 2004-11-24 | 2018-04-17 | Medicinal Bioconvergence Research Center | Antibody specific to the AIMP2-DX2 |
US8003780B2 (en) * | 2004-11-24 | 2011-08-23 | Neomics Co., Ltd. | AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2 |
ATE539758T1 (en) * | 2004-11-24 | 2012-01-15 | Alnylam Pharmaceuticals Inc | RNAI MODULATION OF THE BCR-ABL FUSION GENE AND USES THEREOF |
US20060121040A1 (en) * | 2004-12-08 | 2006-06-08 | Wisconsin Alumni Research Foundation | Compositions and methods for treating neuroendocrine tumors |
EP1828415A4 (en) * | 2004-12-08 | 2009-07-01 | Bioneer Corp | Method of inhibiting expression of target mrna using sirna consisting of nucleotide sequence complementary to said target mrna |
CN101128207A (en) * | 2004-12-09 | 2008-02-20 | 森托科尔公司 | Oxytocin receptor antagonists and their use for the treatment of pulmonary related diseases |
AU2005313883B2 (en) * | 2004-12-09 | 2011-03-31 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
US7361752B2 (en) * | 2004-12-14 | 2008-04-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of MLL-AF4 and uses thereof |
US7332591B2 (en) * | 2004-12-21 | 2008-02-19 | The University Of Iowa Research Foundation | Bardet-Biedl susceptibility gene and uses thereof |
CA2592099A1 (en) * | 2004-12-22 | 2006-06-29 | Nucleonics, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
TWI401316B (en) * | 2004-12-23 | 2013-07-11 | Alcon Inc | Rnai inhibition of serum amyloid a for treatment of glaucoma |
US20060166920A1 (en) * | 2005-12-27 | 2006-07-27 | Regents Of The University Of Michigan | Oligonucleotide based therapeutics |
JP5081630B2 (en) | 2005-01-07 | 2012-11-28 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | RNAi regulation of RSV and methods of its therapeutic use |
DE102005003788A1 (en) * | 2005-01-19 | 2006-07-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | siRNA molecules for the treatment of blood vessels |
EP1841464B1 (en) * | 2005-01-24 | 2012-06-27 | Alnylam Pharmaceuticals Inc. | Rnai modulation of the nogo-l or nogo-r gene and uses thereof |
US7879992B2 (en) * | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
TW200639253A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
EP1859040A2 (en) | 2005-02-25 | 2007-11-28 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to il-4r alpha |
AU2006219666B2 (en) * | 2005-03-02 | 2011-01-27 | National Institute Of Immunology | Inhibition of SPAG9 expression with siRNAs |
US20070185044A1 (en) * | 2005-03-08 | 2007-08-09 | Dobie Kenneth W | Modulation of ace2 expression |
JP2008533050A (en) * | 2005-03-11 | 2008-08-21 | アルコン,インコーポレイテッド | RNAI-mediated inhibition of Frizzled-related protein-1 to treat glaucoma |
GB0505081D0 (en) | 2005-03-14 | 2005-04-20 | Genomica Sau | Downregulation of interleukin-12 expression by means of rnai technology |
EP1877556B1 (en) * | 2005-03-25 | 2011-09-14 | Medtronic, Inc. | Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain |
JP4131271B2 (en) * | 2005-03-30 | 2008-08-13 | ソニー株式会社 | Information processing apparatus and method, and program |
EP1866414B9 (en) * | 2005-03-31 | 2012-10-03 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
US8299041B2 (en) * | 2005-04-08 | 2012-10-30 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to acetyl-CoA carboxylases |
US20070213293A1 (en) * | 2005-04-08 | 2007-09-13 | Nastech Pharmaceutical Company Inc. | Rnai therapeutic for respiratory virus infection |
BRPI0610499A2 (en) | 2005-04-12 | 2010-06-22 | Intradigm Corp | nucleic acid molecules, compositions and uses of said molecules |
US20090117539A1 (en) * | 2005-04-12 | 2009-05-07 | Larry Gilbertson | DNA sequences for gene suppression |
US7985852B2 (en) * | 2005-04-15 | 2011-07-26 | National University Corporation Tottori University | hTERT gene expression regulatory gene |
WO2006113743A2 (en) * | 2005-04-18 | 2006-10-26 | Massachusetts Institute Of Technology | Compositions and methods for rna interference with sialidase expression and uses thereof |
US20060253068A1 (en) * | 2005-04-20 | 2006-11-09 | Van Bilsen Paul | Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart |
EP1714970A1 (en) * | 2005-04-22 | 2006-10-25 | Universität des Saarlandes | Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity |
EP2631294A3 (en) | 2005-04-29 | 2013-11-20 | The Rockefeller University | Human microRNAs and methods for inhibiting same |
US7902352B2 (en) * | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
EP1885854B1 (en) * | 2005-05-06 | 2012-10-17 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
KR20060119412A (en) * | 2005-05-20 | 2006-11-24 | 아주대학교산학협력단 | Sirna for inhibiting il-6 expression and composition containing them |
EP1888083B1 (en) * | 2005-05-24 | 2011-12-28 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to lmw-ptpase |
EP1728514A1 (en) * | 2005-06-03 | 2006-12-06 | Immunotech S.A. | Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation |
JP5254012B2 (en) | 2005-06-06 | 2013-08-07 | ジェン−プロウブ インコーポレイテッド | Compositions, methods and kits for determining the presence of Chlamydophila pneumoniae in a test sample |
US20100266574A1 (en) * | 2005-06-10 | 2010-10-21 | Orna Mor | Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases |
EP1734118A1 (en) * | 2005-06-15 | 2006-12-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening |
FI20050640A0 (en) * | 2005-06-16 | 2005-06-16 | Faron Pharmaceuticals Oy | Compounds for treating or preventing diseases or disorders related to amine oxidases |
EP1910395B1 (en) * | 2005-06-23 | 2012-10-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of SMN2 splicing |
WO2007002718A2 (en) * | 2005-06-27 | 2007-01-04 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of hif-1 and theraputic uses thereof |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US20080280843A1 (en) * | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
EP1909850A4 (en) * | 2005-07-21 | 2010-05-12 | Alnylam Pharmaceuticals Inc | Rnai modulation of the rho-a gene and uses thereof |
US20090155241A1 (en) * | 2005-07-22 | 2009-06-18 | Japanese Foundation For Cancer Research | Prophylactic/therapeutic agent for cancer |
EP2311986B1 (en) | 2005-07-27 | 2015-04-15 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
EP1913153A4 (en) * | 2005-07-28 | 2008-10-15 | Univ Massachusetts | Glucose transport-related genes, polypeptides, and methods of use thereof |
AU2006279280A1 (en) | 2005-08-18 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating neurological disease |
ATE532878T1 (en) * | 2005-08-24 | 2011-11-15 | Life Technologies Corp | METHOD FOR QUANTIFYING SIRNAS, MIRNAS AND POLYMORPHOIC MIRNAS |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
CA2622671C (en) * | 2005-09-16 | 2020-12-22 | Devgen Nv | Methods for controlling pests using rnai |
BRPI0616370A2 (en) * | 2005-09-19 | 2011-06-14 | Johnson & Johnson Pharmaceutical Res & Dev L L C | modulation of glucocorticoid receptor expression |
WO2007033475A1 (en) * | 2005-09-20 | 2007-03-29 | London Health Sciences Centre Research Inc. | THE USE OF siRNAs IN ORGAN STORAGE/REPERFUSION SOLUTIONS |
US20120164730A1 (en) * | 2005-10-11 | 2012-06-28 | Ben-Gurion University Of The Negev Research And Development Authority Ltd. | Compositions for silencing the expression of vdac1 and uses thereof |
AU2006304321B2 (en) | 2005-10-14 | 2012-10-04 | Musc Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8258109B2 (en) * | 2005-10-20 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of LMNA expression |
GB0521351D0 (en) * | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
JPWO2007049624A1 (en) * | 2005-10-24 | 2009-04-30 | 武田薬品工業株式会社 | Cancer preventive / therapeutic agent |
GB0521716D0 (en) * | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
EP1948680A4 (en) * | 2005-10-28 | 2010-01-13 | Univ California | Methods and compounds for lymphoma cell detection and isolation |
US7723314B1 (en) * | 2005-10-28 | 2010-05-25 | Transderm, Inc. | Methods and compositions for treating pachyonychia congenita |
EP1941059A4 (en) | 2005-10-28 | 2010-11-03 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of huntingtin gene |
US20080090775A1 (en) * | 2005-10-31 | 2008-04-17 | Chong Huang | Antagonist of TEB4 and Methods of Use |
EP2395012B8 (en) * | 2005-11-02 | 2018-06-06 | Arbutus Biopharma Corporation | Modified siRNA molecules and uses thereof |
WO2007056326A2 (en) * | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
US20100069461A1 (en) | 2005-11-09 | 2010-03-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
US8067558B2 (en) | 2005-12-19 | 2011-11-29 | New York University | Constitutively active fragments of eukaryotic heat shock RNA |
US7919603B2 (en) * | 2005-12-19 | 2011-04-05 | New York University | Heat shock RNA |
EP1969143A4 (en) * | 2005-12-20 | 2009-07-22 | Isis Pharmaceuticals Inc | Double stranded nucleic acid molecules targeted to il-4 receptor alpha |
US8258287B2 (en) * | 2005-12-21 | 2012-09-04 | Centre de Cooperation Internationale en Recherche Agronomique pour le Developpment (CIRAD) | Interfering RNAs targeting the morbillivirus nucleoprotein gene |
DE602006014026D1 (en) * | 2005-12-22 | 2010-06-10 | Opko Ophthalmics Llc | COMPOSITIONS AND METHOD FOR REGULATING A COMPLEMENT SYSTEM |
AR057252A1 (en) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | INHIBITION OF RHO KINASE MEDIATED BY ARNI FOR THE TREATMENT OF EYE DISORDERS |
US8673873B1 (en) | 2005-12-28 | 2014-03-18 | Alcon Research, Ltd. | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders |
TW200731980A (en) | 2005-12-29 | 2007-09-01 | Alcon Mfg Ltd | RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis |
US7444453B2 (en) * | 2006-01-03 | 2008-10-28 | International Business Machines Corporation | Address translation device |
EP1984400B1 (en) | 2006-01-05 | 2012-11-28 | Immune Disease Institute, Inc. | Regulators of nfat |
CA2637254A1 (en) * | 2006-01-17 | 2007-07-26 | Biolex Therapeutics, Inc. | Compositions and methods for humanization and optimization of n-glycans in plants |
US20090060921A1 (en) * | 2006-01-17 | 2009-03-05 | Biolex Therapeutics, Inc. | Glycan-optimized anti-cd20 antibodies |
WO2007084954A2 (en) * | 2006-01-19 | 2007-07-26 | The Board Of Trustees Of The University Of Illinois | Selective inhibition of ig20 splice variants to treat cancers |
US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
NL2000439C2 (en) | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutic applications of inhibitors of RTP801. |
EP3210633B1 (en) * | 2006-01-26 | 2019-06-19 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
US8229398B2 (en) * | 2006-01-30 | 2012-07-24 | Qualcomm Incorporated | GSM authentication in a CDMA network |
WO2008048342A2 (en) * | 2006-02-08 | 2008-04-24 | Dharmacon, Inc. | Microarray for detecting and quantifying microrna |
CA2836368C (en) | 2006-02-13 | 2020-04-07 | Monsanto Technology Llc | Method for managing crop pest resistance |
JP4961549B2 (en) * | 2006-02-16 | 2012-06-27 | 国立大学法人愛媛大学 | SiRNA specific for androgen receptor gene |
US7910566B2 (en) * | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
FI20060246A0 (en) * | 2006-03-16 | 2006-03-16 | Jukka Westermarck | A new growth stimulating protein and its use |
EP1993611A4 (en) * | 2006-03-16 | 2013-05-22 | Alnylam Pharmaceuticals Inc | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF |
BRPI0709147A2 (en) * | 2006-03-24 | 2011-06-28 | Novartis Ag | dsrna compositions and methods for treating hpv infection |
WO2007115168A2 (en) | 2006-03-31 | 2007-10-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 gene |
EP2371957A1 (en) * | 2006-04-12 | 2011-10-05 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
EP2003971A4 (en) * | 2006-04-13 | 2010-10-27 | Alcon Res Ltd | Rnai-mediated inhibition of histamine receptor h1-related conditions |
TW200808360A (en) * | 2006-04-13 | 2008-02-16 | Alcon Mfg Ltd | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
WO2007123391A1 (en) * | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
US7691824B2 (en) * | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
WO2007131232A2 (en) * | 2006-05-05 | 2007-11-15 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to ptpr alpha |
CA3044969A1 (en) * | 2006-05-05 | 2007-12-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
TWI322690B (en) * | 2006-05-11 | 2010-04-01 | Flysun Dev Co Ltd | Short interference ribonucleic acids for treating allergic dieases |
NZ572666A (en) * | 2006-05-11 | 2010-11-26 | Alnylam Pharmaceuticals Inc | Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene |
US8243715B2 (en) * | 2006-05-15 | 2012-08-14 | Oracle Israel Ltd. | Delivering sip-based call services to circuit-switched terminals |
US20090130212A1 (en) * | 2006-05-15 | 2009-05-21 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
WO2007137129A2 (en) * | 2006-05-19 | 2007-11-29 | Alcon Research, Ltd. | RNAI-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR α-RELATED CONDITIONS |
US8198252B2 (en) * | 2006-05-19 | 2012-06-12 | Board Of Regents, The University Of Texas System | SIRNA inhibition of PI3K P85, P110, and AKT2 and methods of use |
EP1857548A1 (en) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
AU2012201409B2 (en) * | 2006-05-19 | 2014-06-12 | Arrowhead Research Corporation | RNAi-Mediated inhibition of tumor necrosis factor alpha-related conditions |
EP2021352A4 (en) * | 2006-05-19 | 2009-10-28 | Scripps Research Inst | Treatment of protein misfolding |
EP2023937B1 (en) * | 2006-05-19 | 2011-10-12 | Alnylam Pharmaceuticals Inc. | Rnai modulation of aha and therapeutic uses thereof |
WO2007137220A2 (en) * | 2006-05-22 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of ikk-b gene |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
WO2007143584A2 (en) * | 2006-06-02 | 2007-12-13 | Alcon Research, Ltd. | RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS |
CA2771971A1 (en) * | 2006-06-09 | 2007-12-13 | Kabushiki Kaisha Yakult Honsha | Gene involved in immortalization of human cancer cell and use thereof |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
WO2007141796A2 (en) * | 2006-06-09 | 2007-12-13 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of rtp801l |
JP2009540011A (en) * | 2006-06-12 | 2009-11-19 | エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. | Compositions and methods for siRNA inhibition of angiogenesis |
KR100794705B1 (en) * | 2006-06-13 | 2008-01-14 | (주)바이오니아 | Method of Inhibiting Expression of Target mRNA Using siRNA Considering Alternative Splicing of Genes |
GB0612342D0 (en) | 2006-06-21 | 2006-08-02 | Glaxosmithkline Biolog Sa | Method |
WO2008005769A2 (en) * | 2006-06-30 | 2008-01-10 | Immusol, Incorporated | Methods of inhibiting hcv replication |
US8124752B2 (en) * | 2006-07-10 | 2012-02-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the MYC gene |
JP4756271B2 (en) * | 2006-07-18 | 2011-08-24 | 独立行政法人産業技術総合研究所 | Cancer cell aging, apoptosis inducer |
EP1884569A1 (en) | 2006-07-31 | 2008-02-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sensitization of cancer cells to therapy using siNA targeting genes from the 1p and 19q chromosomal regions |
US8138160B2 (en) | 2006-08-03 | 2012-03-20 | Warsaw Orthopedic, Inc. | Reagents, methods and systems to suppress pro-inflammatory cytokines |
US8003620B2 (en) * | 2006-08-04 | 2011-08-23 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to diacylglycerol acyltransferase 1 |
CA2660052A1 (en) * | 2006-08-04 | 2008-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of jnk proteins |
PL2056845T3 (en) | 2006-08-08 | 2018-01-31 | Univ Bonn Rheinische Friedrich Wilhelms | Structure and use of 5' phosphate oligonucleotides |
US20080039415A1 (en) * | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
AU2007282224B2 (en) | 2006-08-11 | 2013-08-29 | Vico Therapeutics B.V. | Methods and means for treating DNA repeat instability associated genetic disorders |
EP2077326A4 (en) * | 2006-09-04 | 2010-11-10 | Kyowa Hakko Kirin Co Ltd | Novel nucleic acid |
US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
EP2069380B1 (en) * | 2006-09-18 | 2014-11-12 | Alnylam Pharmaceuticals Inc. | Rnai modulation of scap and therapeutic uses thereof |
US20100144830A1 (en) * | 2006-09-19 | 2010-06-10 | Masahiko Kuroda | Cancer cell identification marker and cancer cell proliferation inhibitor |
US20090209478A1 (en) * | 2006-09-21 | 2009-08-20 | Tomoko Nakayama | Compositions and methods for inhibiting expression of the hamp gene |
AR055648A1 (en) * | 2006-09-21 | 2007-08-29 | Gen Med Sa | A DOUBLE-CHAIN RNA OLIGONUCLEOTIDE A PHARMACEUTICAL OR COSMETIC COMPOSITION THAT UNDERSTANDS AND USES IT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO ANDROGEN METABOLISM |
WO2008036825A2 (en) | 2006-09-22 | 2008-03-27 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
WO2008063760A2 (en) * | 2006-10-18 | 2008-05-29 | The University Of Texas M.D. Anderson Cancer Center | Methods for treating cancer targeting transglutaminase |
JP5876637B2 (en) * | 2006-10-18 | 2016-03-02 | マリーナ バイオテック,インコーポレイテッド | Nicked or gapped nucleic acid molecules and their use |
JP2010507387A (en) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | Novel siRNA and method of using the same |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
CA2668346A1 (en) * | 2006-11-09 | 2008-05-15 | Unibioscreen S.A. | Targeting of alpha-1 or alpha-3 subunit of na+, k+-atpase in the treatment of proliferative diseases |
US8304399B2 (en) * | 2006-11-09 | 2012-11-06 | The Board Of Regents Of The University Of Texas System | Hedgehog signaling pathway proteins and uses thereof |
US7994306B2 (en) * | 2006-11-13 | 2011-08-09 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods of treating cancer using siRNA molecules directed against CD24 |
US8034921B2 (en) * | 2006-11-21 | 2011-10-11 | Alnylam Pharmaceuticals, Inc. | IRNA agents targeting CCR5 expressing cells and uses thereof |
US7819842B2 (en) | 2006-11-21 | 2010-10-26 | Medtronic, Inc. | Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites |
US7988668B2 (en) * | 2006-11-21 | 2011-08-02 | Medtronic, Inc. | Microsyringe for pre-packaged delivery of pharmaceuticals |
CA2670563A1 (en) * | 2006-11-27 | 2008-06-05 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
WO2008067373A2 (en) * | 2006-11-28 | 2008-06-05 | Alcon Research, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS |
US20100099746A1 (en) * | 2006-12-18 | 2010-04-22 | Kyowa Hakko Kirin Co., Ltd. | Novel nucleic acid |
CN101563460A (en) * | 2006-12-22 | 2009-10-21 | 弗·哈夫曼-拉罗切有限公司 | Selection method |
US8476243B2 (en) | 2006-12-29 | 2013-07-02 | Transderm, Inc. | Methods and compositions for treating keratin hyperproliferative disorders |
US7754698B2 (en) * | 2007-01-09 | 2010-07-13 | Isis Pharmaceuticals, Inc. | Modulation of FR-alpha expression |
AU2007344641B2 (en) | 2007-01-16 | 2014-05-22 | The University Of Queensland | Method of inducing an immune response |
US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US20100183696A1 (en) * | 2007-01-30 | 2010-07-22 | Allergan, Inc | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists |
MX2009008104A (en) | 2007-02-02 | 2009-08-07 | Amgen Inc | Hepcidin, hepcidin antagonists and methods of use. |
US20080188433A1 (en) * | 2007-02-07 | 2008-08-07 | Academia Sinica | Methods of diagnosis of spinal muscular atrophy and treatments thereof |
US20090163431A1 (en) * | 2007-02-14 | 2009-06-25 | Ontherex Llc | Compositions and methods for modulation of pdx-1 |
JP2010518880A (en) | 2007-02-26 | 2010-06-03 | クアーク・ファーマスーティカルス、インコーポレイテッド | Inhibitors of RTP801 and their use in the treatment of diseases |
WO2008104978A2 (en) * | 2007-02-28 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
US20100055784A1 (en) * | 2007-03-02 | 2010-03-04 | Mdrna, Inc. | Nucleic acid compounds for inhibiting wnt gene expression and uses thereof |
WO2008109362A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf gene expression and uses thereof |
WO2008109373A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
US20100041140A1 (en) * | 2007-03-02 | 2010-02-18 | Mdrna, Inc. | Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof |
WO2008109516A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
US20100055782A1 (en) * | 2007-03-02 | 2010-03-04 | Mdrna, Inc. | Nucleic acid compounds for inhibiting myc gene expression and uses thereof |
MY148472A (en) * | 2007-03-02 | 2013-04-30 | Boehringer Ingelheim Pharma | Improvement of protein production |
US20100105134A1 (en) * | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
CA2679342A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof |
US20080299659A1 (en) * | 2007-03-02 | 2008-12-04 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting apob gene expression and uses thereof |
WO2008109352A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting akt gene expression and uses thereof |
EP2121923A1 (en) * | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
US20090018099A1 (en) * | 2007-03-02 | 2009-01-15 | Hitto Kaufmann | Protein production |
US20100047909A1 (en) * | 2007-03-02 | 2010-02-25 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof |
WO2008106796A1 (en) * | 2007-03-08 | 2008-09-12 | University Health Network | Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity |
WO2008110624A2 (en) | 2007-03-14 | 2008-09-18 | Universita' Degli Studi Di Milano-Bicocca | Sirna-mediated silencing of genes for treating chemotherapeutic drug-resistant epithelial tumors |
JP5103621B2 (en) * | 2007-03-20 | 2012-12-19 | 国立大学法人愛媛大学 | SiRNA specific for the ADAT1 gene |
US7812002B2 (en) * | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
WO2008118883A1 (en) | 2007-03-24 | 2008-10-02 | Isis Pharmaceuticals, Inc. | Administering antisense oligonucleotides complementary to human apolipoprotein b |
PE20090064A1 (en) * | 2007-03-26 | 2009-03-02 | Novartis Ag | DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
WO2008121604A2 (en) * | 2007-03-29 | 2008-10-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the ebola |
GB0707069D0 (en) * | 2007-04-12 | 2007-05-23 | Medical Res Council | Methods and uses |
WO2008124927A1 (en) * | 2007-04-13 | 2008-10-23 | Vincent Research & Consulting Inc. | Sirna against thymidylate synthase and uses thereof in cancer treatment regimens |
EA018986B1 (en) | 2007-05-01 | 2013-12-30 | Сантарис Фарма А/С | Rna antagonist compounds for the modulation of beta-catenin |
WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
WO2008136748A1 (en) * | 2007-05-04 | 2008-11-13 | Index Pharmaceuticals Ab | Tumour growth inhibitory compounds and methods of their use |
WO2008138066A1 (en) * | 2007-05-15 | 2008-11-20 | Johnson & Johnson Research Pty Limited | Suppression of viruses involved in respiratory infection or disease |
AU2008256886B2 (en) | 2007-05-23 | 2013-02-28 | Dharmacon, Inc. | Micro-RNA scaffolds and non-naturally occurring micro-RNAs |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
WO2008148304A1 (en) * | 2007-05-31 | 2008-12-11 | Xiamen University | Rna interference target for treating aids |
EP2152897B1 (en) * | 2007-06-05 | 2015-02-18 | Melica HB | Methods and materials related to hair pigmentation and cancer |
AR066984A1 (en) * | 2007-06-15 | 2009-09-23 | Novartis Ag | INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA) |
US20100273854A1 (en) * | 2007-06-15 | 2010-10-28 | Hagar Kalinski | Compositions and methods for inhibiting nadph oxidase expression |
AU2012203768B2 (en) * | 2007-06-15 | 2012-12-13 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US20090054366A1 (en) * | 2007-06-15 | 2009-02-26 | Reliance Life Sciences Pvt. Ltd. | RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY |
ES2474176T3 (en) | 2007-06-27 | 2014-07-08 | Quark Pharmaceuticals, Inc. | Compositions and methods to inhibit the expression of pro-apoptotic genes |
CA2691166A1 (en) * | 2007-06-27 | 2008-12-31 | Liu Dongxu | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
AU2008272051A1 (en) * | 2007-07-03 | 2009-01-08 | Cytopathfinder, Inc. | Treatment of influenza |
EP2164966A2 (en) | 2007-07-05 | 2010-03-24 | Novartis Ag | Dsrna for treating viral infection |
EP2167136B1 (en) * | 2007-07-12 | 2016-04-20 | BioMarin Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
EP2167135A2 (en) * | 2007-07-12 | 2010-03-31 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
EP2017340A1 (en) * | 2007-07-16 | 2009-01-21 | Qiagen GmbH | Positive controls for expression modulating experiments |
WO2009020848A2 (en) * | 2007-08-03 | 2009-02-12 | Alcon Research, Ltd. | RNAI-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA |
UY31267A1 (en) | 2007-08-03 | 2009-01-05 | Alcon Res Ltd | INHIBITION OF THE TNFA SENALIZATION PASSAGE RELATED TO ARNI FOR THE TREATMENT OF OCULAR ANGIOGENESIS |
WO2009021150A2 (en) * | 2007-08-08 | 2009-02-12 | California Pacific Medical Center | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
US8263571B2 (en) * | 2007-08-10 | 2012-09-11 | Vendevia Group, Llc | Gene silencing of the brother of the regulator of imprinted sites (BORIS) |
CA2697055A1 (en) * | 2007-08-21 | 2009-02-26 | Scott And White Memorial Hospital And Scott, Sherwood And Brindley Found Ation | Methods and compositions for post-transcriptional gene silencing |
BRPI0816150A2 (en) * | 2007-08-24 | 2019-09-24 | Oncotherapy Science Inc | cancer related genes, cdca5, eph47, stk31 and w-dhd1. |
US20100286378A1 (en) * | 2007-08-27 | 2010-11-11 | Boston Biomedical, Inc. | Composition of Asymmetric RNA Duplex As MicroRNA Mimetic or Inhibitor |
CL2008002775A1 (en) | 2007-09-17 | 2008-11-07 | Amgen Inc | Use of a sclerostin binding agent to inhibit bone resorption. |
JP2010538678A (en) * | 2007-09-18 | 2010-12-16 | イントラドイグム コーポレーション | K-rassiRNA-containing compositions and methods for their use |
JP5723154B2 (en) | 2007-09-19 | 2015-05-27 | アプライド バイオシステムズ リミテッド ライアビリティー カンパニー | SiRNA sequence-independent modification format for reducing the influence of off-target phenotype in RNAi and its stabilized form |
CA2701128A1 (en) | 2007-10-01 | 2009-04-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
CN101815521B (en) * | 2007-10-03 | 2014-12-10 | 夸克制药公司 | Novel siRNA structures |
CA2702180A1 (en) * | 2007-10-12 | 2009-04-16 | Peter Humphries | Method for opening tight junctions |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
WO2009054725A2 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
EP2222283A2 (en) * | 2007-10-29 | 2010-09-01 | University of Massachusetts | Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna) |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
EP3000884B1 (en) | 2007-11-09 | 2018-09-12 | Ionis Pharmaceuticals, Inc. | Modulation of factor 7 expression |
EP2220230A2 (en) * | 2007-11-09 | 2010-08-25 | Isis Pharmaceuticals, Inc. | Modulation of factor 9 expression |
EP2245159A2 (en) | 2007-12-10 | 2010-11-03 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of factor vii gene |
US20100204305A1 (en) * | 2007-12-11 | 2010-08-12 | Lorus Therapeutics Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
WO2009074990A2 (en) * | 2007-12-12 | 2009-06-18 | Quark Pharmaceuticals, Inc. | Rtp801l sirna compounds and methods of use thereof |
NZ585784A (en) | 2007-12-13 | 2012-09-28 | Alnylam Pharmaceuticals Inc | siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection |
CA2707400A1 (en) | 2007-12-14 | 2009-06-25 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
KR100949791B1 (en) * | 2007-12-18 | 2010-03-30 | 이동기 | Novel siRNA Structure for Minimizing Off-target Effects and Relaxing Saturation of RNAi Machinery and the Use Thereof |
JP2011505846A (en) * | 2007-12-20 | 2011-03-03 | アンジオケム,インコーポレーテッド | Polypeptide-nucleic acid conjugates and uses thereof |
EP2077335A1 (en) * | 2007-12-22 | 2009-07-08 | Universitätsklinikum Schleswig-Holstein | EXO1 promoter polymorphism associated with exceptional life expectancy in humans |
KR100942807B1 (en) * | 2007-12-26 | 2010-02-18 | 재단법인서울대학교산학협력재단 | Gene Therapy and Pharmaceutical Composition for Preventing or Treating Lung Cancer |
EP2238251B1 (en) * | 2007-12-27 | 2015-02-11 | Protiva Biotherapeutics Inc. | Silencing of polo-like kinase expression using interfering rna |
EP2075333A1 (en) * | 2007-12-28 | 2009-07-01 | Qiagen GmbH | Positive controls for expression modulating experiments |
EP2242854A4 (en) * | 2008-01-15 | 2012-08-15 | Quark Pharmaceuticals Inc | Sirna compounds and methods of use thereof |
EP2246422A4 (en) * | 2008-01-24 | 2012-07-25 | Nat Inst Of Advanced Ind Scien | Polynucleotide or analogue thereof, and gene expression regulation method using the polynucleotide or the analogue thereof |
WO2009096612A1 (en) * | 2008-01-30 | 2009-08-06 | Korea Institute Of Science And Technology | Regulation of neutrotransmittter release through anion channels |
BRPI0907008A2 (en) * | 2008-01-31 | 2015-07-07 | Alnylam Pharmaceuticals Inc | Optimized methods for dsrna release by targeting the pcsk9 gene |
AU2009210872A1 (en) * | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating DNA repeat instability associated genetic disorders |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
CA2715289C (en) | 2008-02-11 | 2019-12-24 | Rxi Pharmaceuticals Corporation | Modified rnai polynucleotides and uses thereof |
US8288525B2 (en) * | 2008-02-12 | 2012-10-16 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD45 gene |
WO2009103067A2 (en) * | 2008-02-14 | 2009-08-20 | The Children's Hospital Of Philadelphia | Compositions and methods to treat asthma |
KR100870314B1 (en) * | 2008-02-19 | 2008-11-25 | 고려대학교 산학협력단 | Pharmaceutical composition containing nucleic acid for treating cancer |
DE112009000372A5 (en) * | 2008-02-20 | 2011-01-27 | Technische Universität Dresden | Use of substances for sensitizing tumor cells to radiation and / or chemotherapy |
WO2009111658A2 (en) * | 2008-03-05 | 2009-09-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 and vegf genes |
KR101123130B1 (en) * | 2008-03-17 | 2012-03-30 | 연세대학교 산학협력단 | Inhibitors of cell migration, invasion, or angiogenesis by blocking the function of PTK7 protein |
JP2011517404A (en) * | 2008-03-20 | 2011-06-09 | クォーク・ファーマシューティカルズ・インク | Novel siRNA compound for inhibiting RTP801 |
EP2105145A1 (en) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
WO2009122639A1 (en) * | 2008-03-31 | 2009-10-08 | Sugimoto Yoshikazu | Abc transporter protein expression inhibitor |
US9040492B2 (en) * | 2008-03-31 | 2015-05-26 | National Institute Of Advanced Industrial Science And Technology | Double-stranded lipid-modified RNA having high RNA interference effect |
US8936941B2 (en) | 2008-04-03 | 2015-01-20 | The Board Of Regents Of The University Of Oklahoma | Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof |
US7902166B2 (en) * | 2008-04-03 | 2011-03-08 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same |
US8198255B2 (en) * | 2008-05-16 | 2012-06-12 | The Board Of Regents Of The University Of Oklahoma | SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1 |
TWI348916B (en) * | 2008-04-03 | 2011-09-21 | Univ Nat Taiwan | A novel treatment tool for cancer: rna interference of bcas2 |
US7956044B1 (en) | 2008-04-03 | 2011-06-07 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same |
BRPI0911332A2 (en) * | 2008-04-04 | 2019-09-24 | Calando Pharmaceuticals Inc | compositions and use of epas1 inhibitors |
WO2009124973A1 (en) * | 2008-04-09 | 2009-10-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of stim1 for the treatment of cardiovascular disorders |
CA2721380A1 (en) * | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Silencing of csn5 gene expression using interfering rna |
US8278287B2 (en) * | 2008-04-15 | 2012-10-02 | Quark Pharmaceuticals Inc. | siRNA compounds for inhibiting NRF2 |
US7875711B2 (en) * | 2008-04-17 | 2011-01-25 | Alnylam Pharamaceuticals, Inc. | Compositions and methods for inhibiting expression of XBP-1 gene |
ES2721148T3 (en) * | 2008-04-18 | 2019-07-29 | Angiochem Inc | Pharmaceutical compositions of paclitaxel, paclitaxel analogues or paclitaxel conjugates and related methods of preparation and use |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
WO2009141541A2 (en) | 2008-04-22 | 2009-11-26 | Centre National De La Recherche Scientifique | Novel compositions which inhibit melanogenesis and uses thereof |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
AU2009246134B2 (en) | 2008-05-16 | 2016-03-03 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes |
US9663585B2 (en) | 2008-05-16 | 2017-05-30 | The Board Of Regents Of The University Of Oklahoma | Anti-DCLK1 monoclonal antibodies and methods of production and use thereof |
WO2009141146A1 (en) | 2008-05-21 | 2009-11-26 | Gunther Hartmann | 5' triphosphate oligonucleotide with blunt end and uses thereof |
US8541388B2 (en) | 2008-05-22 | 2013-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating expression of RBP4 |
WO2009143391A2 (en) * | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc | Methods for modulation expression of creb |
WO2009148137A1 (en) * | 2008-06-04 | 2009-12-10 | 協和発酵キリン株式会社 | Nucleic acid capable of controlling degranulation of mast cell |
WO2009147246A1 (en) * | 2008-06-06 | 2009-12-10 | Medizinische Universität Graz | Compounds reducing or inhibiting the expression of pkd1 for diagnosis and therapy of brain tumors |
AU2008357371A1 (en) * | 2008-06-06 | 2009-12-10 | Gene Techno Science Co., Ltd. | siRNA of human osteopontin |
WO2009147684A2 (en) * | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
US20110053226A1 (en) * | 2008-06-13 | 2011-03-03 | Riboxx Gmbh | Method for enzymatic synthesis of chemically modified rna |
US20090312194A1 (en) * | 2008-06-13 | 2009-12-17 | Oregon Health & Science University | Selection of personalized cancer therapy regimens using interfering rna functional screening |
TWI455944B (en) * | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | Double-stranded polynucleotides |
EP2310507A4 (en) * | 2008-07-08 | 2013-03-20 | David Gladstone Inst | Methods and compositions for modulating angiogenesis |
HUE027169T2 (en) | 2008-07-10 | 2016-10-28 | Regenesance B V | Complement antagonists and uses thereof |
WO2010006111A2 (en) * | 2008-07-10 | 2010-01-14 | Merck & Co., Inc. | Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer |
US20110184046A1 (en) * | 2008-07-11 | 2011-07-28 | Dinah Wen-Yee Sah | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes |
EP2313506A1 (en) * | 2008-07-11 | 2011-04-27 | Medizinische Universität Innsbruck | Antagonists of nr2f6 for augmenting the immune response |
US8309791B2 (en) | 2008-07-16 | 2012-11-13 | Recombinectics, Inc. | Method for producing a transgenic pig using a hyper-methylated transposon |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
EP2316491B1 (en) | 2008-07-18 | 2016-10-12 | National University Corporation Nagoya University | Cell proliferation inhibitor |
CN101632833B (en) * | 2008-07-25 | 2013-11-06 | 上海市计划生育科学研究所 | Prostatic cancer related gene and application thereof |
WO2010014592A1 (en) | 2008-07-29 | 2010-02-04 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
EP2323667A4 (en) * | 2008-08-07 | 2012-07-25 | Isis Pharmaceuticals Inc | Modulation of transthyretin expression for the treatment of cns related disorders |
WO2010019270A1 (en) | 2008-08-14 | 2010-02-18 | Isis Pharmaceuticals, Inc. | Modulation of prion expression |
US8946172B2 (en) * | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
EP3081648A1 (en) | 2008-08-25 | 2016-10-19 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US20130324478A1 (en) * | 2008-09-08 | 2013-12-05 | Laurence Faure | Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration |
AU2009291752B2 (en) | 2008-09-10 | 2015-12-17 | Rutgers, The State University Of New Jersey | Imaging individual mRNA molecules using multiple singly labeled probes |
WO2010030963A2 (en) * | 2008-09-15 | 2010-03-18 | Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
JP2010068723A (en) * | 2008-09-16 | 2010-04-02 | Tokyo Medical & Dental Univ | Nucleic acid medicine for treating allergic disease |
US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
EP3109321B1 (en) | 2008-09-25 | 2019-05-01 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
US8592570B2 (en) | 2008-10-06 | 2013-11-26 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of an RNA from West Nile virus |
JP2012504962A (en) * | 2008-10-07 | 2012-03-01 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Telomerase inhibitors and methods of use thereof |
CN102245636A (en) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | Etoposide and doxorubicin conjugates for drug delivery |
AU2009305636A1 (en) | 2008-10-15 | 2010-04-22 | Ionis Pharmaceuticals, Inc. | Modulation of Factor 11 expression |
WO2010045369A2 (en) * | 2008-10-15 | 2010-04-22 | Promising Future, Llc | Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells |
AU2009304560A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of GLP-1 agonists and uses thereof |
AU2015249072C1 (en) * | 2008-10-20 | 2022-10-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
NO2937418T3 (en) * | 2008-10-20 | 2018-03-17 | ||
WO2010048590A1 (en) * | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules |
CN105779453A (en) | 2008-10-24 | 2016-07-20 | 萨雷普塔治疗公司 | Multiple exon skipping compositions for DMD |
EP2350656B1 (en) * | 2008-10-30 | 2015-01-07 | The Translational Genomics Research Institute | Methods and kits to identify invasive glioblastoma |
US9095592B2 (en) * | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US20100267803A1 (en) * | 2008-11-07 | 2010-10-21 | The Research Foundation Of State University Of New York | Regulators Of Fat Metabolism As Anti-Cancer Targets |
MX2011004891A (en) * | 2008-11-13 | 2011-10-06 | Modgene Llc | Modification of amyloid-beta load in non-brain tissue. |
WO2010059226A2 (en) * | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
JP2012509331A (en) | 2008-11-21 | 2012-04-19 | アイシス ファーマシューティカルズ, インコーポレーテッド | Combination therapy for the treatment of cancer |
WO2010064851A2 (en) * | 2008-12-02 | 2010-06-10 | 울산대학교 산학협력단 | Mtor-targeted sirna having an interspecific cross reaction, recombination vector containing same, and pharmaceutical composition containing same |
ES2616051T3 (en) | 2008-12-02 | 2017-06-09 | Wave Life Sciences Japan, Inc. | Method for the synthesis of modified nucleic acids in the phosphorus atom |
RU2746478C2 (en) | 2008-12-04 | 2021-04-14 | КьюРНА, Инк. | Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene |
EP2370580B1 (en) * | 2008-12-04 | 2019-09-11 | CuRNA, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
NZ593743A (en) | 2008-12-04 | 2012-07-27 | Opko Ophthalmics Llc | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
CA2746514C (en) | 2008-12-10 | 2018-11-27 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
BRPI0923005A2 (en) * | 2008-12-17 | 2015-08-04 | Commw Scient Ind Res Org | Methods for modulating bird exo |
US8513207B2 (en) | 2008-12-18 | 2013-08-20 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
US11408003B2 (en) | 2008-12-18 | 2022-08-09 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
JP2012512642A (en) * | 2008-12-18 | 2012-06-07 | サントル・ナショナル・ドゥ・ラ・レシェルシュ・サイエンティフィーク−セ・エン・エール・エス− | Method for identifying gene related to TRAIL-induced apoptosis and therapeutic application thereof |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
US20120035242A1 (en) * | 2009-01-08 | 2012-02-09 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating obesity or diabetes |
US9127273B2 (en) * | 2009-01-13 | 2015-09-08 | The Board Of Regents Of The University Of Texas System | UNC-45A splice variants based cancer diagnostics and therapeutics |
SG173182A1 (en) * | 2009-02-03 | 2011-09-29 | Hoffmann La Roche | Compositions and methods for inhibiting expression of ptp1b genes |
WO2010093263A1 (en) * | 2009-02-03 | 2010-08-19 | Solilrna Biosciences Limited | Compositions and methods for the treatment and prevention of neoplastic disorders |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
WO2010091396A2 (en) * | 2009-02-09 | 2010-08-12 | Archemix Corp. | Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics |
WO2010093788A2 (en) * | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
PT2396038E (en) * | 2009-02-12 | 2016-02-19 | Curna Inc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2010091878A2 (en) * | 2009-02-13 | 2010-08-19 | Silence Therapeutics Ag | Means for inhibiting the expression of opa1 |
JP2012518401A (en) * | 2009-02-24 | 2012-08-16 | リボックス・ゲーエムベーハー | Improved design of small interfering RNA |
GB2468477A (en) * | 2009-03-02 | 2010-09-15 | Mina Therapeutics Ltd | Double stranded RNA molecule comprising siRNA and miRNA precursors |
CA2754749C (en) * | 2009-03-04 | 2019-04-30 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1 |
EP2404997B1 (en) | 2009-03-06 | 2017-10-18 | Mie University | Method for enhancing t cell function |
NZ594995A (en) * | 2009-03-12 | 2013-06-28 | Alnylam Pharmaceuticals Inc | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES |
WO2010107838A1 (en) | 2009-03-16 | 2010-09-23 | Isis Pharmaceuticals, Inc. | Targeting apolipoprotein b for the reduction of apolipoprotein c-iii |
ES2656290T3 (en) * | 2009-03-16 | 2018-02-26 | Curna, Inc. | Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2 |
BRPI1009271A8 (en) * | 2009-03-19 | 2016-02-10 | Merck Sharp & Dohme | DOUBLE-STRAND SHORT INTERFERING NUCLEIC ACID MOLECULE, PHARMACEUTICAL COMPOSITION, AND, METHOD FOR TREATMENT A HUMAN INDIVIDUAL SUFFERING FROM A CONDITION THAT IS MEDIATED BY THE ACTION, OR LOSS OF ACTION, OF BACH1 |
JP2012520686A (en) * | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of signal transduction transcription factor 6 (STAT6) gene expression using small interfering nucleic acids (siNA) |
CA2753388C (en) | 2009-03-23 | 2016-11-29 | Quark Pharmaceuticals, Inc. | Endo180 antibody to treat cancer and fibrotic disease |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
JP2012521760A (en) * | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA) |
EP2411520A2 (en) * | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2411018A2 (en) * | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
ES2599153T3 (en) * | 2009-03-31 | 2017-01-31 | Delta-Fly Pharma, Inc. | RNAi molecule for thymidylate synthase and use thereof |
US20120088814A1 (en) | 2009-03-31 | 2012-04-12 | Isis Pharmaceuticals, Inc. | Methods of modulating an immune response to a viral infection |
WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
JP6010458B2 (en) * | 2009-04-03 | 2016-10-19 | ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. | Methods and compositions for specific inhibition by asymmetric double-stranded RNA |
AU2010239069B2 (en) | 2009-04-20 | 2015-05-14 | Angiochem Inc | Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog |
JP2012524540A (en) | 2009-04-24 | 2012-10-18 | プロセンサ テクノロジーズ ビー.ブイ. | Oligonucleotides containing inosine for treating DMD |
US8349808B2 (en) * | 2009-05-05 | 2013-01-08 | Medical Diagnostic Laboratories, Llc | Identification of a novel repressor on IFN-lambda promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-lambda gene activity |
EP2427557B1 (en) | 2009-05-05 | 2015-03-18 | Boehringer Ingelheim International GmbH | Cho/cert cell lines |
CN103223177B (en) * | 2009-05-06 | 2016-08-10 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
KR101224828B1 (en) | 2009-05-14 | 2013-01-22 | (주)바이오니아 | SiRNA conjugate and preparing method thereof |
GB0908467D0 (en) * | 2009-05-15 | 2009-06-24 | Univ Gent | Use of the gtpase rab27b as biomarker to stratify patients with estrogen-receptor-positive breast cancer and to monitor their disease progression |
WO2011005363A2 (en) * | 2009-05-18 | 2011-01-13 | Ensysce Biosciences, Inc. | Carbon nanotubes complexed with multiple bioactive agents and methods related thereto |
EP2432882B1 (en) * | 2009-05-22 | 2019-12-25 | CuRNA, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
US9034838B2 (en) * | 2009-05-25 | 2015-05-19 | Universita Degli Studi Di Roma “La Sapienza” | miR-31 in duchenne muscular dystrophy therapy |
US8848602B2 (en) * | 2009-05-27 | 2014-09-30 | Oracle Israel Ltd. | Providing session-based services to event-based networks in multi-leg calls |
GB2471065A (en) * | 2009-06-10 | 2010-12-22 | Univ Sheffield | Modulator of claspin for treatment of cell proliferative disorder |
US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
MX2011013421A (en) | 2009-06-15 | 2012-03-16 | Alnylam Pharmaceuticals Inc | Lipid formulated dsrna targeting the pcsk9 gene. |
WO2010148249A1 (en) | 2009-06-17 | 2010-12-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
CN102482672B (en) * | 2009-06-26 | 2016-11-09 | 库尔纳公司 | By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene |
EP2449114B9 (en) | 2009-07-01 | 2017-04-19 | Protiva Biotherapeutics Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
EP2448965A4 (en) | 2009-07-02 | 2015-02-11 | Angiochem Inc | Multimeric peptide conjugates and uses thereof |
US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
US8603814B2 (en) | 2009-07-20 | 2013-12-10 | Rutgers The State University Of New Jersey | Method of inhibiting nonsense-mediated mRNA decay |
US9849146B2 (en) | 2009-07-20 | 2017-12-26 | Rutgers, The State University Of New Jersey | Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A |
CA2768947C (en) * | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
WO2011019763A2 (en) * | 2009-08-10 | 2011-02-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for the treatment of krabbe and other neurodegenerative diseases |
KR101827015B1 (en) * | 2009-08-11 | 2018-02-07 | 큐알엔에이, 인크. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
JP5883384B2 (en) | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | How to regulate immune function |
AP3574A (en) | 2009-08-14 | 2016-02-08 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
US8598327B2 (en) * | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
EP2982755B1 (en) * | 2009-08-21 | 2020-10-07 | CuRNA, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
US20120171213A1 (en) * | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
KR102279458B1 (en) | 2009-09-11 | 2021-07-21 | 아이오니스 파마수티컬즈, 인코포레이티드 | Modulation of huntingtin expression |
WO2011034798A1 (en) | 2009-09-15 | 2011-03-24 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
WO2011038031A1 (en) | 2009-09-22 | 2011-03-31 | Alnylam Pharmaceuticals, Inc. | Dual targeting sirna agents |
CA2775092A1 (en) * | 2009-09-23 | 2011-03-31 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
CN102028947B (en) * | 2009-09-29 | 2014-02-05 | 苏州瑞博生物技术有限公司 | Inhibitor, inhibitor composition and inhibiting method of FAM3B gene, fatty liver treatment method and pharmaceutical application of inhibitor |
EP2483407A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
US8394778B1 (en) | 2009-10-08 | 2013-03-12 | Immune Disease Institute, Inc. | Regulators of NFAT and/or store-operated calcium entry |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
WO2011053774A1 (en) | 2009-10-30 | 2011-05-05 | Alcon Research, Ltd. | Single nucleotide polymorphisms and genes associated with age-related macular degeneration |
JP5723378B2 (en) | 2009-11-03 | 2015-05-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Lipid formulation composition and method for inhibiting transthyretin (TTR) |
EP2496243A2 (en) * | 2009-11-04 | 2012-09-12 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
CN101708328A (en) * | 2009-11-06 | 2010-05-19 | 上海市免疫学研究所 | Pharmaceutical application of CYR61 protein |
US9799416B2 (en) * | 2009-11-06 | 2017-10-24 | Terrapower, Llc | Methods and systems for migrating fuel assemblies in a nuclear fission reactor |
US8901097B2 (en) | 2009-11-08 | 2014-12-02 | Quark Pharmaceuticals, Inc. | Methods for delivery of siRNA to the spinal cord and therapies arising therefrom |
NZ626359A (en) | 2009-11-12 | 2016-02-26 | Univ Western Australia | Antisense molecules and methods for treating pathologies |
EP2322927A1 (en) * | 2009-11-16 | 2011-05-18 | Deutsches Krebsforschungszentrum | Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer |
TW201124160A (en) | 2009-11-26 | 2011-07-16 | Quark Pharmaceuticals Inc | SiRNA compounds comprising terminal substitutions |
KR101168726B1 (en) * | 2009-11-30 | 2012-07-30 | 한국생명공학연구원 | Pharmaceutical composition for treating cancer |
KR101692063B1 (en) | 2009-12-09 | 2017-01-03 | 닛토덴코 가부시키가이샤 | MODULATION OF hsp47 EXPRESSION |
US8293718B2 (en) | 2009-12-18 | 2012-10-23 | Novartis Ag | Organic compositions to treat HSF1-related diseases |
AU2014280918B2 (en) * | 2009-12-18 | 2016-11-17 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat HSF1-related diseases |
GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
US8940708B2 (en) * | 2009-12-23 | 2015-01-27 | Curna, Inc. | Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF |
JP6031356B2 (en) * | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー,インコーポレイテッド | Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2. |
ES2616561T3 (en) | 2009-12-24 | 2017-06-13 | Biomarin Technologies B.V. | Molecule to treat an inflammatory disorder |
WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
ES2677969T3 (en) | 2010-01-08 | 2018-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin 3 expression |
EP2524039B1 (en) * | 2010-01-11 | 2017-11-29 | CuRNA, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
EP2524038A4 (en) * | 2010-01-12 | 2013-11-20 | Isis Pharmaceuticals Inc | Modulation of transforming growth factor-beta 1 expression |
US9198983B2 (en) * | 2010-01-25 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Mylip/Idol gene |
ES2733708T3 (en) | 2010-02-08 | 2019-12-02 | Ionis Pharmaceuticals Inc | Selective reduction of allelic variants |
EP2534262B1 (en) | 2010-02-08 | 2016-12-14 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
WO2011106689A1 (en) * | 2010-02-26 | 2011-09-01 | Isis Pharmaceuticals, Inc. | Modulation of smad3 expression |
CA2790211C (en) | 2010-03-08 | 2020-06-09 | Monsanto Technology Llc | Methods and compositions for delivering polynucleotides into plants |
US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
EP2550002B1 (en) | 2010-03-24 | 2019-05-08 | Phio Pharmaceuticals Corp. | Rna interference in dermal and fibrotic indications |
WO2011119871A1 (en) * | 2010-03-24 | 2011-09-29 | Rxi Phrmaceuticals Corporation | Rna interference in ocular indications |
US8796240B2 (en) | 2010-03-26 | 2014-08-05 | The University Of Tokyo | Cell growth inhibitor and screening method thereof |
US8853182B2 (en) * | 2010-03-26 | 2014-10-07 | The University Of Tokyo | Cell growth inhibitor and screening method thereof |
AU2011235276B2 (en) | 2010-03-29 | 2015-09-03 | Alnylam Pharmaceuticals, Inc. | SiRNA therapy for transthyretin (TTR) related ocular amyloidosis |
AU2015268740B2 (en) * | 2010-04-06 | 2017-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
AU2011237630B2 (en) * | 2010-04-06 | 2016-01-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD274/PD-L1 gene |
EP2561077B1 (en) * | 2010-04-23 | 2016-04-13 | Arrowhead Research Corporation | ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES |
BR112012027547B1 (en) | 2010-04-29 | 2022-06-14 | Ionis Pharmaceuticals, Inc | SINGLE STRIP MODIFIED OLIGONUCLEOTIDE, COMPOSITION, AND ITS USES TO TREAT TRANSTHIRRETIN AYLOIDOSIS, REDUCE ITS SYMPTOMS, AND TO REDUCE TRANSTHIRRETIN MRNA OR PROTEIN EXPRESSION |
KR101915115B1 (en) * | 2010-05-03 | 2018-11-05 | 큐알엔에이, 인크. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US9226972B2 (en) * | 2010-05-05 | 2016-01-05 | Auburn University | Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid |
EP3190187A1 (en) * | 2010-05-21 | 2017-07-12 | Peptimed, Inc. | Reagents and methods for treating cancer |
EP2576579B1 (en) * | 2010-06-02 | 2018-08-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
PT2585596T (en) * | 2010-06-23 | 2021-03-23 | Curna Inc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
FR2962041B1 (en) * | 2010-07-01 | 2012-07-27 | Genethon | INHIBITORS OF CALPAIN 3 FOR THE TREATMENT OF MUSCULAR DYSTROPHIES AND CARDIOMYOPATHIES |
JP2013534424A (en) | 2010-07-06 | 2013-09-05 | ダイセルナ ファーマシューティカルズ, インコーポレイテッド | Methods and compounds for the specific inhibition of androgen receptor by double-stranded RNA |
AU2011282217B2 (en) | 2010-07-19 | 2015-12-03 | Ionis Pharmaceuticals, Inc. | Modulation of dystrophia myotonica-protein kinase (DMPK) expression |
WO2012015775A2 (en) | 2010-07-28 | 2012-02-02 | Dharmacon, Inc. | Sirna targeting vegfa and methods for treatment in vivo |
US8455304B2 (en) | 2010-07-30 | 2013-06-04 | Atmel Corporation | Routable array metal integrated circuit package fabricated using partial etching process |
WO2012023288A1 (en) * | 2010-08-20 | 2012-02-23 | Oncotherapy Science, Inc. | Fam161a as a target gene for cancer therapy and diagnosis |
US9233997B2 (en) * | 2010-08-26 | 2016-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) |
EP3118316A1 (en) | 2010-09-02 | 2017-01-18 | Université de Mons | Agents useful in treating facioscapulohumeral muscular dystrophy |
MY162737A (en) | 2010-09-09 | 2017-07-14 | Pfizer | 4-1bb binding molecules |
US20140141015A1 (en) * | 2010-09-20 | 2014-05-22 | Douglas Lake | QSOX1 as an Anti-Neoplastic Drug Target |
US8946186B2 (en) * | 2010-09-20 | 2015-02-03 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | QSOX1 as an anti-neoplastic drug target |
US8217163B2 (en) * | 2010-09-20 | 2012-07-10 | Biomics Biotechnologies Co., Ltd. | Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas |
WO2012039137A2 (en) * | 2010-09-22 | 2012-03-29 | National University Corporation Hokkaido University | A nucleic acid having an anti-metabolic syndrome effect |
JP5868324B2 (en) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | Asymmetric auxiliary group |
US20130030034A9 (en) * | 2010-09-30 | 2013-01-31 | Quark Pharmaceuticals, Inc. | Modulation of timp1 and timp2 expression |
CN103080314B (en) * | 2010-09-30 | 2016-04-13 | Lsip基金运营联合公司 | Dominant mutant genes expression inhibitor |
US20120083035A1 (en) | 2010-09-30 | 2012-04-05 | Dharmacon, Inc. | Modified Cell Lines for Increasing Lentiviral Titers |
US9567580B2 (en) | 2010-10-08 | 2017-02-14 | Anjana Rao | Regulators of NFAT and/or store-operated calcium entry |
ES2732929T3 (en) | 2010-10-22 | 2019-11-26 | Olix Pharmaceuticals Inc | Nucleic acid molecules that induce RNA interference and uses thereof |
RU2662995C2 (en) | 2010-10-27 | 2018-07-31 | Девген Нв | Reducing gene expression in insect pests |
WO2012056441A1 (en) * | 2010-10-28 | 2012-05-03 | Nanodoc Ltd. | Compositions and methods for specific cleavage of exogenous rna in a cell |
CA2816321A1 (en) * | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
US9150864B2 (en) | 2010-11-08 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
EP2638163B1 (en) | 2010-11-12 | 2017-05-17 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
AU2011329777B2 (en) | 2010-11-17 | 2016-06-09 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
KR102010598B1 (en) * | 2010-11-23 | 2019-08-13 | 큐알엔에이, 인크. | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
WO2012075114A2 (en) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Nucleic acid-polymer conjugates and uses thereof |
US20130324591A1 (en) * | 2010-12-06 | 2013-12-05 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
EP2649182A4 (en) * | 2010-12-10 | 2015-05-06 | Alnylam Pharmaceuticals Inc | Compositions and methods for increasing erythropoietin (epo) production |
WO2012079046A2 (en) * | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
US9644042B2 (en) | 2010-12-17 | 2017-05-09 | Carnegie Mellon University | Electrochemically mediated atom transfer radical polymerization |
CA2820440A1 (en) * | 2010-12-17 | 2012-06-21 | Universite Pierre Et Marie Curie (Paris 6) | The abcg1 gene as a marker and a target gene for treating obesity |
ES2710109T3 (en) * | 2010-12-17 | 2019-04-23 | Inst Nat Sante Rech Med | Nucleic acids that target TCTP for use in the treatment of chemoresistant or hormone-resistant cancers |
WO2012094115A1 (en) * | 2010-12-17 | 2012-07-12 | Arrowhead Research Corporation | Compositions and methods for inhibiting expression of flt3 genes |
US10301620B2 (en) * | 2010-12-22 | 2019-05-28 | Murdoch Childrens Research Institute | Method of treatment |
AU2011353283A1 (en) * | 2010-12-30 | 2013-07-18 | Samyang Biopharmaceuticals Corporation | siRNA for inhibition of Hif1alpha expression and anticancer composition containing the same |
BR112013018924A2 (en) | 2011-01-25 | 2018-05-08 | Almac Diagnostics Ltd | Colon cancer gene expression signatures and methods of use |
WO2012106175A1 (en) * | 2011-02-02 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma |
KR101697396B1 (en) | 2011-02-02 | 2017-01-17 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
US9359605B2 (en) * | 2011-03-11 | 2016-06-07 | Sarissa Inc. | Method of treating cancer by inhibition of DNA repair proteins |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
MX360349B (en) | 2011-03-29 | 2018-10-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of tmprss6 gene. |
JP5943993B2 (en) | 2011-04-01 | 2016-07-05 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Transcriptional signaling and regulation of activator 3 (STAT3) expression |
CA2832972C (en) | 2011-04-13 | 2019-04-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of ptp1b expression |
WO2012142480A1 (en) * | 2011-04-14 | 2012-10-18 | Beth Israel Deaconess Medical Center, Inc. | Chimeric rna oligonucleotides and uses thereof |
CN111172162A (en) | 2011-04-21 | 2020-05-19 | 葛兰素史克公司 | Modulation of Hepatitis B Virus (HBV) expression |
TW201243330A (en) * | 2011-04-22 | 2012-11-01 | Univ Nat Cheng Kung | Method for analyzing sectretome, biomarker for lung cancer metastasis, and siRNA compound for inhibiting lung cancer metastasis |
ES2622112T3 (en) | 2011-05-02 | 2017-07-05 | Stichting Vumc | Protection against endothelial barrier dysfunction through inhibition of the tyrosine-related gene Abl kinase (ARG) |
EP2704751B1 (en) | 2011-05-02 | 2019-04-17 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
CA2834610A1 (en) * | 2011-06-06 | 2012-12-13 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression |
CA2838588C (en) * | 2011-06-09 | 2021-09-14 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
US9315811B2 (en) | 2011-06-10 | 2016-04-19 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
CN103597074A (en) | 2011-06-16 | 2014-02-19 | Isis制药公司 | Antisense modulation of fibroblast growth factor receptor 4 expression |
EP2723756B1 (en) | 2011-06-21 | 2020-03-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
EP2723351B1 (en) | 2011-06-21 | 2018-02-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
EP3456828B1 (en) | 2011-06-21 | 2022-04-27 | MiNA Therapeutics Limited | Albumin production and cell proliferation |
EP2723861A4 (en) * | 2011-06-21 | 2014-12-10 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression |
SG10201800715PA (en) * | 2011-06-21 | 2018-02-27 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
FI20115640A0 (en) | 2011-06-22 | 2011-06-22 | Turun Yliopisto | combination therapy |
US20140235693A1 (en) | 2011-06-23 | 2014-08-21 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
WO2013003808A1 (en) | 2011-06-29 | 2013-01-03 | Isis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
CA3205596A1 (en) * | 2011-07-18 | 2013-01-24 | University Of Kentucky Research Foundation | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells |
SG10201700554VA (en) | 2011-07-19 | 2017-03-30 | Wave Life Sciences Pte Ltd | Methods for the synthesis of functionalized nucleic acids |
US20140328811A1 (en) * | 2011-08-01 | 2014-11-06 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
US20150051389A1 (en) | 2011-08-11 | 2015-02-19 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
US20140275420A1 (en) | 2011-08-22 | 2014-09-18 | Carnegie Mellon University | Atom transfer radical polymerization under biologically compatible conditions |
KR101275264B1 (en) * | 2011-08-24 | 2013-06-17 | 포항공과대학교 산학협력단 | Method of screening for chaperonin modulator |
US9617538B2 (en) * | 2011-08-29 | 2017-04-11 | Niigata University Of Pharmacy And Applied Life Science | Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells |
WO2013033230A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
EP2751272A2 (en) * | 2011-09-02 | 2014-07-09 | Novartis AG | Organic compositions to treat hsf1-related diseases |
FI20115876A0 (en) | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Combination therapy |
US20130064881A1 (en) * | 2011-09-08 | 2013-03-14 | Gradalis, Inc. | Compositions and methods for treating prostate cancer |
MX343072B (en) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Methods and compositions for weed control. |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
EP2755467B1 (en) | 2011-09-13 | 2017-07-19 | Monsanto Technology LLC | Methods and compositions for weed control |
MX343071B (en) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Methods and compositions for weed control. |
MX348495B (en) * | 2011-09-13 | 2017-06-14 | Monsanto Technology Llc | Methods and compositions for weed control. |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
BR112014005975A8 (en) | 2011-09-13 | 2017-09-12 | Monsanto Technology Llc | PLANT CONTROL METHOD, METHOD OF REDUCING EXPRESSION OF A PDS GENE IN A PLANT, MICROBIAL EXPRESSION CASSETTE, METHOD OF MAKING A POLYNUCLEOTIDE, METHOD OF IDENTIFICATION OF POLYNUCLEOTIDES, AND COMPOSITIONS FOR WEED CONTROL |
BR112014005331A2 (en) * | 2011-09-14 | 2017-04-11 | Nippon Kayaku Kk | methods for inhibiting cell growth, and for screening for anticancer agents, nucleic acid molecule, expression vector, composition for inhibiting gene expression, and, anticancer agent |
US11058708B2 (en) * | 2011-09-19 | 2021-07-13 | Sweyshen Chen | RNA interference of galectin-3 expression and methods of use thereof |
US9453261B2 (en) * | 2011-09-20 | 2016-09-27 | The George Washington University | Alternative splicing variants of genes associated with prostate cancer risk and survival |
EP2758533B1 (en) | 2011-09-20 | 2018-04-11 | Ionis Pharmaceuticals, Inc. | Antisense modulation of gcgr expression |
US9481895B2 (en) | 2011-09-23 | 2016-11-01 | Ge Healthcare Dharmacon, Inc. | Introduction of modular vector elements during production of a lentivirus |
SG11201400976WA (en) * | 2011-09-28 | 2014-04-28 | Agency Science Tech & Res | Methods and pharmaceutical compositions for treating cancer |
JP2013079210A (en) * | 2011-10-04 | 2013-05-02 | Nagoya City Univ | Therapeutic agent, gene therapy agent, and method for preventing invasion of eosinophil |
US9382534B2 (en) | 2011-10-05 | 2016-07-05 | Ge Healthcare Dharmacon, Inc. | Optimization of vectors for effective delivery and expression of genetic content |
CA2853373A1 (en) | 2011-10-25 | 2013-05-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of gccr expression |
WO2013067001A1 (en) * | 2011-10-31 | 2013-05-10 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
CN102373206B (en) * | 2011-10-31 | 2013-02-27 | 暨南大学 | PPP2R5C-siRNA799 for targeted inhabitation of PPP2R5C gene expression and tumor T cell multiplication and application thereof |
US9773091B2 (en) | 2011-10-31 | 2017-09-26 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
EP2776564B1 (en) | 2011-11-07 | 2019-10-02 | Ionis Pharmaceuticals, Inc. | Modulation of tmprss6 expression |
US9567585B2 (en) | 2011-11-10 | 2017-02-14 | Shire Human Genetic Therapies, Inc. | Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof |
EP2725103A3 (en) * | 2011-11-14 | 2016-01-06 | Silenseed Ltd | Methods and compositions for treating prostate cancer |
WO2013075140A1 (en) * | 2011-11-17 | 2013-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Auto -recognizing therapeutic rna/dna chimeric nanoparticles (np) |
SG11201402392QA (en) | 2011-11-18 | 2014-06-27 | Alnylam Pharmaceuticals Inc | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
WO2013075233A1 (en) * | 2011-11-21 | 2013-05-30 | The Royal Institution For The Advancement Of Learning / Mcgill University | Method for treating brain cancer |
WO2013086433A1 (en) * | 2011-12-07 | 2013-06-13 | The Methodist Hospital Research Institute | Sirna compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer |
CN104302768A (en) | 2012-01-09 | 2015-01-21 | 诺华股份有限公司 | Rnai agents to treat beta-catenin related diseases |
US9707235B1 (en) | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
WO2013112053A1 (en) | 2012-01-27 | 2013-08-01 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
WO2013120726A2 (en) | 2012-02-13 | 2013-08-22 | Unilever N.V. | A skin lightening composition |
BR112014020824B1 (en) | 2012-02-24 | 2022-10-04 | Protiva Biotherapeutics Inc | LIPID, LIPID PARTICLE AND PHARMACEUTICAL COMPOSITION |
US9139829B2 (en) * | 2012-02-28 | 2015-09-22 | Medical Diagnostic Laboratories, Llc | SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment |
US9708605B2 (en) | 2012-03-16 | 2017-07-18 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of MCL1 by double-stranded RNA |
US9340784B2 (en) | 2012-03-19 | 2016-05-17 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
US9410156B2 (en) | 2012-03-28 | 2016-08-09 | Somalogic, Inc. | Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions |
WO2013149191A1 (en) * | 2012-03-29 | 2013-10-03 | The Trustees Of Columbia University In The City Of New York | Methods for regulating hair growth disorders |
AU2013241099A1 (en) * | 2012-03-29 | 2014-10-09 | Aqua Therapeutics Co., Ltd. | Nucleic acid molecule capable of inhibiting expression of periostin gene, method for inhibiting expression of periostin gene, and use of said nucleic acid molecule |
AU2013203395A1 (en) | 2012-03-30 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome |
JP6482869B2 (en) * | 2012-04-03 | 2019-03-13 | 国立研究開発法人国立成育医療研究センター | DNA for controlling expression of miR-140 and method for screening drug using the DNA |
US9133461B2 (en) * | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
US20150211004A1 (en) * | 2012-04-20 | 2015-07-30 | Agency For Science, Technology And Research | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies |
US9127274B2 (en) * | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
US10407677B2 (en) * | 2012-04-26 | 2019-09-10 | Intana Bioscience Gmbh | High complexity siRNA pools |
TWI480043B (en) * | 2012-05-01 | 2015-04-11 | Univ Kaohsiung Medical | A medication for phthalates-induced estrogen receptor-negative breast cancer |
EP3272868A1 (en) * | 2012-05-02 | 2018-01-24 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat kras-related diseases |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
CN104583399A (en) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | Compositions and methods for modulating hemoglobin gene family expression |
CA2873766A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating atp2a2 expression |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
SG11201407483YA (en) | 2012-05-16 | 2014-12-30 | Rana Therapeutics Inc | Compositions and methods for modulating smn gene family expression |
WO2013173645A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating utrn expression |
CN104583402A (en) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | Compositions and methods for modulating MECP2 expression |
US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
WO2013173789A2 (en) | 2012-05-17 | 2013-11-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
WO2013177248A2 (en) | 2012-05-22 | 2013-11-28 | Isis Pharmaceuticals, Inc. | Modulation of enhancer rna mediated gene expression |
JP6139671B2 (en) | 2012-05-22 | 2017-05-31 | オリックス ファーマシューティカルズ インコーポレイテッドOlix Pharmaceuticals Inc. | Nucleic acid molecule that induces RNA interference with intracellular penetration ability and use thereof |
AU2013264742B2 (en) | 2012-05-24 | 2018-10-04 | A.B. Seeds Ltd. | Compositions and methods for silencing gene expression |
WO2013181665A1 (en) * | 2012-06-01 | 2013-12-05 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
WO2013181666A2 (en) | 2012-06-01 | 2013-12-05 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
US9201916B2 (en) * | 2012-06-13 | 2015-12-01 | Infosys Limited | Method, system, and computer-readable medium for providing a scalable bio-informatics sequence search on cloud |
CN102703451B (en) * | 2012-06-21 | 2013-04-17 | 浙江省医学科学院 | Expression box for inhibiting expression of Bcl12 gene and vector containing expression box |
CN102703452B (en) * | 2012-06-21 | 2013-06-05 | 浙江省医学科学院 | siRNA double-strand for inhibiting Bcl2 gene expression and application thereof |
CA2890235A1 (en) * | 2012-06-22 | 2013-12-27 | Syngenta Participations Ag | Biological control of coleopteran pests |
DK3461895T3 (en) | 2012-06-25 | 2020-07-20 | Ionis Pharmaceuticals Inc | MODULATION OF UBE3A-ATS EXPRESSION |
CN104797267A (en) | 2012-06-26 | 2015-07-22 | 德玛医药 | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
CA2878873C (en) | 2012-07-13 | 2018-08-21 | Turun Yliopisto | A pharmaceutical combination including a histone deacetylase 4 (hdac4) silencing agent for treating cancer |
AU2013288048A1 (en) | 2012-07-13 | 2015-01-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
CA2878945A1 (en) | 2012-07-13 | 2014-01-16 | Wave Life Sciences Pte. Ltd. | Chiral control |
CN103540655A (en) * | 2012-07-16 | 2014-01-29 | 复旦大学 | Application of MK5 gene for screening anti-liver cancer drug |
US9604988B2 (en) | 2012-07-27 | 2017-03-28 | Riken | Agent for treating or inhibiting recurrence of acute myeloid leukemia |
WO2014022655A1 (en) * | 2012-08-01 | 2014-02-06 | The Trustees Of Columbia University In The City Of New York | Methods for regulating hair growth disorders |
KR101520383B1 (en) * | 2012-08-02 | 2015-05-15 | 에이비온 주식회사 | Composition for Treating HPV-related Cancers |
US9315567B2 (en) | 2012-08-14 | 2016-04-19 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
JP6367802B2 (en) * | 2012-08-30 | 2018-08-01 | トゥルン イリオピスト | How to choose individual brain cancer therapy |
EP3441467A3 (en) * | 2012-08-31 | 2019-04-24 | The General Hospital Corporation | Biotin complexes for treatment and diagnosis of alzheimer's disease |
US20140066595A1 (en) * | 2012-09-04 | 2014-03-06 | Thermo Fisher Scientific Biosciences Inc. | Modulators of Protein Production in a Human Cell Line and Cell-free Extracts Produced Therefrom |
GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
AU2012389270B2 (en) | 2012-09-05 | 2018-11-08 | Sylentis S.A.U. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
JP6364009B2 (en) | 2012-09-12 | 2018-07-25 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | Double-stranded oligonucleotide molecules against P53 and methods of use thereof |
AU2013224684B2 (en) * | 2012-09-13 | 2017-07-06 | Plant Bioscience Limited | GENETIC MARKERS FOR Myb28 |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
EP4052709A1 (en) | 2012-10-11 | 2022-09-07 | Ionis Pharmaceuticals, Inc. | Methods of treating kennedy's disease |
AR092982A1 (en) * | 2012-10-11 | 2015-05-13 | Isis Pharmaceuticals Inc | MODULATION OF THE EXPRESSION OF ANDROGEN RECEIVERS |
EP2906696B2 (en) | 2012-10-15 | 2022-12-14 | Ionis Pharmaceuticals, Inc. | Methods for modulating c9orf72 expression |
EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | Methods for monitoring c9orf72 expression |
RU2730677C2 (en) | 2012-10-15 | 2020-08-24 | Ионис Фармасьютикалз, Инк. | Compound for modulation of c9orf72 gene expression and use thereof |
WO2014060392A1 (en) * | 2012-10-16 | 2014-04-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Caspase-6 inhibitors for treating t cell activation and/or proliferation disorders |
WO2014066864A2 (en) | 2012-10-26 | 2014-05-01 | Memorial Sloan-Kettering Cancer Center | Androgen receptor variants and methods for making and using |
WO2014076703A1 (en) * | 2012-11-14 | 2014-05-22 | Silenseed Ltd. | Methods and compositions for treating cancer |
WO2014077693A1 (en) * | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
SG10202110062SA (en) | 2012-11-27 | 2021-11-29 | Childrens Medical Center | Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction |
JP6574383B2 (en) | 2012-12-05 | 2019-09-11 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | PCSK9 iRNA composition and method of use thereof |
TW201437368A (en) * | 2012-12-14 | 2014-10-01 | Dicerna Pharmaceuticals Inc | Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA |
WO2014106837A2 (en) | 2013-01-01 | 2014-07-10 | A. B. Seeds Ltd. | ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
US9926559B2 (en) | 2013-01-09 | 2018-03-27 | Biogen Ma Inc. | Compositions and methods for modulation of SMN2 splicing in a subject |
US9593332B2 (en) * | 2013-01-15 | 2017-03-14 | Tufts Medical Center | Methods and compositions for targeting immunoglobulins |
KR101409445B1 (en) * | 2013-01-17 | 2014-06-24 | 한국과학기술연구원 | siRNA for Inhibition of OTUB1 Expression and Pharmaceutical Composition Containing the same |
KR101480523B1 (en) * | 2013-02-07 | 2015-01-08 | 고려대학교 산학협력단 | siRNA for Inhibiting Endogenous rpS3 Expression |
AU2014216137B2 (en) | 2013-02-14 | 2018-05-10 | Ionis Pharmaceuticals, Inc. | Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations |
DE102013003869B4 (en) * | 2013-02-27 | 2016-11-24 | Friedrich-Schiller-Universität Jena | A method for the targeted killing of cells by mRNA binding aligned nucleotide molecules and nucleotide molecules and application kit for such use |
EP2961843A2 (en) * | 2013-02-28 | 2016-01-06 | Arrowhead Research Corporation | Organic compositions to treat epas1-related diseases |
US9265789B2 (en) * | 2013-03-12 | 2016-02-23 | The Medical College Of Wisconsin, Inc. | Targeting CLPTM1L by RNA interference for treatment and prevention of cancer |
CA2905027A1 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
AR095233A1 (en) | 2013-03-13 | 2015-09-30 | Monsanto Technology Llc | METHODS AND COMPOSITIONS FOR WEED CONTROL |
US20160138027A1 (en) * | 2013-03-14 | 2016-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
EP3998339A1 (en) | 2013-03-14 | 2022-05-18 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
KR20230162998A (en) * | 2013-03-14 | 2023-11-29 | 알닐람 파마슈티칼스 인코포레이티드 | Complement component c5 irna compositions and methods of use thereof |
CN111254145A (en) | 2013-03-14 | 2020-06-09 | Ionis制药公司 | Compositions and methods for modulating TAU expression |
US9132174B2 (en) | 2013-03-15 | 2015-09-15 | Anchored Rsk3 Inhibitors, Llc | Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3) |
EP2970976A4 (en) * | 2013-03-15 | 2016-11-02 | Techulon Inc | Antisense molecules for treatment of staphylococcus aureus infection |
US10059944B2 (en) | 2013-03-15 | 2018-08-28 | New York University | SiRNA targeting HSR1 |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
EP3662912A1 (en) | 2013-03-15 | 2020-06-10 | Sarepta Therapeutics, Inc. | Improved dosages of eteplirsen for treating duchenne muscular dystrophy |
CA2942811A1 (en) | 2013-03-15 | 2014-09-25 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
US11342048B2 (en) | 2013-03-15 | 2022-05-24 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
US9418203B2 (en) | 2013-03-15 | 2016-08-16 | Cypher Genomics, Inc. | Systems and methods for genomic variant annotation |
WO2014140856A2 (en) | 2013-03-15 | 2014-09-18 | Graham Lord | Mir-142 and antagonists thereof for treating disease |
WO2014148529A1 (en) * | 2013-03-21 | 2014-09-25 | 学校法人埼玉医科大学 | Double-stranded nucleic acid molecule, dna, vector, cancer cell proliferation inhibitor, and pharmaceutical product |
CN103205400B (en) * | 2013-04-19 | 2014-09-17 | 青岛大学医学院附属医院 | Recombinant lentiviral vector containing ubiquitin-specific protease gene USP39-shRNA (short hairpin ribonucleic acid) and application thereof |
US9264644B2 (en) * | 2013-04-25 | 2016-02-16 | Forza Silicon Corporation | Analog-to-digital conversion for image sensor with non-destructive read pixel |
EP3633039A1 (en) | 2013-05-01 | 2020-04-08 | Ionis Pharmaceuticals, Inc. | Compositions and methods |
US10294480B2 (en) | 2013-05-03 | 2019-05-21 | President And Fellows Of Harvard College | Foreign DNA surveillance protein |
HUE038146T2 (en) | 2013-05-22 | 2018-09-28 | Alnylam Pharmaceuticals Inc | Serpina1 irna compositions and methods of use thereof |
KR102365809B1 (en) | 2013-05-22 | 2022-02-23 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 compositions and methods of use thereof |
US20160083733A1 (en) * | 2013-05-23 | 2016-03-24 | University Of Bremen | Novel treatment of metabolic diseases |
US9790504B2 (en) * | 2013-05-24 | 2017-10-17 | The University Of Chicago | Anti-tumor therapy |
JP2016524621A (en) | 2013-06-03 | 2016-08-18 | バル−イラン ユニバーシティ | Liposomes that modulate Wiscot Aldrich syndrome protein |
WO2014197421A1 (en) * | 2013-06-05 | 2014-12-11 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
KR102306656B1 (en) * | 2013-07-03 | 2021-09-29 | 삼성전자주식회사 | Combination therapy for the treatment of cancer using an anti-c-Met antibody |
JP2016528887A (en) | 2013-07-03 | 2016-09-23 | ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. | Methods and compositions for specific inhibition of alpha-1 antitrypsin by double stranded RNA |
US9512430B2 (en) | 2013-07-03 | 2016-12-06 | Wisconsin Alumni Research Foundation | Compositions and methods to promote erythropoiesis |
KR20150006743A (en) * | 2013-07-09 | 2015-01-19 | (주)바이오니아 | Liver cancer related genes-specific siRNA, double-stranded oligo RNA molecules comprising the siRNA, and composition for the prevention or treatment of cancer comprising the same |
KR20150006742A (en) * | 2013-07-09 | 2015-01-19 | (주)바이오니아 | Liver cancer related genes-specific siRNA, double-stranded oligo RNA molecules comprising the siRNA, and composition for the prevention or treatment of cancer comprising the same |
EP3030663B1 (en) | 2013-07-19 | 2019-09-04 | Monsanto Technology LLC | Compositions and methods for controlling leptinotarsa |
TWI772856B (en) | 2013-07-19 | 2022-08-01 | 美商百健Ma公司 | Compositions for modulating tau expression |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
TW201536329A (en) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression |
WO2015023975A1 (en) * | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Compositions and methods for modulating rna |
US10144928B2 (en) | 2013-08-23 | 2018-12-04 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
US9670492B2 (en) | 2013-08-28 | 2017-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
WO2015035231A1 (en) * | 2013-09-05 | 2015-03-12 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
AR099641A1 (en) * | 2013-09-05 | 2016-08-10 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | OSTEONECTINE (SPARC) AS A THERAPEUTIC WHITE FOR THE TREATMENT AND PREVENTION OF ACUTE LIVER FAILURE, PHARMACEUTICAL COMPOSITION, GENETIC CONSTRUCTION, ARNsi, AGENT INHIBITING EXPRESSION, USE |
EP3693472A1 (en) | 2013-09-09 | 2020-08-12 | Somalogic, Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
EP3043827B1 (en) * | 2013-09-13 | 2019-07-03 | Ionis Pharmaceuticals, Inc. | Modulators of complement factor b |
EP2853596A1 (en) * | 2013-09-30 | 2015-04-01 | IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) | Protein phosphatase inhibitor |
EP3739049A1 (en) * | 2013-10-02 | 2020-11-18 | Albert Einstein College of Medicine | Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing |
EP3052626A1 (en) * | 2013-10-02 | 2016-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
PE20161130A1 (en) * | 2013-10-04 | 2016-11-25 | Icahn School Med Mount Sinai | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF THE ALAS1 GENE |
CN105637090B (en) | 2013-10-11 | 2020-10-16 | Ionis制药公司 | Compositions for modulating expression of C9ORF72 |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
EP2865757A1 (en) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene. |
EP2865758A1 (en) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene |
US9540642B2 (en) | 2013-11-04 | 2017-01-10 | The United States Of America, As Represented By The Secretary Of Agriculture | Compositions and methods for controlling arthropod parasite and pest infestations |
WO2015070158A1 (en) * | 2013-11-11 | 2015-05-14 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
SI3071696T1 (en) | 2013-11-22 | 2019-11-29 | Mina Therapeutics Ltd | C/ebp alpha short activating rna compositions and methods of use |
US10934550B2 (en) | 2013-12-02 | 2021-03-02 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer |
AU2014360314B2 (en) | 2013-12-06 | 2018-04-26 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA |
UA119253C2 (en) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Compositions and methods for virus control in varroa mite and bees |
AU2014362262B2 (en) * | 2013-12-12 | 2021-05-13 | Alnylam Pharmaceuticals, Inc. | Complement component iRNA compositions and methods of use thereof |
HUE052243T2 (en) | 2013-12-24 | 2021-04-28 | Ionis Pharmaceuticals Inc | Modulation of angiopoietin-like 3 expression |
US9701966B2 (en) | 2013-12-27 | 2017-07-11 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
WO2015108047A1 (en) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
AU2015206585A1 (en) | 2014-01-15 | 2016-07-21 | Monsanto Technology Llc | Methods and compositions for weed control using EPSPS polynucleotides |
JPWO2015108048A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antitumor agent having antitumor activity |
KR20220106232A (en) | 2014-01-16 | 2022-07-28 | 웨이브 라이프 사이언시스 리미티드 | Chiral design |
CN104805085A (en) * | 2014-01-29 | 2015-07-29 | 江苏命码生物科技有限公司 | Tandem expressed siRNA and use of tandem expressed siRNA in treatment on chronic lymphocytic leukemia |
CA2938857A1 (en) | 2014-02-11 | 2015-08-20 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
KR101425140B1 (en) * | 2014-02-19 | 2014-08-13 | 한국과학기술원 | Inhibitors of methylation of LIN28A for controlling differentiation of pluripotent stem cells, its screening method and Compositions of the same |
AU2015219495B2 (en) | 2014-02-21 | 2019-11-21 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
WO2015132303A1 (en) | 2014-03-04 | 2015-09-11 | Sylentis Sau | Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions |
CN104894223B (en) * | 2014-03-07 | 2019-03-26 | 上海吉凯基因化学技术有限公司 | The purposes and its related drugs of people's COPB2 gene |
WO2015137459A1 (en) * | 2014-03-13 | 2015-09-17 | 協和発酵キリン株式会社 | Nucleic acid that inhibits expression of irf5 |
ES2856403T3 (en) | 2014-03-18 | 2021-09-27 | Univ Massachusetts | RAAV-based compositions and procedures for the treatment of amyotrophic lateral sclerosis |
US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
CA2942340A1 (en) | 2014-03-19 | 2015-09-24 | Ionis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
DK3119887T3 (en) * | 2014-03-20 | 2019-05-20 | Oommen Varghese | Improved short interfering ribonucleic acid molecules |
EP3420809A1 (en) | 2014-04-01 | 2019-01-02 | Monsanto Technology LLC | Compositions and methods for controlling insect pests |
SG10201906520RA (en) | 2014-04-01 | 2019-09-27 | Biogen Ma Inc | Compositions for modulating sod-1 expression |
JP6426268B2 (en) * | 2014-04-04 | 2018-11-21 | バイオニア コーポレーションBioneer Corporation | Novel double helix oligo RNA and pharmaceutical composition for preventing or treating fibrosis or respiratory disease comprising the same |
MA39835A (en) | 2014-04-17 | 2017-02-22 | Biogen Ma Inc | Compositions and methods for modulation of smn2 splicing in a subject |
BR112016024565A2 (en) | 2014-04-25 | 2018-01-23 | Children's Medical Center Corporation | compositions and methods of treating hemoglobinopathies |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
CN106255755B (en) | 2014-05-01 | 2020-07-24 | Ionis制药公司 | Compositions and methods for modulating angiopoietin-like protein 3 expression |
HUE052709T2 (en) | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression |
PE20170010A1 (en) * | 2014-05-01 | 2017-03-04 | Ionis Pharmaceuticals Inc | COMPOSITIONS AND METHODS TO MODULATE THE EXPRESSION OF THE COMPLEMENT FACTOR B |
WO2015168618A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
DK3145553T3 (en) * | 2014-05-23 | 2019-10-28 | Univ Degli Studi Dellaquila | LITTLE INTERFERRING RNA (SIRNA) FOR TREATMENT OF TYPE 2 (ADO2) AUTOSOMAL DOMINANT OSTEOPETROSE CAUSED BY CLCN7 (ADO2 CLCN7 DEPENDENT) GENUTATION |
KR20150137473A (en) * | 2014-05-29 | 2015-12-09 | 한국과학기술연구원 | siRNA for Inhibition of USP15 Expression and Pharmaceutical Composition Containing the same |
KR20170012366A (en) | 2014-06-04 | 2017-02-02 | 교와 핫꼬 기린 가부시키가이샤 | Ckap5-gene-silencing rnai pharmaceutical composition |
TW201620526A (en) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin |
WO2015200223A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
WO2016018887A1 (en) | 2014-07-29 | 2016-02-04 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
KR20170042625A (en) * | 2014-08-04 | 2017-04-19 | 미라젠 세러퓨틱스 인코포레이티드 | Inhibitors of MYH7B and Uses Thereof |
US20170137820A1 (en) * | 2014-08-06 | 2017-05-18 | Bavarian Nordic A/S | Agonists and antagonists of toll-like receptor (tlr) 13 |
GB2547586A (en) * | 2014-08-20 | 2017-08-23 | Lifesplice Pharma Llc | Splice modulating oligonucleotides and methods of use thereof(In the PCT request) |
EP3185957B1 (en) | 2014-08-29 | 2022-06-01 | Alnylam Pharmaceuticals, Inc. | Patisiran for use in treating transthyretin mediated amyloidosis |
JP2017526367A (en) * | 2014-08-29 | 2017-09-14 | チルドレンズ メディカル センター コーポレーション | Methods and compositions for the treatment of cancer |
US10731163B2 (en) * | 2014-09-02 | 2020-08-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Oligonucleotide targeted to the A20-3′ untranslated region |
CN107073294A (en) | 2014-09-05 | 2017-08-18 | 阿克赛医药公司 | Use the method for targeting TYR or MMP1 exonuclease treatment aging and skin disorder |
WO2016040167A1 (en) * | 2014-09-08 | 2016-03-17 | Brandon Higgs | Compositions and methods for detecting and treating small cell lung cancer |
US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
JP2017529082A (en) * | 2014-09-18 | 2017-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Allele-specific therapy for Huntington's disease haplotypes |
US9777279B2 (en) | 2014-09-24 | 2017-10-03 | University Of Cincinnati | Methods and compositions for treating autoimmune disorders by targeting Kv1.3 ion channels with functionalized lipid-derived nanovesicles |
JOP20200115A1 (en) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression |
WO2016061487A1 (en) * | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
KR101646609B1 (en) * | 2014-10-24 | 2016-08-08 | 한국원자력의학원 | Composition for diagnosing laryngeal cancer or radio resistance of laryngeal cancer and diagnosing method |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
EP3212824A4 (en) | 2014-10-30 | 2018-08-08 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
US10302644B2 (en) * | 2014-11-04 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US10287584B2 (en) * | 2014-11-12 | 2019-05-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of COMP |
WO2016077566A1 (en) * | 2014-11-12 | 2016-05-19 | Research Institute At Nationwide Children's Hospital | Modulation of alternative mdm2 splicing |
EP3218484A4 (en) | 2014-11-14 | 2018-05-30 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
WO2016077704A1 (en) | 2014-11-14 | 2016-05-19 | The Regents Of The University Of California | Modulation of agpat5 expression |
CN113846101A (en) | 2014-11-17 | 2021-12-28 | 阿尔尼拉姆医药品有限公司 | Apolipoprotein C3(APOC3) iRNA compositions and methods of use thereof |
WO2016085852A1 (en) | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
WO2016086104A1 (en) | 2014-11-25 | 2016-06-02 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
CN104450710B (en) * | 2014-11-28 | 2018-06-05 | 广州市锐博生物科技有限公司 | Inhibit nucleic acid oligomer and its application of MYD88 genes |
US9714424B1 (en) * | 2014-12-16 | 2017-07-25 | Icahn School Of Medicine At Mount Sinai | RNAi inhibition of USP10 to treat ocular disorders |
EP3237617B1 (en) | 2014-12-23 | 2019-03-06 | Syngenta Participations AG | Biological control of coleopteran pests |
EP3237642A4 (en) * | 2014-12-24 | 2018-09-19 | Massachusetts Institute of Technology | Compositions and methods for manipulation of adipocyte energy consumption regulatory pathway |
ES2833028T3 (en) * | 2014-12-25 | 2021-06-14 | Guangzhou Ribobio Co Ltd | Compositions and methods to inhibit the expression of ADAMTS-5 and ADAM17 |
US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
US10264976B2 (en) * | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
US10793855B2 (en) * | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
US9982070B2 (en) | 2015-01-12 | 2018-05-29 | Carnegie Mellon University | Aqueous ATRP in the presence of an activator regenerator |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
US9434947B2 (en) * | 2015-01-20 | 2016-09-06 | Oregon Health & Science University | Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome |
US10968449B2 (en) | 2015-01-22 | 2021-04-06 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
WO2016130943A1 (en) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
WO2016130806A2 (en) * | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
US10036017B2 (en) | 2015-02-17 | 2018-07-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA |
EP3259356B1 (en) | 2015-02-20 | 2021-12-01 | Rosalind Franklin University of Medicine and Science | Antisense compounds targeting genes associated with cystic fibrosis |
US10525076B2 (en) * | 2015-02-20 | 2020-01-07 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting genes associated with cystic fibrosis |
WO2016137937A1 (en) * | 2015-02-24 | 2016-09-01 | Dcb-Usa Llc | Short interfering rna for treating cancer |
MX2017011010A (en) | 2015-02-26 | 2017-10-20 | Ionis Pharmaceuticals Inc | Allele specific modulators of p23h rhodopsin. |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
WO2016149455A2 (en) | 2015-03-17 | 2016-09-22 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
EP3270881B1 (en) | 2015-03-20 | 2018-12-26 | Unilever PLC, a company registered in England and Wales under company no. 41424 of | Antiperspirant composition |
EP3072969A1 (en) * | 2015-03-23 | 2016-09-28 | DKFZ Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance |
CA2981068C (en) | 2015-03-26 | 2021-12-14 | Women & Infants Hospital Of Rhode Island | Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors |
US20180371523A1 (en) * | 2015-04-01 | 2018-12-27 | Institute Of Environmental Science And Research | Methods and materials for detecting rna sequences |
WO2016161429A1 (en) | 2015-04-03 | 2016-10-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating tmprss6 expression |
PT3277815T (en) | 2015-04-03 | 2021-11-11 | Beth Israel Deaconess Medical Ct Inc | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
EP3277811B1 (en) * | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
ES2808750T3 (en) * | 2015-04-03 | 2021-03-01 | Univ Massachusetts | Oligonucleotide compounds targeting huntingtin mRNA |
US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
MX2017013102A (en) | 2015-04-13 | 2018-02-23 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof. |
DK3283080T3 (en) | 2015-04-16 | 2020-04-06 | Ionis Pharmaceuticals Inc | COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION |
US20180117166A1 (en) * | 2015-04-17 | 2018-05-03 | Genisphere, Llc | siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer |
EP3286318A2 (en) * | 2015-04-22 | 2018-02-28 | Mina Therapeutics Limited | Sarna compositions and methods of use |
WO2016182917A1 (en) | 2015-05-08 | 2016-11-17 | Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
JP6949728B2 (en) | 2015-05-29 | 2021-10-13 | ジュノー セラピューティクス インコーポレイテッド | Compositions and Methods for Modulating Inhibitory Interactions in Genetically Engineered Cells |
UY36703A (en) | 2015-06-02 | 2016-12-30 | Monsanto Technology Llc | COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF A POLINUCLEOTIDE ON A PLANT |
EP3302030A4 (en) | 2015-06-03 | 2019-04-24 | Monsanto Technology LLC | Methods and compositions for introducing nucleic acids into plants |
CN107921143B (en) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | Method for treating leptomeningeal carcinomatosis |
WO2016209862A1 (en) * | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
WO2016210098A1 (en) * | 2015-06-24 | 2016-12-29 | Board Of Regents, The University Of Texas System | Dual assembly nanoparticles |
EP3112466A1 (en) * | 2015-07-01 | 2017-01-04 | Samsung Electronics Co., Ltd. | Composition for reducing cellular senescence level including activity inhibitor inhibiting dcun1d3 activity or expression inhibitor inhibiting expression of dcun1d3-encoding gene and use thereof |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
CA2991598A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
WO2017011286A1 (en) * | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
EP4092119A3 (en) | 2015-07-10 | 2023-03-22 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
JPWO2017010500A1 (en) * | 2015-07-13 | 2018-04-26 | 協和発酵キリン株式会社 | Antisense oligonucleotide that suppresses expression of β2GPI |
US20170051282A1 (en) * | 2015-07-23 | 2017-02-23 | Cold Spring Harbor Laboratory | Extracellular vesicle methods and compositions |
WO2017019660A1 (en) * | 2015-07-27 | 2017-02-02 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
RU2018106970A (en) * | 2015-07-30 | 2019-08-28 | Байер Кропсайенс Акциенгезельшафт | METHODS AND COMPOSITIONS FOR THE FIGHT AGAINST RUST MUSHROOMS BY INHIBITING EXPRESSION OF THE NXT1 GENE |
ES2842300T3 (en) | 2015-07-31 | 2021-07-13 | Alnylam Pharmaceuticals Inc | Transthyretin (TTR) RNAi Compositions and Methods for Their Use for the Treatment or Prevention of TTR-Associated Diseases |
CN105063048A (en) * | 2015-08-13 | 2015-11-18 | 吉林大学 | SiRNA (small interfering ribonucleic acid) capable of inhibiting expression of Survivin genes and application of siRNA |
EP3334746B1 (en) * | 2015-08-14 | 2021-11-24 | The University Of Sydney | Connexin 45 inhibition for therapy |
CN106467914A (en) * | 2015-08-18 | 2017-03-01 | 华东理工大学 | The siRNA of targeting people's TSPAN8 gene and its application |
WO2017029391A1 (en) * | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
CN114469984A (en) | 2015-08-25 | 2022-05-13 | 阿尔尼拉姆医药品有限公司 | Methods and compositions for treating proprotein convertase subtilisin KEXIN (PCSK9) gene-related disorders |
SG10202007937SA (en) | 2015-09-02 | 2020-09-29 | Alnylam Pharmaceuticals Inc | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2017042239A1 (en) * | 2015-09-08 | 2017-03-16 | Sylentis Sau | siRNA and their use in methods and compositions for inhibiting the expression of the CHI3L1 gene |
MA44908A (en) * | 2015-09-08 | 2018-07-18 | Sylentis Sau | ARNSI MOLECULES AND THEIR USE IN PROCESSES AND COMPOSITIONS TO INHIBIT NRARP GENE EXPRESSION |
GB201516685D0 (en) * | 2015-09-21 | 2015-11-04 | Varghese Oommen P And Oommen Oommen P | Nucleic acid molecules with enhanced activity |
WO2017053681A1 (en) | 2015-09-24 | 2017-03-30 | Wisconsin Alumni Research Foundation | Methods of expanding hematopoietic stem cells, compositions, and methods of use thereof |
EP3353303B1 (en) | 2015-09-25 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
CN106554962B (en) * | 2015-09-30 | 2021-06-04 | 中国科学院上海药物研究所 | Prevention, diagnosis and treatment of GPR160 overexpressing cancers |
US10543286B2 (en) | 2015-10-07 | 2020-01-28 | The Research Foundation For The State University Of New York | Methods for increasing platelet count by inhibiting biliverdin IXβ reductase |
EP3359164A4 (en) | 2015-10-08 | 2019-06-12 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
CA3001853A1 (en) * | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Nucleic acid based tia-1 inhibitors |
WO2017066697A1 (en) * | 2015-10-14 | 2017-04-20 | Dou Qingping | Treatments and diagnostics for cancers |
KR101842679B1 (en) * | 2015-10-15 | 2018-03-28 | 한국과학기술원 | Rna oligonucleotide and enhancer of immune system comprising the same |
WO2017065369A1 (en) * | 2015-10-15 | 2017-04-20 | 한국과학기술원 | Rna oligonucleotide and immune activator comprising same |
US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
WO2017068791A1 (en) * | 2015-10-23 | 2017-04-27 | レナセラピューティクス株式会社 | Nucleic acid complex having at least one bulge structure |
US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
WO2017079227A1 (en) | 2015-11-05 | 2017-05-11 | University Of Connecticut | Compositions and methods for the treatment of liver fibrosis |
JP2018531605A (en) | 2015-11-06 | 2018-11-01 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Regulation of apolipoprotein (a) expression |
WO2017081686A1 (en) | 2015-11-10 | 2017-05-18 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Means and methods for reducing tumorigenicity of cancer stem cells |
CA3005411C (en) | 2015-11-16 | 2024-01-09 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3 |
WO2017086467A1 (en) | 2015-11-19 | 2017-05-26 | 公立大学法人名古屋市立大学 | Antitumor drug delivery formulation |
AU2016363683B2 (en) * | 2015-11-30 | 2023-04-27 | The University Of British Columbia | Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer |
EP3389670A4 (en) | 2015-12-04 | 2020-01-08 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
BR112018011450A2 (en) | 2015-12-07 | 2018-11-27 | Genzyme Corp | methods and compositions for treating a serpinc1-associated disorder |
EP3386544B1 (en) | 2015-12-10 | 2020-11-25 | Fibrogen, Inc. | Methods for treatment of motor neuron diseases |
WO2017100542A1 (en) * | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
BR112018008344A2 (en) | 2015-12-13 | 2018-10-30 | Nitto Denko Corp | nucleic acid molecule, pharmaceutical composition, vector or cell, method for preventing, treating or ameliorating a disease, and use of a composition |
EP3181698A1 (en) | 2015-12-16 | 2017-06-21 | European Molecular Biology Laboratory (EMBL) | Microrna mir-142 as stem cell marker |
CA3006599A1 (en) | 2016-01-05 | 2017-07-13 | Ionis Pharmaceuticals, Inc. | Methods for reducing lrrk2 expression |
CA3011894A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
JP6944942B2 (en) * | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ,インコーポレーテッド | Treatment of atopic dermatitis and asthma with RNA complexes targeting IL4Rα, TRPA1, or F2RL1 |
WO2017134526A1 (en) | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb |
US10519442B2 (en) | 2016-02-11 | 2019-12-31 | City Of Hope | Twist signaling inhibitor compositions and methods of using the same |
CN108495640B (en) * | 2016-02-19 | 2022-11-04 | 加利福尼亚大学董事会 | Short hairpin RNA (SHRNA 734) and its use for positive selection and elimination of genetically modified cells |
CA3013797A1 (en) | 2016-03-09 | 2017-09-14 | Ionis Pharmaceuticals, Inc. | Methods and compositions for inhibiting pmp22 expression |
WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
CA3013799A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Methods of modulating keap1 |
CN105925576B (en) * | 2016-03-24 | 2018-04-20 | 嘉兴市第一医院 | SiRNA, ShorthairpinRNA and carrier and application for mammal R Spondin3 gene targets |
MA45328A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
ES2640524B1 (en) * | 2016-04-01 | 2018-09-24 | Universidad Autónoma de Madrid | USE OF TCFL5 / CHA AS A NEW MARKER FOR THE PROGNOSIS AND / OR DIFFERENTIAL DIAGNOSIS OF ACUTE LYMPHOBLASTIC LEUKEMIES |
MA45340A (en) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | ANDROGEN RECEPTOR NUCLEIC ACIDS AND THEIR USES |
CA3020487C (en) | 2016-04-11 | 2022-05-31 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor |
AU2017250017B2 (en) * | 2016-04-14 | 2022-12-22 | Benitec IP Holdings Inc. | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
AU2017254106A1 (en) | 2016-04-18 | 2018-11-01 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
CN107345230A (en) | 2016-05-05 | 2017-11-14 | 江苏命码生物科技有限公司 | A kind of siRNA of suppression K-RAS gene expressions and its precursor and application |
CN105969771A (en) * | 2016-05-30 | 2016-09-28 | 东北师范大学 | shRNA targeted to silent FOXG1 |
EP3469081A1 (en) * | 2016-06-08 | 2019-04-17 | Aalborg Universitet | Antisense oligonucleotides for modulation of long noncoding rnas |
PT109454A (en) * | 2016-06-14 | 2017-12-14 | Phyzat Biopharmaceuticals Lda | NUCLEIC ACIDS OF INTERFERENCE AND COMPOSITIONS THAT UNDERSTAND THEM |
US11198867B2 (en) | 2016-06-16 | 2021-12-14 | Ionis Pharmaceuticals, Inc. | Combinations for the modulation of SMN expression |
MA45496A (en) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION |
US11236339B2 (en) | 2016-06-17 | 2022-02-01 | Ionis Pharmaceuticals, Inc. | Modulation of GYS1 expression |
KR101916652B1 (en) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | Compounds improving RNA interference of small interfering RNA and use thereof |
CN107557363B (en) * | 2016-06-30 | 2021-03-12 | 中国科学院分子细胞科学卓越创新中心 | Inducible siRNA expression vector and preparation and application thereof |
EP3481432A4 (en) * | 2016-07-05 | 2020-05-06 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Diagnosing col6-related disorders and methods for treating same |
US11252965B2 (en) * | 2016-07-13 | 2022-02-22 | Indiana University Research And Technology Corporation | RNAi insecticide materials and methods |
AR109207A1 (en) * | 2016-08-05 | 2018-11-07 | Syngenta Participations Ag | PATHOPE CONTROL OF COLEOPTERS USING RNA MOLECULES |
EP3496758A4 (en) | 2016-08-12 | 2020-11-11 | University of Massachusetts | Conjugated oligonucleotides |
UY37376A (en) | 2016-08-26 | 2018-03-23 | Amgen Inc | ARNI CONSTRUCTIONS TO INHIBIT EXPRESSION OF ASGR1 AND METHODS FOR USE |
EP3512527A4 (en) | 2016-09-15 | 2020-05-20 | The Brigham and Women's Hospital, Inc. | Modulation of pcsk9 and ldlr through drp1 inhibition |
EP3516062A1 (en) | 2016-09-21 | 2019-07-31 | Alnylam Pharmaceuticals, Inc. | Myostatin irna compositions and methods of use thereof |
JOP20190065A1 (en) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing tau expression |
EP3522898A4 (en) | 2016-10-06 | 2020-05-27 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
JP2019533676A (en) | 2016-10-13 | 2019-11-21 | ジュノー セラピューティクス インコーポレイテッド | Immunotherapy methods and compositions comprising tryptophan metabolic pathway modulators |
US10806715B2 (en) * | 2016-10-25 | 2020-10-20 | Council Of Scientific & Industrial Research | Gold nanoparticle based formulation for use in cancer therapy |
JOP20190104A1 (en) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
US10646540B2 (en) | 2016-11-18 | 2020-05-12 | City Of Hope | Peptide inhibitors of twist |
TW202313978A (en) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | Serpina1 irna compositions and methods of use thereof |
CN106421790B (en) * | 2016-11-25 | 2018-12-25 | 复旦大学附属金山医院 | Application of the inhibitor of CMPK in the drug of preparation treatment oophoroma |
US11033570B2 (en) | 2016-12-02 | 2021-06-15 | Cold Spring Harbor Laboratory | Modulation of Lnc05 expression |
WO2018106732A1 (en) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
WO2018117253A1 (en) * | 2016-12-23 | 2018-06-28 | 協和発酵キリン株式会社 | Nucleic acid inhibiting expression of complement factor b |
CA3049424A1 (en) | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
CA3045045A1 (en) | 2017-01-10 | 2018-07-19 | Zhen Li | Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use |
US11174325B2 (en) | 2017-01-12 | 2021-11-16 | Carnegie Mellon University | Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes |
US20190345495A1 (en) * | 2017-01-13 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb2 expression |
JP7424728B2 (en) | 2017-02-10 | 2024-01-30 | オリック パルマセゥティカルズ インコーポレイテッド | Long double-stranded RNA for RNA interference |
CN106668863B (en) * | 2017-02-21 | 2019-04-23 | 南方医科大学 | Target the drug of KTN1 treatment cutaneous squamous cell carcinoma |
WO2018164186A1 (en) * | 2017-03-09 | 2018-09-13 | 協和発酵キリン株式会社 | Nucleic acid capable of inhibiting expression of masp2 |
US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
PL3607068T3 (en) * | 2017-04-05 | 2023-03-20 | Silence Therapeutics Gmbh | Rna interference mediated inhibition of tmprss6 |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
CA3058018A1 (en) | 2017-04-19 | 2018-10-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for stat3 inhibition |
NO344051B1 (en) * | 2017-05-04 | 2019-08-26 | Patogen As | Novel virus in Fish and Method for detection |
JP2020518258A (en) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | Amyotrophic lateral sclerosis (ALS) treatment composition and method |
AU2018264996A1 (en) | 2017-05-09 | 2019-12-05 | University Of Massachusetts | Methods of treating Amyotrophic Lateral Sclerosis (ALS) |
WO2018218135A1 (en) | 2017-05-25 | 2018-11-29 | The Children's Medical Center Corporation | Bcl11a guide delivery |
WO2018221649A1 (en) * | 2017-05-31 | 2018-12-06 | 協和発酵キリン株式会社 | Apcs-expression-suppressing nucleic acids |
KR101940061B1 (en) * | 2017-06-02 | 2019-01-21 | 김준 | Composition for Inhibition of Metastasis in Cancer Cells Including Ribosomal Protein S3 siRNAs |
CN107177594B (en) * | 2017-06-07 | 2020-03-03 | 浙江大学 | siRNA for specifically inhibiting CA7 gene expression and recombinant vector and application thereof |
FR3067933B1 (en) * | 2017-06-21 | 2020-07-17 | L'oreal | MODULATORS OF OPSIN 3 IN THE MODULATION OF PIGMENTATION OF THE SKIN |
CA3068312A1 (en) * | 2017-06-30 | 2019-01-03 | The Trustees Of Princeton University | Genetic variants associated with human-directed hyper-social behavior in domestic dogs |
ES2958662T3 (en) * | 2017-07-06 | 2024-02-13 | Michael S Kapiloff | Treatment of heart disease by inhibition of the action of muscle kinase A anchoring protein (mAKAP) |
BR112019023650A2 (en) | 2017-07-06 | 2020-06-02 | Arrowhead Pharmaceuticals, Inc. | RNAI AGENTS TO INHIBIT ALFA-ENAC EXPRESSION AND METHODS OF USE |
CA3069451A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
US10961537B2 (en) | 2017-07-18 | 2021-03-30 | Csl Behring Gene Therapy, Inc. | Compositions and methods for treating beta-hemoglobinopathies |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
CN111201024A (en) * | 2017-08-07 | 2020-05-26 | 菲奥医药公司 | Chemically modified oligonucleotides |
CN110020273B (en) * | 2017-08-16 | 2021-06-29 | 北京京东尚科信息技术有限公司 | Method, device and system for generating thermodynamic diagram |
WO2019036613A1 (en) | 2017-08-18 | 2019-02-21 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
EP3678674A4 (en) * | 2017-09-06 | 2021-06-16 | Baylor College of Medicine | Hippo pathway deficiency reverses systolic heart failure post-infarction |
WO2019047914A1 (en) * | 2017-09-07 | 2019-03-14 | 北京泰德制药股份有限公司 | Double-stranded rna molecule targeting ckip-1 and use thereof |
CA3075219A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Hnf4a sarna compositions and methods of use |
WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | Modulators of smad7 expression |
SG11201912178VA (en) | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
US10995335B2 (en) | 2017-09-14 | 2021-05-04 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use |
KR20200089656A (en) | 2017-09-19 | 2020-07-27 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for treating transthyretin (TTR) mediated amyloidosis |
CN111448321A (en) | 2017-09-22 | 2020-07-24 | 马萨诸塞大学 | SOD1 double expression vector and its use |
EP3688160A2 (en) | 2017-09-28 | 2020-08-05 | Secarna Pharmaceuticals GmbH & Co. KG | Oligonucleotide inhibiting the expression of chop |
US20200345756A1 (en) * | 2017-10-10 | 2020-11-05 | University Of Virginia Patent Foundation | Compositions and methods for treating age-related macular degeneration and geographic atrophy |
TWI816066B (en) | 2017-10-16 | 2023-09-21 | 瑞士商赫孚孟拉羅股份公司 | NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION |
EP3697905A1 (en) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
EP4197544A1 (en) | 2017-10-20 | 2023-06-21 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
US11866701B2 (en) | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
US20230201357A1 (en) * | 2017-11-08 | 2023-06-29 | Aptamer Diagnostic, Inc. | D-dimer-specific aptamers and methods of use in diagnostics, therapeutic and theranostic purposes |
TWI809004B (en) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | Compounds and methods for reducing snca expression |
CN109777800A (en) * | 2017-11-15 | 2019-05-21 | 信雅生物科技(苏州)有限公司 | It is a kind of be capable of specificity inhibit ZBED1 gene siRNA construction method and its application |
EP3714054A1 (en) * | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
GB201719680D0 (en) * | 2017-11-27 | 2018-01-10 | Devgen Nv | Improvements in or relating to gene silencing |
WO2019105419A1 (en) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | Nucleic acid, composition and conjugate containing same, preparation method, and use |
EP3719126A4 (en) * | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
AU2018374219C1 (en) | 2017-12-01 | 2023-05-11 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
CN111902148A (en) | 2017-12-06 | 2020-11-06 | 艾维迪提生物科学公司 | Compositions and methods for treating muscular atrophy and myotonic dystrophy |
EP3724333A2 (en) * | 2017-12-11 | 2020-10-21 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating fndc3b expression |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
JP7436030B2 (en) | 2017-12-29 | 2024-02-21 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | Complexes and their preparation and use |
MX2020007046A (en) | 2018-01-08 | 2020-09-07 | Iovance Biotherapeutics Inc | Processes for generating til products enriched for tumor antigen-specific t-cells. |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
GB201800370D0 (en) * | 2018-01-10 | 2018-02-21 | Ucl Business Plc | Anionic nanocomplexes for nucleic acid delivery |
CN108387621B (en) * | 2018-01-10 | 2019-11-26 | 暨南大学 | Cadmium ion aptamer and screen printing electrode electrochemica biological sensor |
MA51645A (en) | 2018-01-15 | 2020-11-25 | Ionis Pharmaceuticals Inc | DNM2 EXPRESSION MODULATORS |
WO2019143621A1 (en) * | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
PE20211197A1 (en) | 2018-02-09 | 2021-07-01 | Genentech Inc | OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF TMEM106B |
JP7453921B2 (en) * | 2018-03-02 | 2024-03-21 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Compositions and methods for inhibiting GYS2 expression |
WO2019169219A1 (en) | 2018-03-02 | 2019-09-06 | Ionis Pharmaceuticals, Inc. | Modulators of irf4 expression |
US11732260B2 (en) | 2018-03-02 | 2023-08-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-β precursor protein |
US20190284553A1 (en) * | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
SG11202007583SA (en) * | 2018-03-21 | 2020-09-29 | Regeneron Pharma | 17β-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2019183440A1 (en) | 2018-03-22 | 2019-09-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating fmr1 expression |
JP2021519283A (en) * | 2018-03-29 | 2021-08-10 | テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド | Vesicles containing PTEN inhibitors and their use |
US11365416B2 (en) | 2018-04-11 | 2022-06-21 | Ionis Pharmaceuticals, Inc. | Modulators of EZH2 expression |
BR112020020957B1 (en) | 2018-05-09 | 2022-05-10 | Ionis Pharmaceuticals, Inc | Oligomeric compounds, population and pharmaceutical composition thereof and their uses |
PE20212131A1 (en) | 2018-05-09 | 2021-11-05 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN3 |
JP2021526823A (en) * | 2018-06-14 | 2021-10-11 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Compounds and methods for increasing STMN2 expression |
NO344698B1 (en) * | 2018-06-15 | 2020-03-09 | Patogen As | Novel fish virus |
AU2019294838A1 (en) | 2018-06-27 | 2021-01-07 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing LRRK2 expression |
JP7102557B2 (en) | 2018-07-03 | 2022-07-19 | エフ.ホフマン-ラ ロシュ アーゲー | Oligonucleotide for TAU expression regulation |
WO2020011653A1 (en) * | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
WO2020011744A2 (en) * | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers5 |
US11078486B2 (en) | 2018-07-25 | 2021-08-03 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ATXN2 expression |
EP3598995A1 (en) * | 2018-07-26 | 2020-01-29 | Silence Therapeutics GmbH | Products and compositions |
JP2021533200A (en) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | Muscle-targeted complexes and their use for treating facial, scapular, and brachial muscular dystrophy |
KR20210093227A (en) | 2018-08-10 | 2021-07-27 | 유니버시티 오브 매사추세츠 | Modified oligonucleotides targeting SNPs |
AR114551A1 (en) | 2018-08-13 | 2020-09-16 | Alnylam Pharmaceuticals Inc | COMPOSITIONS OF hdRNA AGENTS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS FOR THEIR USE |
CN111655849A (en) | 2018-08-21 | 2020-09-11 | 苏州瑞博生物技术有限公司 | Nucleic acid, pharmaceutical composition containing nucleic acid, conjugate and application of conjugate |
CN109085365B (en) * | 2018-08-27 | 2020-06-23 | 山东农业大学 | Blocking agent for inhibiting highly pathogenic porcine reproductive and respiratory syndrome virus infection |
US20220033826A1 (en) * | 2018-08-31 | 2022-02-03 | University Of Florida Research Foundation, Incorporated | Adeno-associated viral vectors for the treatment of best disease |
CN111655297A (en) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | siRNA conjugate and preparation method and application thereof |
JP7191301B2 (en) * | 2018-10-02 | 2022-12-19 | 小胞体ストレス研究所株式会社 | Growth inhibitor for cancer cells with poor prognosis |
BR112021008069A2 (en) * | 2018-11-02 | 2021-11-03 | Biomarin Tech B V | Bispecific antisense oligonucleotides for dystrophin exon skipping |
TW202028222A (en) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Modulators of foxp3 expression |
MX2021005758A (en) | 2018-11-15 | 2021-09-21 | Ionis Pharmaceuticals Inc | Modulators of irf5 expression. |
JP2022513111A (en) * | 2018-11-23 | 2022-02-07 | サノフイ | Novel RNA Compositions and Methods for Inhibiting ANGPTL8 |
CN111228289A (en) * | 2018-11-28 | 2020-06-05 | 中国科学院大连化学物理研究所 | Application of PLIN2 inhibitor and medicine mixture for treating tumor |
ES2766950A1 (en) * | 2018-12-14 | 2020-06-15 | Consejo Superior Investigacion | ARHGEF6 as a pharmaceutical target for neurological disorders (Machine-translation by Google Translate, not legally binding) |
ES2766855A1 (en) * | 2018-12-14 | 2020-06-15 | Consejo Superior Investigacion | Rhoq as a pharmaceutical target for neurological disorders (Machine-translation by Google Translate, not legally binding) |
MX2021007368A (en) | 2018-12-21 | 2021-07-15 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof. |
US11452738B2 (en) * | 2019-01-04 | 2022-09-27 | Empirico Inc. | Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts |
EP3908328A1 (en) | 2019-01-10 | 2021-11-17 | BioNTech RNA Pharmaceuticals GmbH | Localized administration of rna molecules for therapy |
US20220088051A1 (en) * | 2019-01-15 | 2022-03-24 | Bioneer Corporation | Double-stranded oligonucleotide targeting dkk1 gene, construct including same, and hair loss prevention or hair growth composition containing same |
EP3911747A4 (en) * | 2019-01-18 | 2023-05-24 | University Of Massachusetts | Dynamic pharmacokinetic-modifying anchors |
US11214803B2 (en) | 2019-01-31 | 2022-01-04 | Ionis Pharmaceuticals, Inc. | Modulators of YAP1 expression |
WO2020176771A1 (en) * | 2019-02-27 | 2020-09-03 | Ionis Pharmaceuticals, Inc. | Modulators of malat1 expression |
US20220099661A1 (en) * | 2019-03-01 | 2022-03-31 | Meso Scale Technologies, Llc. | Electrochemiluminescent labeled probes for use in immunoassay methods, methods using such and kits comprising same |
AU2020239987A1 (en) * | 2019-03-15 | 2021-11-04 | University Of Massachusetts | Oligonucleotides for tissue specific ApoE modulation |
US20220152278A1 (en) * | 2019-03-15 | 2022-05-19 | University Of Washington | Improved survival of human cells differentiated in vitro by prpf31 gene expression knockdown |
CN113728104B (en) | 2019-03-29 | 2023-10-27 | Ionis制药公司 | Compounds and methods for modulating UBE3A-ATS |
EP3969032A1 (en) | 2019-05-15 | 2022-03-23 | University Of Miami | Treatment of heart disease by disruption of the anchoring of pp2a |
JP2022533722A (en) * | 2019-05-22 | 2022-07-25 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | Nucleic acids, drug compositions and conjugates and methods of preparation and uses |
US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
WO2020242896A2 (en) * | 2019-05-24 | 2020-12-03 | Empirico Inc. | Treatment of angiopoietin like 7 (angptl7) related diseases |
CN113795582A (en) * | 2019-05-24 | 2021-12-14 | 苏州瑞博生物技术股份有限公司 | Nucleic acid, pharmaceutical composition and conjugate, preparation method and application |
WO2020238758A1 (en) * | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof |
WO2021021673A1 (en) * | 2019-07-26 | 2021-02-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gfap |
US20220267778A1 (en) | 2019-07-30 | 2022-08-25 | Shionogi & Co., Ltd. | Nucleic acid drug targeting murf1 |
WO2021030358A1 (en) | 2019-08-12 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
US20220340890A1 (en) * | 2019-08-30 | 2022-10-27 | Inari Agriculture Technology, Inc. | Rna-guided nucleases and dna binding proteins |
EP4021448A4 (en) * | 2019-08-30 | 2023-12-20 | Agency for Science, Technology and Research | A method of promoting survival and/or function of a motor neuron and related agents, uses and methods |
KR102100163B1 (en) * | 2019-09-24 | 2020-04-13 | 테고사이언스 (주) | Compositions of Prevention or Treatment of Keloid or Hypertrophic scar |
US20230304012A1 (en) * | 2019-10-16 | 2023-09-28 | Brown University | Muscle regeneration and growth |
WO2021092459A1 (en) * | 2019-11-08 | 2021-05-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing spdef expression |
EP4054655A4 (en) * | 2019-11-08 | 2024-02-28 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing spdef expression |
CN110859960B (en) * | 2019-11-26 | 2022-03-04 | 深圳先进技术研究院 | Application of combination of AMPK-targeted inhibitor/siRNA and proteasome inhibitor in preparation of antitumor drugs |
WO2021119019A1 (en) * | 2019-12-09 | 2021-06-17 | Empirico Inc. | Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases |
CN114829603A (en) * | 2019-12-20 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Enhancer oligonucleotides for inhibiting expression of SCN9A |
AU2020415455A1 (en) * | 2019-12-23 | 2022-07-14 | University Of Massachusetts | Oligonucleotides for tissue specific gene expression modulation |
WO2021160937A1 (en) | 2020-02-11 | 2021-08-19 | Turun Yliopisto | Therapy of ras-dependent cancers |
IL295593A (en) * | 2020-02-21 | 2022-10-01 | Replicor Inc | Methods and compositions for the inhibition of hepatitis b and hepatitis d virus infections |
KR20220148230A (en) | 2020-02-28 | 2022-11-04 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compounds and methods for modulating SMN2 |
WO2021173984A2 (en) * | 2020-02-28 | 2021-09-02 | University Of Massachusetts | Oligonucleotides for prnp modulation |
WO2021178769A1 (en) * | 2020-03-06 | 2021-09-10 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating kcnq2 |
CA3174725A1 (en) * | 2020-03-06 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
EP4121063A1 (en) | 2020-03-19 | 2023-01-25 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
CN113444723A (en) * | 2020-03-27 | 2021-09-28 | 北京键凯科技股份有限公司 | Interfering RNA for inhibiting vascular endothelial growth factor receptor 2 gene expression and application thereof |
CA3177180A1 (en) | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
EP4136263A1 (en) * | 2020-04-14 | 2023-02-22 | Amgen Inc. | Kif18a inhibitors for treatment of neoplastic diseases |
JP2023524065A (en) | 2020-05-01 | 2023-06-08 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Compounds and methods for modulating ATXN1 |
US20230287410A1 (en) | 2020-05-11 | 2023-09-14 | Stoke Therapeutics, Inc. | Opa1 antisense oligomers for treatment of conditions and diseases |
TW202208628A (en) * | 2020-05-13 | 2022-03-01 | 瑞士商赫孚孟拉羅股份公司 | Oligonucleotide agonists targeting progranulin |
EP4150093A2 (en) * | 2020-05-14 | 2023-03-22 | Ariz Precision Medicine, Inc. | Cancer treatment using sirna to modulate expression of prdm2/riz protein |
CN111714510B (en) * | 2020-05-18 | 2021-07-06 | 北京航空航天大学 | Application of long-chain non-coding RNA SNHG12 inhibitor in preparation of anti-osteoporosis drugs |
US20230272401A1 (en) * | 2020-06-11 | 2023-08-31 | Genetic Intelligence, Inc | Compositions for flcn gene modulation and methods thereof |
US11459567B2 (en) | 2020-06-24 | 2022-10-04 | Patricia Virginia Elizalde | Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer |
MX2022016338A (en) | 2020-06-29 | 2023-01-24 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating plp1. |
WO2022031591A2 (en) * | 2020-08-03 | 2022-02-10 | University Of Massachusetts | Oligonucleotides for htt-1a modulation |
UY39417A (en) * | 2020-09-11 | 2022-03-31 | Arrowhead Pharmaceuticals Inc | ARNI AGENTS FOR INHIBITING DUX4 EXPRESSION, COMPOSITIONS OF SUCH AGENTS, AND METHODS OF USE |
WO2022071367A1 (en) * | 2020-09-30 | 2022-04-07 | 富士フイルム株式会社 | Double-stranded rna that inhibits production of hepatitis b virus protein, and pharmaceutical composition |
WO2022089486A1 (en) * | 2020-10-28 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | Sirna for inhibiting pcsk9 gene expression and modifier thereof and use thereof |
JP2023549563A (en) | 2020-11-18 | 2023-11-27 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Compounds and methods for modulating angiotensinogen expression |
KR20220080720A (en) * | 2020-12-07 | 2022-06-14 | 올릭스 주식회사 | Asymmetric nucleic acid molecules inducing RNA interference that Inhibits Expression of ROR-beta |
BR112023017737A2 (en) | 2021-03-04 | 2023-10-03 | Alnylam Pharmaceuticals Inc | ANGIOPOIETIN-SIMILAR IRNA COMPOSITIONS 3 (ANGPTL3) AND METHODS OF USE THEREOF |
US20220411802A1 (en) * | 2021-03-17 | 2022-12-29 | Sirnaomics, Inc. | METHODS OF CANCER TREATMENT BY DELIVERY OF siRNAs AGAINST NSD3 |
US20220348918A1 (en) * | 2021-03-29 | 2022-11-03 | University Of Massachusetts | Oligonucleotides for syngr-3 modulation |
WO2022216920A1 (en) * | 2021-04-08 | 2022-10-13 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
CA3215478A1 (en) * | 2021-04-16 | 2022-10-20 | Adeline VANDERVER | Compositions and methods useful for the treatment of h-abc leukodystrophy |
CA3213775A1 (en) | 2021-04-19 | 2022-10-27 | Utsav SAXENA | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
IL307926A (en) | 2021-04-26 | 2023-12-01 | Alnylam Pharmaceuticals Inc | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof |
BR112023024615A2 (en) * | 2021-05-28 | 2024-02-20 | Arrowhead Pharmaceuticals Inc | RNAI AGENTS FOR INHIBITING MUCIN 5AC (MUC5AC) EXPRESSION, COMPOSITIONS THEREOF, AND METHODS OF USE |
AR125992A1 (en) | 2021-05-28 | 2023-08-30 | Novo Nordisk As | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MITOCHONDRIAL AMIDOXIMA REDUCTION COMPONENT 1 (MARC1) |
BR112023026050A2 (en) | 2021-06-18 | 2024-03-05 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO REDUCE IFNAR1 EXPRESSION |
CN113416776B (en) * | 2021-06-21 | 2022-04-01 | 深圳市儿童医院 | Biomarker for detecting ventricular septal defect and application thereof |
AU2022298603A1 (en) * | 2021-06-21 | 2024-02-01 | Shanghai Junshi Biosciences Co., Ltd. | Sirna inhibiting angptl3 gene expression, and use thereof |
US11629349B2 (en) | 2021-06-21 | 2023-04-18 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use |
TW202315943A (en) | 2021-06-23 | 2023-04-16 | 麻薩諸塞大學 | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
WO2022269016A1 (en) * | 2021-06-25 | 2022-12-29 | Stichting Radboud Universitair Medisch Centrum | Allele-specific silencing therapy for dfna21 using antisense oligonucleotides |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
CA3225937A1 (en) * | 2021-07-17 | 2023-02-16 | Dmitry Samarsky | Products and compositions |
AU2022323090A1 (en) | 2021-08-03 | 2024-02-01 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof |
CA3230404A1 (en) * | 2021-08-31 | 2023-03-09 | Alnylam Pharmaceuticals, Inc. | Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof |
WO2023034870A2 (en) | 2021-09-01 | 2023-03-09 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dmpk expression |
US20230079754A1 (en) * | 2021-09-16 | 2023-03-16 | Washington University | Methods and compositions for reducing pathogenic isoforms |
CA3231330A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
AU2022378567A1 (en) | 2021-10-29 | 2024-04-11 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
WO2023076450A2 (en) * | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
US20230167447A1 (en) * | 2021-11-30 | 2023-06-01 | Genetic Intelligence, Inc | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof |
WO2023108020A2 (en) * | 2021-12-07 | 2023-06-15 | Alnylam Pharmaceuticals, Inc. | iRNA COMPOSITIONS AND METHODS FOR SILENCING MYLIP |
WO2023122805A1 (en) | 2021-12-20 | 2023-06-29 | Vestaron Corporation | Sorbitol driven selection pressure method |
WO2023129496A2 (en) * | 2021-12-27 | 2023-07-06 | Apellis Pharmaceuticals, Inc. | Rnas for complement inhibition |
WO2023150578A2 (en) * | 2022-02-01 | 2023-08-10 | 4D Path Inc. | Systems and methods for image-based disease characterization |
WO2023178144A2 (en) | 2022-03-16 | 2023-09-21 | Empirico Inc. | Galnac compositions for improving sirna bioavailability |
WO2023220566A1 (en) * | 2022-05-09 | 2023-11-16 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
US20240102017A1 (en) * | 2022-05-10 | 2024-03-28 | Amylyx Pharmaceuticals, Inc. | Oligonucleotide compositions and methods thereof |
WO2023250368A2 (en) * | 2022-06-24 | 2023-12-28 | Eli Lilly And Company | Atxn2 rna interference agents |
US20240084301A1 (en) * | 2022-07-25 | 2024-03-14 | Amgen Inc. | Rnai constructs and methods for inhibiting fam13a expression |
Citations (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US647526A (en) * | 1899-06-26 | 1900-04-17 | William Allen Runyan | Freight-car door. |
US3719760A (en) * | 1968-01-29 | 1973-03-06 | Bayer Ag | N-trityl-imidazolium salts as a fungicide |
US3811449A (en) * | 1972-03-08 | 1974-05-21 | Becton Dickinson Co | Dilating apparatus and method |
US4350151A (en) * | 1981-03-12 | 1982-09-21 | Lone Star Medical Products, Inc. | Expanding dilator |
US4369790A (en) * | 1981-03-05 | 1983-01-25 | Mccarthy John M | Catheter |
US4401433A (en) * | 1980-06-13 | 1983-08-30 | Luther Ronald B | Apparatus for advancing oversized catheter through cannula, and the like |
US4449532A (en) * | 1980-07-08 | 1984-05-22 | Karl Storz | Dilator to facilitate endoscope insertion into the body |
US4451256A (en) * | 1981-05-06 | 1984-05-29 | Intermedicat Gmbh | Catheter set |
US4573448A (en) * | 1983-10-05 | 1986-03-04 | Pilling Co. | Method for decompressing herniated intervertebral discs |
US4601710A (en) * | 1983-08-24 | 1986-07-22 | Endotherapeutics Corporation | Trocar assembly |
US4686984A (en) * | 1984-03-15 | 1987-08-18 | Richard Wolf Gmbh | Catheter for widening a puncture channel |
US4802479A (en) * | 1986-10-31 | 1989-02-07 | C. R. Bard, Inc. | Hand-held instrument for implanting, dispensing, and inflating an inflatable membrane |
US4862891A (en) * | 1988-03-14 | 1989-09-05 | Canyon Medical Products | Device for sequential percutaneous dilation |
US4981482A (en) * | 1987-08-20 | 1991-01-01 | Kazuo Ichikawa | Device for forming an inserting hole for an endoscope |
US4994027A (en) * | 1988-06-08 | 1991-02-19 | Farrell Edward M | Percutaneous femoral bypass system |
US5002557A (en) * | 1989-04-06 | 1991-03-26 | Hasson Harrith M | Laparoscopic cannula |
US5114407A (en) * | 1990-08-30 | 1992-05-19 | Ethicon, Inc. | Safety mechanism for trocar |
US5176651A (en) * | 1991-04-01 | 1993-01-05 | Dexide, Inc. | Combination surgical trocar housing and selective reducer sleeve assembly |
US5176697A (en) * | 1989-04-06 | 1993-01-05 | Hasson Harrith M | Laparoscopic cannula |
US5183464A (en) * | 1991-05-17 | 1993-02-02 | Interventional Thermodynamics, Inc. | Radially expandable dilator |
US5188118A (en) * | 1990-11-07 | 1993-02-23 | Terwilliger Richard A | Automatic biopsy instrument with independently actuated stylet and cannula |
US5195506A (en) * | 1991-10-18 | 1993-03-23 | Life Medical Products, Inc. | Surgical retractor for puncture operation |
US5224952A (en) * | 1988-07-06 | 1993-07-06 | Ethicon, Inc. | Safety trocar |
US5241972A (en) * | 1991-05-03 | 1993-09-07 | Meditron Devices, Inc. | Method for debulking tissue to remove pressure on a nerve |
US5280782A (en) * | 1991-11-15 | 1994-01-25 | Wilk Peter J | Variable length laparoscopic retractor and associated method of use |
US5290243A (en) * | 1992-07-16 | 1994-03-01 | Technalytics, Inc. | Trocar system |
US5312417A (en) * | 1992-07-29 | 1994-05-17 | Wilk Peter J | Laparoscopic cannula assembly and associated method |
US5324261A (en) * | 1991-01-04 | 1994-06-28 | Medtronic, Inc. | Drug delivery balloon catheter with line of weakness |
US5342382A (en) * | 1991-01-15 | 1994-08-30 | Ethicon, Inc. | Surgical trocar |
US5407430A (en) * | 1994-03-21 | 1995-04-18 | Peters; Michael J. | Intravenous catheter |
US5486190A (en) * | 1991-04-30 | 1996-01-23 | United States Surgical Corporation | Safety trocar |
US5505710A (en) * | 1994-08-22 | 1996-04-09 | C. R. Bard, Inc. | Telescoping probe |
US5512037A (en) * | 1994-05-12 | 1996-04-30 | United States Surgical Corporation | Percutaneous surgical retractor |
US5613950A (en) * | 1988-07-22 | 1997-03-25 | Yoon; Inbae | Multifunctional manipulating instrument for various surgical procedures |
US5624447A (en) * | 1995-03-20 | 1997-04-29 | Othy, Inc. | Surgical tool guide and entry hole positioner |
US5647857A (en) * | 1995-03-16 | 1997-07-15 | Endotex Interventional Systems, Inc. | Protective intraluminal sheath |
US5707359A (en) * | 1995-11-14 | 1998-01-13 | Bufalini; Bruno | Expanding trocar assembly |
US5713870A (en) * | 1991-11-27 | 1998-02-03 | Yoon; Inbae | Retractable safety penetrating instrument with laterally extendable spring strip |
US5728097A (en) * | 1992-03-17 | 1998-03-17 | Sdgi Holding, Inc. | Method for subcutaneous suprafascial internal fixation |
US5743881A (en) * | 1995-11-03 | 1998-04-28 | Aptec Medical Corporation | Laparoscopic surgical instrument and method of using same |
US5752969A (en) * | 1993-06-17 | 1998-05-19 | Sofamor S.N.C. | Instrument for the surgical treatment of an intervertebral disc by the anterior route |
US5772678A (en) * | 1995-10-20 | 1998-06-30 | Inlet Medical, Inc. | Retractable disposable tip reusable trocar obturator |
US5776156A (en) * | 1995-09-05 | 1998-07-07 | United States Surgical Corporation | Endoscopic cutting instrument |
US5782800A (en) * | 1988-07-22 | 1998-07-21 | Yoon; Inbae | Expandable multifunctional manipulating instruments for various medical procedures and methods therefor |
US5792044A (en) * | 1996-03-22 | 1998-08-11 | Danek Medical, Inc. | Devices and methods for percutaneous surgery |
US5810866A (en) * | 1991-11-27 | 1998-09-22 | Yoon; Inbae | Automatic retractable safety penetrating instrument for portal sleeve introduction |
US5810721A (en) * | 1996-03-04 | 1998-09-22 | Heartport, Inc. | Soft tissue retractor and method for providing surgical access |
US5957902A (en) * | 1998-09-28 | 1999-09-28 | Teves; Leonides Y. | Surgical tool for enlarging puncture opening made by trocar |
US6030364A (en) * | 1997-10-03 | 2000-02-29 | Boston Scientific Corporation | Apparatus and method for percutaneous placement of gastro-intestinal tubes |
US6048309A (en) * | 1996-03-04 | 2000-04-11 | Heartport, Inc. | Soft tissue retractor and delivery device therefor |
US6053935A (en) * | 1996-11-08 | 2000-04-25 | Boston Scientific Corporation | Transvaginal anchor implantation device |
US6117174A (en) * | 1998-09-16 | 2000-09-12 | Nolan; Wesley A. | Spinal implant device |
US6197041B1 (en) * | 1991-06-26 | 2001-03-06 | United States Surgical Corporation | Trocar |
US6200322B1 (en) * | 1999-08-13 | 2001-03-13 | Sdgi Holdings, Inc. | Minimal exposure posterior spinal interbody instrumentation and technique |
US6206826B1 (en) * | 1997-12-18 | 2001-03-27 | Sdgi Holdings, Inc. | Devices and methods for percutaneous surgery |
US6206922B1 (en) * | 1995-03-27 | 2001-03-27 | Sdgi Holdings, Inc. | Methods and instruments for interbody fusion |
US6213957B1 (en) * | 1995-09-08 | 2001-04-10 | United States Surgical Corporation | Apparatus and method for removing tissue |
US6217509B1 (en) * | 1996-03-22 | 2001-04-17 | Sdgi Holdings, Inc. | Devices and methods for percutaneous surgery |
US6228058B1 (en) * | 1997-04-03 | 2001-05-08 | Core Dynamics, Inc. | Sleeve trocar with penetration indicator |
US6264676B1 (en) * | 1996-11-08 | 2001-07-24 | Scimed Life Systems, Inc. | Protective sheath for transvaginal anchor implantation devices |
US20010012950A1 (en) * | 1997-10-01 | 2001-08-09 | Srinivas Nishtala | Dilation systems and related methods |
US6293952B1 (en) * | 1997-07-31 | 2001-09-25 | Circon Corporation | Medical instrument system for piercing through tissue |
US6293909B1 (en) * | 1998-08-07 | 2001-09-25 | Scimed Life Systems, Inc. | Device and method of using a surgical assembly with mesh sheath |
US20020001476A1 (en) * | 1998-06-26 | 2002-01-03 | Tomoyuki Nagamine | Image forming apparatus |
US6348053B1 (en) * | 1996-11-12 | 2002-02-19 | Triage Medical, Inc. | Bone fixation device |
US6364897B1 (en) * | 1993-02-04 | 2002-04-02 | Peter M. Bonutti | Method and apparatus for positioning a suture anchor |
US20020087152A1 (en) * | 2001-01-04 | 2002-07-04 | Endocare, Inc. | Systems and methods for delivering a probe into tissue |
US6428541B1 (en) * | 1998-04-09 | 2002-08-06 | Sdgi Holdings, Inc. | Method and instrumentation for vertebral interbody fusion |
US6428556B1 (en) * | 1999-08-25 | 2002-08-06 | Origin Medsystems, Inc. | Longitudinal dilator and method |
US6447527B1 (en) * | 1998-04-23 | 2002-09-10 | Ronald J. Thompson | Apparatus and methods for the penetration of tissue |
US6447540B1 (en) * | 1996-11-15 | 2002-09-10 | Cook Incorporated | Stent deployment device including splittable sleeve containing the stent |
US6511481B2 (en) * | 2001-03-30 | 2003-01-28 | Triage Medical, Inc. | Method and apparatus for fixation of proximal femoral fractures |
US20030083688A1 (en) * | 2001-10-30 | 2003-05-01 | Simonson Robert E. | Configured and sized cannula |
US6562049B1 (en) * | 2000-03-01 | 2003-05-13 | Cook Vascular Incorporated | Medical introducer apparatus |
US6562046B2 (en) * | 1999-11-23 | 2003-05-13 | Sdgi Holdings, Inc. | Screw delivery system and method |
US6582437B2 (en) * | 1999-08-26 | 2003-06-24 | Sdgi Holdings, Inc. | Devices and methods for implanting fusion cages |
US6582441B1 (en) * | 2000-02-24 | 2003-06-24 | Advanced Bionics Corporation | Surgical insertion tool |
US6589240B2 (en) * | 2001-08-28 | 2003-07-08 | Rex Medical, L.P. | Tissue biopsy apparatus with collapsible cutter |
US6592553B2 (en) * | 2000-07-05 | 2003-07-15 | Cardiac Pacemakers, Inc. | Introducer assembly and method therefor |
US6607530B1 (en) * | 1999-05-10 | 2003-08-19 | Highgate Orthopedics, Inc. | Systems and methods for spinal fixation |
US6679833B2 (en) * | 1996-03-22 | 2004-01-20 | Sdgi Holdings, Inc. | Devices and methods for percutaneous surgery |
US20040019359A1 (en) * | 2002-07-24 | 2004-01-29 | Worley Seth J. | Telescopic introducer with a compound curvature for inducing alignment and method of using the same |
US6685706B2 (en) * | 2001-11-19 | 2004-02-03 | Triage Medical, Inc. | Proximal anchors for bone fixation system |
US6689152B2 (en) * | 1998-09-09 | 2004-02-10 | Edwards Lifesciences Corp. | Introducer/dilator with balloon protection and methods of use |
US20040059339A1 (en) * | 2002-09-19 | 2004-03-25 | Roehm Thomas E. | Oval dilator and retractor set and method |
US20040059350A1 (en) * | 1992-09-04 | 2004-03-25 | Scimed Life Systems, Inc. | Suturing instruments and methods of use |
US6743166B2 (en) * | 1999-02-12 | 2004-06-01 | Karl Storz Gmbh & Co. Kg | Apparatus for introducing an intubation tube into the trachea |
US6746451B2 (en) * | 2001-06-01 | 2004-06-08 | Lance M. Middleton | Tissue cavitation device and method |
US20040147877A1 (en) * | 2003-01-27 | 2004-07-29 | Heuser Richard R | Catheter introducer system |
US20040158258A1 (en) * | 2003-02-12 | 2004-08-12 | Bonati Alfred O. | Method for removing orthopaedic hardware |
US7025746B2 (en) * | 2001-12-26 | 2006-04-11 | Yale University | Vascular access device |
US7172612B2 (en) * | 2000-12-12 | 2007-02-06 | Olympus Corporation | Trocar and trocar system |
Family Cites Families (250)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1541453A (en) * | 1922-12-20 | 1925-06-09 | Watkins Clayton Stuart | Demountable rim and wheell for automobiles and other vehicles |
US3260656A (en) * | 1962-09-27 | 1966-07-12 | Corning Glass Works | Method and apparatus for electrolytically determining a species in a fluid |
US3653841A (en) * | 1969-12-19 | 1972-04-04 | Hoffmann La Roche | Methods and compositions for determining glucose in blood |
US3719564A (en) * | 1971-05-10 | 1973-03-06 | Philip Morris Inc | Method of determining a reducible gas concentration and sensor therefor |
US3837339A (en) * | 1972-02-03 | 1974-09-24 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
US4184429A (en) * | 1972-02-09 | 1980-01-22 | Max Datwyler & Co. | Constant bevel doctor blade and method and apparatus using same |
US3908657A (en) * | 1973-01-15 | 1975-09-30 | Univ Johns Hopkins | System for continuous withdrawal of blood |
US4100048A (en) * | 1973-09-20 | 1978-07-11 | U.S. Philips Corporation | Polarographic cell |
US3911901A (en) * | 1974-07-24 | 1975-10-14 | Gen Electric | In vivo hydrogen ion sensor |
US3972320A (en) * | 1974-08-12 | 1976-08-03 | Gabor Ujhelyi Kalman | Patient monitoring system |
US3979274A (en) * | 1975-09-24 | 1976-09-07 | The Yellow Springs Instrument Company, Inc. | Membrane for enzyme electrodes |
US4016866A (en) * | 1975-12-18 | 1977-04-12 | General Electric Company | Implantable electrochemical sensor |
US4055175A (en) * | 1976-05-07 | 1977-10-25 | Miles Laboratories, Inc. | Blood glucose control apparatus |
DE2625834B2 (en) * | 1976-06-09 | 1978-10-12 | Boehringer Mannheim Gmbh, 6800 Mannheim | Method for the determination of substrates or enzyme activities |
US4076596A (en) * | 1976-10-07 | 1978-02-28 | Leeds & Northrup Company | Apparatus for electrolytically determining a species in a fluid and method of use |
FR2387659A1 (en) * | 1977-04-21 | 1978-11-17 | Armines | GLYCEMIA CONTROL AND REGULATION DEVICE |
US4098574A (en) * | 1977-08-01 | 1978-07-04 | Eastman Kodak Company | Glucose detection system free from fluoride-ion interference |
JPS5912135B2 (en) * | 1977-09-28 | 1984-03-21 | 松下電器産業株式会社 | enzyme electrode |
US4151845A (en) * | 1977-11-25 | 1979-05-01 | Miles Laboratories, Inc. | Blood glucose control apparatus |
DK151000C (en) * | 1978-02-17 | 1988-06-13 | Radiometer As | PROCEDURE AND APPARATUS FOR DETERMINING A PATIENT'S IN VIVO PLASMA-PH VALUE |
US4172770A (en) * | 1978-03-27 | 1979-10-30 | Technicon Instruments Corporation | Flow-through electrochemical system analytical method |
HU177369B (en) * | 1978-09-08 | 1981-09-28 | Radelkis Electrokemiai | Industrial molecule-selective sensing device and method for producing same |
US4247297A (en) * | 1979-02-23 | 1981-01-27 | Miles Laboratories, Inc. | Test means and method for interference resistant determination of oxidizing substances |
US4573994A (en) * | 1979-04-27 | 1986-03-04 | The Johns Hopkins University | Refillable medication infusion apparatus |
US4401122A (en) * | 1979-08-02 | 1983-08-30 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
US4458686A (en) * | 1979-08-02 | 1984-07-10 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
US4450842A (en) * | 1980-04-25 | 1984-05-29 | Cordis Corporation | Solid state reference electrode |
US4340458A (en) * | 1980-06-02 | 1982-07-20 | Joslin Diabetes Center, Inc. | Glucose sensor |
US4356074A (en) * | 1980-08-25 | 1982-10-26 | The Yellow Springs Instrument Company, Inc. | Substrate specific galactose oxidase enzyme electrodes |
US4404066A (en) * | 1980-08-25 | 1983-09-13 | The Yellow Springs Instrument Company | Method for quantitatively determining a particular substrate catalyzed by a multisubstrate enzyme |
US4352960A (en) * | 1980-09-30 | 1982-10-05 | Baptist Medical Center Of Oklahoma, Inc. | Magnetic transcutaneous mount for external device of an associated implant |
US4390621A (en) * | 1980-12-15 | 1983-06-28 | Miles Laboratories, Inc. | Method and device for detecting glucose concentration |
US4436094A (en) * | 1981-03-09 | 1984-03-13 | Evreka, Inc. | Monitor for continuous in vivo measurement of glucose concentration |
AT369254B (en) * | 1981-05-07 | 1982-12-27 | Otto Dipl Ing Dr Tech Prohaska | MEDICAL PROBE |
FR2508305B1 (en) * | 1981-06-25 | 1986-04-11 | Slama Gerard | DEVICE FOR CAUSING A LITTLE BITE TO COLLECT A BLOOD DROP |
US4440175A (en) * | 1981-08-10 | 1984-04-03 | University Patents, Inc. | Membrane electrode for non-ionic species |
DE3278334D1 (en) * | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
US4431004A (en) * | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
JPS58153154A (en) * | 1982-03-09 | 1983-09-12 | Ajinomoto Co Inc | Qualified electrode |
US4581336A (en) * | 1982-04-26 | 1986-04-08 | Uop Inc. | Surface-modified electrodes |
DE3221339A1 (en) * | 1982-06-05 | 1983-12-08 | Basf Ag, 6700 Ludwigshafen | METHOD FOR THE ELECTROCHEMICAL HYDRATION OF NICOTINAMIDADENINE-DINUCLEOTIDE |
US4427770A (en) * | 1982-06-14 | 1984-01-24 | Miles Laboratories, Inc. | High glucose-determining analytical element |
DE3228551A1 (en) * | 1982-07-30 | 1984-02-02 | Siemens AG, 1000 Berlin und 8000 München | METHOD FOR DETERMINING SUGAR CONCENTRATION |
US4534356A (en) * | 1982-07-30 | 1985-08-13 | Diamond Shamrock Chemicals Company | Solid state transcutaneous blood gas sensors |
US4571292A (en) * | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
US4461691A (en) * | 1983-02-10 | 1984-07-24 | The United States Of America As Represented By The United States Department Of Energy | Organic conductive films for semiconductor electrodes |
US4679562A (en) * | 1983-02-16 | 1987-07-14 | Cardiac Pacemakers, Inc. | Glucose sensor |
IT1170375B (en) * | 1983-04-19 | 1987-06-03 | Giuseppe Bombardieri | Implantable device for measuring body fluid parameters |
CA1218704A (en) * | 1983-05-05 | 1987-03-03 | Graham Davis | Assay systems using more than one enzyme |
US4650547A (en) * | 1983-05-19 | 1987-03-17 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4524114A (en) * | 1983-07-05 | 1985-06-18 | Allied Corporation | Bifunctional air electrode |
US4538616A (en) * | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
US4543955A (en) * | 1983-08-01 | 1985-10-01 | Cordis Corporation | System for controlling body implantable action device |
US4655880A (en) * | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
US4522690A (en) * | 1983-12-01 | 1985-06-11 | Honeywell Inc. | Electrochemical sensing of carbon monoxide |
WO1985002627A1 (en) * | 1983-12-16 | 1985-06-20 | Genetics International, Inc. | Assay for nucleic acids |
JPS60135756A (en) * | 1983-12-24 | 1985-07-19 | Ngk Insulators Ltd | Production of electrochemical cell |
WO1985005119A1 (en) * | 1984-04-30 | 1985-11-21 | Stiftung, R., E. | Process for the sensitization of an oxidoreduction photocalatyst, and photocatalyst thus obtained |
DK8601218A (en) * | 1984-07-18 | 1986-03-17 | ||
US4820399A (en) * | 1984-08-31 | 1989-04-11 | Shimadzu Corporation | Enzyme electrodes |
CA1254091A (en) * | 1984-09-28 | 1989-05-16 | Vladimir Feingold | Implantable medication infusion system |
US4717673A (en) * | 1984-11-23 | 1988-01-05 | Massachusetts Institute Of Technology | Microelectrochemical devices |
US4721601A (en) * | 1984-11-23 | 1988-01-26 | Massachusetts Institute Of Technology | Molecule-based microelectronic devices |
JPH0617889B2 (en) * | 1984-11-27 | 1994-03-09 | 株式会社日立製作所 | Biochemical sensor |
GB8500729D0 (en) * | 1985-01-11 | 1985-02-13 | Hill H A O | Surface-modified electrode |
US4627445A (en) * | 1985-04-08 | 1986-12-09 | Garid, Inc. | Glucose medical monitoring system |
US4671288A (en) * | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
EP0230472B2 (en) * | 1985-06-21 | 2000-12-13 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method of manufacturing same |
US4796634A (en) * | 1985-08-09 | 1989-01-10 | Lawrence Medical Systems, Inc. | Methods and apparatus for monitoring cardiac output |
US4805624A (en) * | 1985-09-09 | 1989-02-21 | The Montefiore Hospital Association Of Western Pa | Low-potential electrochemical redox sensors |
US4680268A (en) * | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
US4890620A (en) * | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
CA1254616A (en) * | 1985-11-11 | 1989-05-23 | Calum J. Mcneil | Electrochemical enzymic assay procedures |
GB8529300D0 (en) * | 1985-11-28 | 1986-01-02 | Ici Plc | Membrane |
US4776944A (en) * | 1986-03-20 | 1988-10-11 | Jiri Janata | Chemical selective sensors utilizing admittance modulated membranes |
US4685463A (en) * | 1986-04-03 | 1987-08-11 | Williams R Bruce | Device for continuous in vivo measurement of blood glucose concentrations |
US4726378A (en) * | 1986-04-11 | 1988-02-23 | Minnesota Mining And Manufacturing Company | Adjustable magnetic supercutaneous device and transcutaneous coupling apparatus |
US4757022A (en) * | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4909908A (en) * | 1986-04-24 | 1990-03-20 | Pepi Ross | Electrochemical cncentration detector method |
US4795542A (en) * | 1986-04-24 | 1989-01-03 | St. Jude Medical, Inc. | Electrochemical concentration detector device |
DE3614821A1 (en) * | 1986-05-02 | 1987-11-05 | Siemens Ag | IMPLANTABLE, CALIBRABLE MEASURING DEVICE FOR A BODY SUBSTANCE AND CALIBRATION METHOD |
US4911794A (en) * | 1986-06-20 | 1990-03-27 | Molecular Devices Corporation | Measuring with zero volume cell |
US4764416A (en) * | 1986-07-01 | 1988-08-16 | Mitsubishi Denki Kabushiki Kaisha | Electric element circuit using oxidation-reduction substances |
US4917800A (en) * | 1986-07-07 | 1990-04-17 | Bend Research, Inc. | Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers |
US4726716A (en) * | 1986-07-21 | 1988-02-23 | Mcguire Thomas V | Fastener for catheter |
US4894137A (en) * | 1986-09-12 | 1990-01-16 | Omron Tateisi Electronics Co. | Enzyme electrode |
DE3700119A1 (en) * | 1987-01-03 | 1988-07-14 | Inst Diabetestechnologie Gemei | IMPLANTABLE ELECTROCHEMICAL SENSOR |
US4848351A (en) * | 1987-03-04 | 1989-07-18 | Sentry Medical Products, Inc. | Medical electrode assembly |
US4759828A (en) * | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
US4822337A (en) * | 1987-06-22 | 1989-04-18 | Stanley Newhouse | Insulin delivery method and apparatus |
JPH07122624B2 (en) * | 1987-07-06 | 1995-12-25 | ダイキン工業株式会社 | Biosensor |
US4874500A (en) * | 1987-07-15 | 1989-10-17 | Sri International | Microelectrochemical sensor and sensor array |
GB8718430D0 (en) * | 1987-08-04 | 1987-09-09 | Ici Plc | Sensor |
US4815469A (en) * | 1987-10-08 | 1989-03-28 | Siemens-Pacesetter, Inc. | Implantable blood oxygen sensor and method of use |
US4813424A (en) * | 1987-12-23 | 1989-03-21 | University Of New Mexico | Long-life membrane electrode for non-ionic species |
US4923442A (en) * | 1988-05-02 | 1990-05-08 | Cryomedical Sciences Inc. | Blood substitute |
US5831066A (en) * | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
WO1991004753A1 (en) * | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
GB9123947D0 (en) * | 1991-11-12 | 1992-01-02 | Imp Cancer Res Tech | Therapeutic compounds |
EP1251170A3 (en) * | 1992-07-17 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of NF-kappaB dependent animal diseases |
US6001992A (en) * | 1999-01-07 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
US20040204380A1 (en) * | 1999-01-07 | 2004-10-14 | Ackermann Elizabeth J | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
US20020086321A1 (en) * | 1993-02-02 | 2002-07-04 | Craig Ruth W. | Myeloid cell leukemia associated gene MCL-1 |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
US6306829B1 (en) * | 1995-12-08 | 2001-10-23 | Hybridon, Inc. | Modified VEGF oligonucleotides for treatment of skin disorders |
US6410322B1 (en) * | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US5641756A (en) * | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
DK0745124T3 (en) * | 1994-02-14 | 1999-02-01 | Amgen Inc | Mammalian cell cycle protein |
US6150092A (en) * | 1994-06-27 | 2000-11-21 | Taogosei Company, Ltd. | Antisense nucleic acid compound targeted to VEGF |
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
JP2000501941A (en) * | 1995-12-08 | 2000-02-22 | ハイブリドン・インコーポレイテッド | Modified VEGF antisense oligonucleotide |
US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
BR9708701A (en) * | 1996-04-17 | 2000-01-04 | Hoechst Marion Roussel De Gmbh | Anti-sense inhibitors of vascular endothelial growth factor expression. |
US20050261485A1 (en) * | 1996-05-23 | 2005-11-24 | Toagosei Co., Ltd., A Japan Corporation | Method of producing antisense oligonucleotide |
CA2259123C (en) | 1996-07-01 | 2003-10-21 | Jim A. Wright | Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth |
WO1998027425A1 (en) * | 1996-12-19 | 1998-06-25 | Isis Pharmaceuticals, Inc. | Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction |
US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
JPH1142091A (en) * | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | Anti-sense nucleic acid compound |
PT1007092E (en) * | 1997-08-26 | 2006-12-29 | Amgen Fremont Inc | A process for inhibiting complement activation via the alternative pathway |
US6046319A (en) * | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
EP1053315A4 (en) | 1998-01-29 | 2003-07-30 | Univ Columbia | Human hairless gene, protein and uses thereof |
US6111086A (en) * | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
US6579702B2 (en) * | 1998-04-03 | 2003-06-17 | Wiconsin Alumni Research Foundation | Mammalian tolloid-like gene and protein |
US20030228597A1 (en) * | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
EP1089764B1 (en) * | 1998-06-10 | 2004-09-01 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Stimulating the immune system |
US20030096775A1 (en) * | 2001-10-23 | 2003-05-22 | Isis Pharmaceuticals Inc. | Antisense modulation of complement component C3 expression |
US6007995A (en) * | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
EP1093373A4 (en) * | 1998-07-02 | 2005-04-13 | Univ Columbia | OLIGONUCLEOTIDE INHIBITORS OF bcl-xL |
US6228642B1 (en) * | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
ATE332969T1 (en) * | 1998-10-26 | 2006-08-15 | Avi Biopharma Inc | MORPHOLINE-BASED P53 ANTISENSE OLIGONUCLEOTIDE AND USES THEREOF |
WO2000027414A2 (en) * | 1998-11-06 | 2000-05-18 | Basf Aktiengesellschaft | Inhibition of the formation of vascular hyperpermeability |
US5958773A (en) * | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
JP4943585B2 (en) * | 1999-02-18 | 2012-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Salicylamide-lanthanide complexes for use as luminescent markers |
CA2365907C (en) | 1999-04-08 | 2010-08-17 | Chiron Corporation | Enhancement of the immune response for vaccine and gene therapy applications |
JP4638098B2 (en) | 1999-06-14 | 2011-02-23 | キャンサー・リサーチ・テクノロジー・リミテッド | Cancer treatment |
US6770633B1 (en) * | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
US7179796B2 (en) * | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
CA2404890C (en) * | 2000-03-30 | 2013-11-19 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
EP1320614A2 (en) * | 2000-06-26 | 2003-06-25 | Sugen, Inc. | Novel proteases |
EP1325121A2 (en) * | 2000-10-13 | 2003-07-09 | Institut de Cardiologie de Montreal | Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof |
AU2002243429A1 (en) * | 2000-10-24 | 2002-06-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of tnfr1 expression |
EP1334132A1 (en) * | 2000-11-01 | 2003-08-13 | BKI Holding Corporation | Cellulose ethers and method of preparing the same |
BRPI0115814B8 (en) * | 2000-12-01 | 2021-05-25 | Europaeisches Laboratorium Fuer Molekularbiologie Embl | double-stranded RNA molecules, their method of preparation and pharmaceutical composition comprising them |
US20030143597A1 (en) | 2000-12-28 | 2003-07-31 | Finney Robert E. | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis |
US20020150945A1 (en) * | 2000-12-28 | 2002-10-17 | Cell Therapeutics, Inc. | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis |
WO2002053161A1 (en) * | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
WO2003035869A1 (en) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene |
EP1372690A4 (en) * | 2001-03-01 | 2005-08-24 | Millennium Pharm Inc | 93870, a human g-protein coupled receptor and uses therefor |
WO2002085285A2 (en) * | 2001-04-18 | 2002-10-31 | Wyeth | Methods and reagents for regulating bone and cartilage formation |
WO2002085309A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent |
WO2002085308A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
WO2002097114A2 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
US20050130181A1 (en) * | 2001-05-18 | 2005-06-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA) |
US20050239731A1 (en) * | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA) |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
US20050048529A1 (en) * | 2002-02-20 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US20040219671A1 (en) * | 2002-02-20 | 2004-11-04 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
WO2003070910A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CA2448320A1 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Ribozyme based treatment of female reproductive diseases |
WO2003006424A1 (en) | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
US6734017B2 (en) * | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
JP4917225B2 (en) | 2001-09-28 | 2012-04-18 | ローム株式会社 | Semiconductor device |
WO2003035870A1 (en) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Drug for treating a carcinoma of the pancreas |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
IL161733A0 (en) * | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
FR2832154B1 (en) * | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE |
US20030186903A1 (en) * | 2001-11-23 | 2003-10-02 | Isis Pharmaceuticals Inc. | Antisense modulation of MyD88 expression |
AU2002358631A1 (en) | 2001-11-26 | 2003-06-10 | Hybrigenics | Protein-protein interactions in human immunodeficiency virus |
US6965025B2 (en) * | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
GB0130955D0 (en) * | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
KR100441894B1 (en) * | 2002-01-26 | 2004-07-27 | 한국전자통신연구원 | Micro-integrated near-field optical recording head and optical recording system using the same |
EP3415625A1 (en) * | 2002-02-01 | 2018-12-19 | Life Technologies Corporation | Double-stranded oligonucleotides |
AU2003213119A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
EP1436314A4 (en) | 2002-02-20 | 2005-08-10 | Sirna Therapeutics Inc | Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina) |
AU2003217550A1 (en) * | 2002-02-20 | 2003-09-09 | Ribozyme Pharmaceuticals, Incorporated | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CA2479530A1 (en) * | 2002-03-20 | 2003-10-02 | Massachusetts Institute Of Technology | Hiv therapeutic |
JP2005521418A (en) * | 2002-03-29 | 2005-07-21 | イェン、ユン | Human ribonucleotide reductase M2 subunit |
US20030224512A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
AU2003231886A1 (en) * | 2002-05-13 | 2003-11-11 | Salviac Limited | Retrieval catheter for an embolic filter |
US20040101857A1 (en) * | 2002-11-23 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of cytokine-inducible kinase expression |
JP2006506961A (en) * | 2002-05-23 | 2006-03-02 | セプティア, インコーポレイテッド | Regulation of PTP1B signal transduction by RNA interference |
US20040102391A1 (en) * | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Gankyrin expression |
JP2005529616A (en) * | 2002-06-18 | 2005-10-06 | アイアールエム エルエルシー | Diagnosis and treatment of chemotherapy-resistant tumors |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US6906186B1 (en) * | 2002-07-30 | 2005-06-14 | Isis Pharmaceuticals, Inc. | Antisense modulation of polo-like kinase expression |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
US20040137471A1 (en) * | 2002-09-18 | 2004-07-15 | Timothy Vickers | Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds |
WO2004031237A1 (en) | 2002-09-30 | 2004-04-15 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human myeloid leukemia |
AU2003304386A1 (en) * | 2002-10-30 | 2005-02-25 | The Center For Blood Research, Inc. | Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
JP5449639B2 (en) * | 2002-11-01 | 2014-03-19 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Compositions and methods for siRNA inhibition of HIF-1 alpha |
ATE443764T1 (en) * | 2002-11-04 | 2009-10-15 | Univ Massachusetts | ALLEL-SPECIFIC RNA INTERFERENCE |
US7691998B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US7592442B2 (en) * | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
JP2006507841A (en) | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | Functional and ultrafunctional siRNA |
US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
US7619081B2 (en) | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
US7582747B2 (en) * | 2002-11-14 | 2009-09-01 | Dharmacon, Inc. | siRNA targeting inner centromere protein antigens (INCENP) |
US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7977471B2 (en) | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
AU2003295539A1 (en) | 2002-11-15 | 2004-06-15 | University Of Massachusetts | Allele-targeted rna interference |
US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
AU2003302167A1 (en) * | 2002-12-12 | 2004-06-30 | The Burnham Institute | Conversion of apoptotic proteins |
US20040248299A1 (en) * | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
FR2835837B1 (en) * | 2003-02-06 | 2007-03-16 | Centre Nat Rech Scient | INHIBITORY OLIGONUCLEOTIDES AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE ENCODING A GROWTH FACTOR |
FR2835838B1 (en) * | 2003-02-06 | 2007-11-16 | Centre Nat Rech Scient | OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE ENCODING A TRANSCRIPTION FACTOR |
WO2004076639A2 (en) * | 2003-02-26 | 2004-09-10 | Wyeth | Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
JP4605799B2 (en) | 2003-04-02 | 2011-01-05 | ダーマコン, インコーポレイテッド | Modified polynucleotides for use in RNA interference |
AU2003224132A1 (en) | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
US7399853B2 (en) * | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
WO2004105774A1 (en) | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
JP4505749B2 (en) | 2003-05-30 | 2010-07-21 | 日本新薬株式会社 | Oligo double-stranded RNA that suppresses expression of Bcl-2 and pharmaceutical composition containing the same |
DK1633767T3 (en) * | 2003-06-02 | 2019-03-25 | Univ Massachusetts | METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING |
WO2005001043A2 (en) | 2003-06-02 | 2005-01-06 | University Of Massachusetts | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
US7750144B2 (en) * | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
ES2905724T3 (en) * | 2003-06-13 | 2022-04-11 | Alnylam Europe Ag | Double-stranded ribonucleic acid with high efficacy in an organism |
US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
DE10341333B4 (en) * | 2003-09-08 | 2006-06-08 | Siemens Ag | Piezoelectric actuator and method for producing a piezoelectric actuator |
KR100568246B1 (en) * | 2003-11-19 | 2006-04-05 | 삼성전자주식회사 | Computer System And Controlling Method Thereof |
US20050176045A1 (en) | 2004-02-06 | 2005-08-11 | Dharmacon, Inc. | SNP discriminatory siRNA |
EP1735009A4 (en) | 2004-03-12 | 2011-03-30 | Alnylam Pharmaceuticals Inc | iRNA AGENTS TARGETING VEGF |
KR101147147B1 (en) * | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Modified polynucleotides for reducing off-target effects in rna interference |
CA2557532A1 (en) * | 2004-04-23 | 2005-11-10 | Angela M. Christiano | Inhibition of hairless protein mrna |
WO2005117991A2 (en) | 2004-05-04 | 2005-12-15 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
US7605250B2 (en) | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
JP2006013252A (en) * | 2004-06-28 | 2006-01-12 | Hitachi Cable Ltd | Method and circuit for controlling laser diode, and optical transmitter |
MX2007003795A (en) * | 2004-09-28 | 2007-07-11 | Quark Biotech Inc | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases. |
WO2006053430A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
BRPI0610499A2 (en) | 2005-04-12 | 2010-06-22 | Intradigm Corp | nucleic acid molecules, compositions and uses of said molecules |
US20060286575A1 (en) * | 2005-04-16 | 2006-12-21 | Cylene Pharmaceuticals, Inc. | MCL-1 quadruplex nucleic acids and uses thereof |
US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
US7910566B2 (en) * | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
WO2007137129A2 (en) | 2006-05-19 | 2007-11-29 | Alcon Research, Ltd. | RNAI-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR α-RELATED CONDITIONS |
US8523707B2 (en) * | 2006-05-31 | 2013-09-03 | Bridgestone Sports Co., Ltd. | Multi-piece solid golf ball |
US8138160B2 (en) * | 2006-08-03 | 2012-03-20 | Warsaw Orthopedic, Inc. | Reagents, methods and systems to suppress pro-inflammatory cytokines |
CN101640467B (en) | 2008-07-28 | 2012-05-30 | 鸿富锦精密工业(深圳)有限公司 | Shrapnel and voice coil motor |
-
2003
- 2003-11-14 JP JP2004570430A patent/JP2006507841A/en active Pending
- 2003-11-14 ES ES10012132.6T patent/ES2440284T3/en not_active Expired - Lifetime
- 2003-11-14 EP EP10012132.6A patent/EP2284266B1/en not_active Expired - Lifetime
- 2003-11-14 PT PT100121326T patent/PT2284266E/en unknown
- 2003-11-14 AU AU2003295600A patent/AU2003295600A1/en not_active Abandoned
- 2003-11-14 EP EP10013100A patent/EP2305813A3/en not_active Withdrawn
- 2003-11-14 EP EP10013098A patent/EP2314691A3/en not_active Withdrawn
- 2003-11-14 US US10/714,333 patent/US8090542B2/en not_active Expired - Fee Related
- 2003-11-14 EP EP10013099A patent/EP2305812A3/en not_active Withdrawn
- 2003-11-14 DK DK10012132.6T patent/DK2284266T3/en active
- 2003-11-14 EP EP10013081A patent/EP2278005A3/en not_active Withdrawn
- 2003-11-14 WO PCT/US2003/036787 patent/WO2004045543A2/en active Search and Examination
- 2003-11-14 EP EP10003382A patent/EP2213738B1/en not_active Expired - Lifetime
- 2003-11-14 AT AT03786798T patent/ATE517992T1/en not_active IP Right Cessation
- 2003-11-14 EP EP03786798A patent/EP1560931B1/en not_active Expired - Lifetime
-
2004
- 2004-09-14 US US10/940,892 patent/US20120052487A9/en not_active Abandoned
-
2005
- 2005-01-19 US US11/038,784 patent/US20050256525A1/en not_active Abandoned
- 2005-03-18 US US11/083,784 patent/US7820809B2/en not_active Expired - Fee Related
- 2005-03-29 US US11/093,832 patent/US20070039072A1/en not_active Abandoned
- 2005-03-30 US US11/095,383 patent/US7834170B2/en active Active
- 2005-04-07 US US11/101,244 patent/US7691997B2/en active Active
-
2006
- 2006-12-04 US US11/633,342 patent/US7608707B2/en not_active Expired - Fee Related
- 2006-12-04 US US11/633,404 patent/US20070093653A1/en not_active Abandoned
- 2006-12-04 US US11/633,383 patent/US7645869B2/en not_active Expired - Lifetime
- 2006-12-04 US US11/633,306 patent/US7507811B2/en not_active Expired - Lifetime
- 2006-12-07 US US11/635,330 patent/US7696344B2/en not_active Expired - Lifetime
- 2006-12-07 US US11/635,618 patent/US7579457B2/en not_active Expired - Fee Related
- 2006-12-07 US US11/635,478 patent/US20070088155A1/en not_active Abandoned
- 2006-12-07 US US11/635,329 patent/US7674896B2/en not_active Expired - Fee Related
-
2007
- 2007-07-23 US US11/880,628 patent/US7595389B2/en not_active Expired - Fee Related
- 2007-07-24 US US11/880,855 patent/US20080300395A1/en not_active Abandoned
- 2007-07-24 US US11/880,755 patent/US20080293595A1/en not_active Abandoned
- 2007-07-24 US US11/880,777 patent/US20080188648A1/en not_active Abandoned
- 2007-07-24 US US11/880,775 patent/US7655788B2/en not_active Expired - Lifetime
- 2007-07-25 US US11/881,385 patent/US20080306015A1/en not_active Abandoned
- 2007-07-25 US US11/881,386 patent/US20080221317A1/en not_active Abandoned
- 2007-09-20 US US11/903,001 patent/US7514550B2/en not_active Expired - Lifetime
- 2007-10-15 US US11/974,610 patent/US20080091001A1/en not_active Abandoned
- 2007-10-16 US US11/974,865 patent/US20080091002A1/en not_active Abandoned
- 2007-10-16 US US11/974,885 patent/US7511132B2/en not_active Expired - Lifetime
- 2007-10-16 US US11/974,878 patent/US20080114162A1/en not_active Abandoned
- 2007-10-16 US US11/974,880 patent/US20080091003A1/en not_active Abandoned
- 2007-10-17 US US11/975,152 patent/US7795420B2/en not_active Expired - Fee Related
- 2007-10-18 US US11/975,331 patent/US20080091004A1/en not_active Abandoned
- 2007-10-19 US US11/975,661 patent/US20080108803A1/en not_active Abandoned
-
2008
- 2008-06-06 US US12/157,137 patent/US7642349B2/en not_active Expired - Lifetime
- 2008-10-14 US US12/287,757 patent/US7576196B2/en not_active Expired - Fee Related
- 2008-12-09 US US12/330,981 patent/US7576197B2/en not_active Expired - Fee Related
-
2009
- 2009-02-10 US US12/322,980 patent/US20090163701A1/en not_active Abandoned
- 2009-02-11 US US12/378,164 patent/US7592444B2/en not_active Expired - Fee Related
- 2009-04-08 US US12/384,768 patent/US8030474B2/en active Active
- 2009-07-01 US US12/459,489 patent/US20090291497A1/en not_active Abandoned
- 2009-07-06 US US12/459,670 patent/US7745611B2/en not_active Expired - Fee Related
- 2009-08-12 US US12/463,000 patent/US20100004142A1/en not_active Abandoned
- 2009-09-10 US US12/584,705 patent/US7807819B2/en not_active Expired - Fee Related
- 2009-11-12 US US12/590,707 patent/US7803933B2/en not_active Expired - Lifetime
- 2009-11-23 US US12/592,335 patent/US7893247B2/en not_active Expired - Lifetime
-
2010
- 2010-01-15 US US12/657,263 patent/US20100152064A1/en not_active Abandoned
- 2010-02-19 JP JP2010035279A patent/JP2010187668A/en active Pending
- 2010-05-03 US US12/799,844 patent/US8008474B2/en not_active Expired - Fee Related
- 2010-06-11 US US12/802,647 patent/US8000902B2/en active Active
- 2010-08-10 US US12/806,320 patent/US7985854B2/en not_active Expired - Lifetime
- 2010-08-13 US US12/806,513 patent/US20100331214A1/en not_active Abandoned
- 2010-12-06 US US12/928,190 patent/US8093370B2/en not_active Expired - Fee Related
-
2011
- 2011-08-17 US US13/199,001 patent/US20110319474A1/en not_active Abandoned
- 2011-12-06 US US13/373,956 patent/US20120135892A1/en not_active Abandoned
-
2019
- 2019-03-05 US US16/292,513 patent/US20190345573A1/en not_active Abandoned
Patent Citations (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US647526A (en) * | 1899-06-26 | 1900-04-17 | William Allen Runyan | Freight-car door. |
US3719760A (en) * | 1968-01-29 | 1973-03-06 | Bayer Ag | N-trityl-imidazolium salts as a fungicide |
US3811449A (en) * | 1972-03-08 | 1974-05-21 | Becton Dickinson Co | Dilating apparatus and method |
US4401433A (en) * | 1980-06-13 | 1983-08-30 | Luther Ronald B | Apparatus for advancing oversized catheter through cannula, and the like |
US4449532A (en) * | 1980-07-08 | 1984-05-22 | Karl Storz | Dilator to facilitate endoscope insertion into the body |
US4369790A (en) * | 1981-03-05 | 1983-01-25 | Mccarthy John M | Catheter |
US4350151A (en) * | 1981-03-12 | 1982-09-21 | Lone Star Medical Products, Inc. | Expanding dilator |
US4451256A (en) * | 1981-05-06 | 1984-05-29 | Intermedicat Gmbh | Catheter set |
US4601710B1 (en) * | 1983-08-24 | 1998-05-05 | United States Surgical Corp | Trocar assembly |
US4601710A (en) * | 1983-08-24 | 1986-07-22 | Endotherapeutics Corporation | Trocar assembly |
US4573448A (en) * | 1983-10-05 | 1986-03-04 | Pilling Co. | Method for decompressing herniated intervertebral discs |
US4686984A (en) * | 1984-03-15 | 1987-08-18 | Richard Wolf Gmbh | Catheter for widening a puncture channel |
US4802479A (en) * | 1986-10-31 | 1989-02-07 | C. R. Bard, Inc. | Hand-held instrument for implanting, dispensing, and inflating an inflatable membrane |
US4981482A (en) * | 1987-08-20 | 1991-01-01 | Kazuo Ichikawa | Device for forming an inserting hole for an endoscope |
US4862891A (en) * | 1988-03-14 | 1989-09-05 | Canyon Medical Products | Device for sequential percutaneous dilation |
US4994027A (en) * | 1988-06-08 | 1991-02-19 | Farrell Edward M | Percutaneous femoral bypass system |
US5224952A (en) * | 1988-07-06 | 1993-07-06 | Ethicon, Inc. | Safety trocar |
US5613950A (en) * | 1988-07-22 | 1997-03-25 | Yoon; Inbae | Multifunctional manipulating instrument for various surgical procedures |
US5782800A (en) * | 1988-07-22 | 1998-07-21 | Yoon; Inbae | Expandable multifunctional manipulating instruments for various medical procedures and methods therefor |
US5002557A (en) * | 1989-04-06 | 1991-03-26 | Hasson Harrith M | Laparoscopic cannula |
US5176697A (en) * | 1989-04-06 | 1993-01-05 | Hasson Harrith M | Laparoscopic cannula |
US5114407A (en) * | 1990-08-30 | 1992-05-19 | Ethicon, Inc. | Safety mechanism for trocar |
US5188118A (en) * | 1990-11-07 | 1993-02-23 | Terwilliger Richard A | Automatic biopsy instrument with independently actuated stylet and cannula |
US5324261A (en) * | 1991-01-04 | 1994-06-28 | Medtronic, Inc. | Drug delivery balloon catheter with line of weakness |
US5342382A (en) * | 1991-01-15 | 1994-08-30 | Ethicon, Inc. | Surgical trocar |
US5176651A (en) * | 1991-04-01 | 1993-01-05 | Dexide, Inc. | Combination surgical trocar housing and selective reducer sleeve assembly |
US5486190A (en) * | 1991-04-30 | 1996-01-23 | United States Surgical Corporation | Safety trocar |
US5241972A (en) * | 1991-05-03 | 1993-09-07 | Meditron Devices, Inc. | Method for debulking tissue to remove pressure on a nerve |
US5183464A (en) * | 1991-05-17 | 1993-02-02 | Interventional Thermodynamics, Inc. | Radially expandable dilator |
US6197041B1 (en) * | 1991-06-26 | 2001-03-06 | United States Surgical Corporation | Trocar |
US5195506A (en) * | 1991-10-18 | 1993-03-23 | Life Medical Products, Inc. | Surgical retractor for puncture operation |
US5280782A (en) * | 1991-11-15 | 1994-01-25 | Wilk Peter J | Variable length laparoscopic retractor and associated method of use |
US5810866A (en) * | 1991-11-27 | 1998-09-22 | Yoon; Inbae | Automatic retractable safety penetrating instrument for portal sleeve introduction |
US5713870A (en) * | 1991-11-27 | 1998-02-03 | Yoon; Inbae | Retractable safety penetrating instrument with laterally extendable spring strip |
US6033406A (en) * | 1992-03-17 | 2000-03-07 | Sdgi Holdings, Inc. | Method for subcutaneous suprafascial pedicular internal fixation |
US5728097A (en) * | 1992-03-17 | 1998-03-17 | Sdgi Holding, Inc. | Method for subcutaneous suprafascial internal fixation |
US5290243A (en) * | 1992-07-16 | 1994-03-01 | Technalytics, Inc. | Trocar system |
US5312417A (en) * | 1992-07-29 | 1994-05-17 | Wilk Peter J | Laparoscopic cannula assembly and associated method |
US20040059350A1 (en) * | 1992-09-04 | 2004-03-25 | Scimed Life Systems, Inc. | Suturing instruments and methods of use |
US6364897B1 (en) * | 1993-02-04 | 2002-04-02 | Peter M. Bonutti | Method and apparatus for positioning a suture anchor |
US5752969A (en) * | 1993-06-17 | 1998-05-19 | Sofamor S.N.C. | Instrument for the surgical treatment of an intervertebral disc by the anterior route |
US5407430A (en) * | 1994-03-21 | 1995-04-18 | Peters; Michael J. | Intravenous catheter |
US5512037A (en) * | 1994-05-12 | 1996-04-30 | United States Surgical Corporation | Percutaneous surgical retractor |
US5505710A (en) * | 1994-08-22 | 1996-04-09 | C. R. Bard, Inc. | Telescoping probe |
US5647857A (en) * | 1995-03-16 | 1997-07-15 | Endotex Interventional Systems, Inc. | Protective intraluminal sheath |
US5624447A (en) * | 1995-03-20 | 1997-04-29 | Othy, Inc. | Surgical tool guide and entry hole positioner |
US6695851B2 (en) * | 1995-03-27 | 2004-02-24 | Sdgi Holdings, Inc. | Methods and instruments for interbody fusion |
US6206922B1 (en) * | 1995-03-27 | 2001-03-27 | Sdgi Holdings, Inc. | Methods and instruments for interbody fusion |
US5776156A (en) * | 1995-09-05 | 1998-07-07 | United States Surgical Corporation | Endoscopic cutting instrument |
US6213957B1 (en) * | 1995-09-08 | 2001-04-10 | United States Surgical Corporation | Apparatus and method for removing tissue |
US5772678A (en) * | 1995-10-20 | 1998-06-30 | Inlet Medical, Inc. | Retractable disposable tip reusable trocar obturator |
US5743881A (en) * | 1995-11-03 | 1998-04-28 | Aptec Medical Corporation | Laparoscopic surgical instrument and method of using same |
US5707359A (en) * | 1995-11-14 | 1998-01-13 | Bufalini; Bruno | Expanding trocar assembly |
US5810721A (en) * | 1996-03-04 | 1998-09-22 | Heartport, Inc. | Soft tissue retractor and method for providing surgical access |
US6048309A (en) * | 1996-03-04 | 2000-04-11 | Heartport, Inc. | Soft tissue retractor and delivery device therefor |
US5902231A (en) * | 1996-03-22 | 1999-05-11 | Sdgi Holdings, Inc. | Devices and methods for percutaneous surgery |
US6520907B1 (en) * | 1996-03-22 | 2003-02-18 | Sdgi Holdings, Inc. | Methods for accessing the spinal column |
US6679833B2 (en) * | 1996-03-22 | 2004-01-20 | Sdgi Holdings, Inc. | Devices and methods for percutaneous surgery |
US6217509B1 (en) * | 1996-03-22 | 2001-04-17 | Sdgi Holdings, Inc. | Devices and methods for percutaneous surgery |
US5792044A (en) * | 1996-03-22 | 1998-08-11 | Danek Medical, Inc. | Devices and methods for percutaneous surgery |
US6053935A (en) * | 1996-11-08 | 2000-04-25 | Boston Scientific Corporation | Transvaginal anchor implantation device |
US6440154B2 (en) * | 1996-11-08 | 2002-08-27 | Scimed Life Systems, Inc. | Protective sheath for transvaginal anchor implantation device |
US6264676B1 (en) * | 1996-11-08 | 2001-07-24 | Scimed Life Systems, Inc. | Protective sheath for transvaginal anchor implantation devices |
US6348053B1 (en) * | 1996-11-12 | 2002-02-19 | Triage Medical, Inc. | Bone fixation device |
US6447540B1 (en) * | 1996-11-15 | 2002-09-10 | Cook Incorporated | Stent deployment device including splittable sleeve containing the stent |
US6228058B1 (en) * | 1997-04-03 | 2001-05-08 | Core Dynamics, Inc. | Sleeve trocar with penetration indicator |
US6293952B1 (en) * | 1997-07-31 | 2001-09-25 | Circon Corporation | Medical instrument system for piercing through tissue |
US20040049223A1 (en) * | 1997-10-01 | 2004-03-11 | Scimed Life Systems, Inc. | Dilation systems and related methods |
US20010012950A1 (en) * | 1997-10-01 | 2001-08-09 | Srinivas Nishtala | Dilation systems and related methods |
US6030364A (en) * | 1997-10-03 | 2000-02-29 | Boston Scientific Corporation | Apparatus and method for percutaneous placement of gastro-intestinal tubes |
US6206826B1 (en) * | 1997-12-18 | 2001-03-27 | Sdgi Holdings, Inc. | Devices and methods for percutaneous surgery |
US6428541B1 (en) * | 1998-04-09 | 2002-08-06 | Sdgi Holdings, Inc. | Method and instrumentation for vertebral interbody fusion |
US6447527B1 (en) * | 1998-04-23 | 2002-09-10 | Ronald J. Thompson | Apparatus and methods for the penetration of tissue |
US20020001476A1 (en) * | 1998-06-26 | 2002-01-03 | Tomoyuki Nagamine | Image forming apparatus |
US6293909B1 (en) * | 1998-08-07 | 2001-09-25 | Scimed Life Systems, Inc. | Device and method of using a surgical assembly with mesh sheath |
US6689152B2 (en) * | 1998-09-09 | 2004-02-10 | Edwards Lifesciences Corp. | Introducer/dilator with balloon protection and methods of use |
US6117174A (en) * | 1998-09-16 | 2000-09-12 | Nolan; Wesley A. | Spinal implant device |
US5957902A (en) * | 1998-09-28 | 1999-09-28 | Teves; Leonides Y. | Surgical tool for enlarging puncture opening made by trocar |
US6743166B2 (en) * | 1999-02-12 | 2004-06-01 | Karl Storz Gmbh & Co. Kg | Apparatus for introducing an intubation tube into the trachea |
US6607530B1 (en) * | 1999-05-10 | 2003-08-19 | Highgate Orthopedics, Inc. | Systems and methods for spinal fixation |
US6200322B1 (en) * | 1999-08-13 | 2001-03-13 | Sdgi Holdings, Inc. | Minimal exposure posterior spinal interbody instrumentation and technique |
US6428556B1 (en) * | 1999-08-25 | 2002-08-06 | Origin Medsystems, Inc. | Longitudinal dilator and method |
US6723096B1 (en) * | 1999-08-26 | 2004-04-20 | Sdgi Holdings, Inc. | Devices and methods for implanting fusion cages |
US6582437B2 (en) * | 1999-08-26 | 2003-06-24 | Sdgi Holdings, Inc. | Devices and methods for implanting fusion cages |
US6562046B2 (en) * | 1999-11-23 | 2003-05-13 | Sdgi Holdings, Inc. | Screw delivery system and method |
US6582441B1 (en) * | 2000-02-24 | 2003-06-24 | Advanced Bionics Corporation | Surgical insertion tool |
US6562049B1 (en) * | 2000-03-01 | 2003-05-13 | Cook Vascular Incorporated | Medical introducer apparatus |
US6592553B2 (en) * | 2000-07-05 | 2003-07-15 | Cardiac Pacemakers, Inc. | Introducer assembly and method therefor |
US7172612B2 (en) * | 2000-12-12 | 2007-02-06 | Olympus Corporation | Trocar and trocar system |
US20020087152A1 (en) * | 2001-01-04 | 2002-07-04 | Endocare, Inc. | Systems and methods for delivering a probe into tissue |
US6511481B2 (en) * | 2001-03-30 | 2003-01-28 | Triage Medical, Inc. | Method and apparatus for fixation of proximal femoral fractures |
US6746451B2 (en) * | 2001-06-01 | 2004-06-08 | Lance M. Middleton | Tissue cavitation device and method |
US6589240B2 (en) * | 2001-08-28 | 2003-07-08 | Rex Medical, L.P. | Tissue biopsy apparatus with collapsible cutter |
US20030083688A1 (en) * | 2001-10-30 | 2003-05-01 | Simonson Robert E. | Configured and sized cannula |
US6685706B2 (en) * | 2001-11-19 | 2004-02-03 | Triage Medical, Inc. | Proximal anchors for bone fixation system |
US7025746B2 (en) * | 2001-12-26 | 2006-04-11 | Yale University | Vascular access device |
US20040019359A1 (en) * | 2002-07-24 | 2004-01-29 | Worley Seth J. | Telescopic introducer with a compound curvature for inducing alignment and method of using the same |
US20040059339A1 (en) * | 2002-09-19 | 2004-03-25 | Roehm Thomas E. | Oval dilator and retractor set and method |
US20040147877A1 (en) * | 2003-01-27 | 2004-07-29 | Heuser Richard R | Catheter introducer system |
US20040158258A1 (en) * | 2003-02-12 | 2004-08-12 | Bonati Alfred O. | Method for removing orthopaedic hardware |
Cited By (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11051862B2 (en) | 2001-11-03 | 2021-07-06 | DePuy Synthes Products, Inc. | Device for straightening and stabilizing the vertebral column |
USD666293S1 (en) * | 2002-06-26 | 2012-08-28 | Nuvasive, Inc. | Dilator |
USD666292S1 (en) * | 2002-06-26 | 2012-08-28 | Nuvasive, Inc. | Dilator |
USD666294S1 (en) * | 2002-06-26 | 2012-08-28 | Nuvasive, Inc. | Dilator |
US9993349B2 (en) | 2002-06-27 | 2018-06-12 | DePuy Synthes Products, Inc. | Intervertebral disc |
US8945190B2 (en) | 2002-07-19 | 2015-02-03 | Interventional Spine, Inc. | Method and apparatus for spinal fixation |
US9713486B2 (en) | 2002-07-19 | 2017-07-25 | DePuy Synthes Products, Inc. | Method and apparatus for spinal fixation |
US8109977B2 (en) | 2002-07-19 | 2012-02-07 | Interventional Spine, Inc. | Method and apparatus for spinal fixation |
US20060004398A1 (en) * | 2004-07-02 | 2006-01-05 | Binder Lawrence J Jr | Sequential dilator system |
US8206157B2 (en) * | 2004-09-21 | 2012-06-26 | Keymed (Medical & Industrial Equipment) Limited | Instrument for use in a medical simulator |
US20060069384A1 (en) * | 2004-09-21 | 2006-03-30 | Daniel Wallaker | Instrument for use in a medical simulator |
US8066730B2 (en) * | 2005-11-14 | 2011-11-29 | Scapa Flow, Llc | Medical dilator system or dilator device |
US20070129747A1 (en) * | 2005-11-14 | 2007-06-07 | Scapa Flow, Llc | Medical dilator system or dilator device |
US20110218575A1 (en) * | 2006-04-21 | 2011-09-08 | Interventional Spine, Inc. | Method and apparatus for spinal fixation |
US9101411B2 (en) | 2006-04-21 | 2015-08-11 | Interventional Spine, Inc. | Method and apparatus for spinal fixation |
US7938832B2 (en) | 2006-04-21 | 2011-05-10 | Interventional Spine, Inc. | Method and apparatus for spinal fixation |
US20080097436A1 (en) * | 2006-04-21 | 2008-04-24 | Culbert Brad S | Method and apparatus for spinal fixation |
US8430813B2 (en) | 2006-05-26 | 2013-04-30 | Depuy Spine, Inc. | Illuminated surgical access system including a surgical access device and integrated light emitter |
US11273050B2 (en) | 2006-12-07 | 2022-03-15 | DePuy Synthes Products, Inc. | Intervertebral implant |
US10390963B2 (en) | 2006-12-07 | 2019-08-27 | DePuy Synthes Products, Inc. | Intervertebral implant |
US10398566B2 (en) | 2006-12-07 | 2019-09-03 | DePuy Synthes Products, Inc. | Intervertebral implant |
US10583015B2 (en) | 2006-12-07 | 2020-03-10 | DePuy Synthes Products, Inc. | Intervertebral implant |
US11497618B2 (en) | 2006-12-07 | 2022-11-15 | DePuy Synthes Products, Inc. | Intervertebral implant |
US11712345B2 (en) | 2006-12-07 | 2023-08-01 | DePuy Synthes Products, Inc. | Intervertebral implant |
US11432942B2 (en) | 2006-12-07 | 2022-09-06 | DePuy Synthes Products, Inc. | Intervertebral implant |
US11642229B2 (en) | 2006-12-07 | 2023-05-09 | DePuy Synthes Products, Inc. | Intervertebral implant |
US11660206B2 (en) | 2006-12-07 | 2023-05-30 | DePuy Synthes Products, Inc. | Intervertebral implant |
US11045324B2 (en) | 2006-12-08 | 2021-06-29 | DePuy Synthes Products, Inc. | Method of implanting a curable implant material |
US8425525B2 (en) * | 2007-05-23 | 2013-04-23 | Rainer Baumgart | Instrument set for minimally invasive preparation for bone nailing |
US20080294172A1 (en) * | 2007-05-23 | 2008-11-27 | Rainer Baumgart | Instrument set for minimally invasive preparation for bone nailing |
US9839530B2 (en) | 2007-06-26 | 2017-12-12 | DePuy Synthes Products, Inc. | Highly lordosed fusion cage |
US11622868B2 (en) | 2007-06-26 | 2023-04-11 | DePuy Synthes Products, Inc. | Highly lordosed fusion cage |
US10973652B2 (en) | 2007-06-26 | 2021-04-13 | DePuy Synthes Products, Inc. | Highly lordosed fusion cage |
US8043343B2 (en) | 2007-06-28 | 2011-10-25 | Zimmer Spine, Inc. | Stabilization system and method |
US10925594B2 (en) | 2007-10-05 | 2021-02-23 | DePuy Synthes Products, Inc. | Dilation system and method of using the same |
US9974533B2 (en) | 2007-10-05 | 2018-05-22 | DePuy Synthes Products, Inc. | Dilation system and method of using the same |
US9387009B2 (en) | 2007-10-05 | 2016-07-12 | DePuy Synthes Products, Inc. | Dilation system and method of using the same |
US10194895B2 (en) | 2007-10-05 | 2019-02-05 | DePuy Synhes Products, Inc. | Dilation system and method of using the same |
US9737290B2 (en) | 2007-10-05 | 2017-08-22 | DePuy Synthes Products, Inc. | Dilation system and method of using the same |
US11737743B2 (en) | 2007-10-05 | 2023-08-29 | DePuy Synthes Products, Inc. | Dilation system and method of using the same |
US10449058B2 (en) | 2008-01-17 | 2019-10-22 | DePuy Synthes Products, Inc. | Expandable intervertebral implant and associated method of manufacturing the same |
US10433977B2 (en) | 2008-01-17 | 2019-10-08 | DePuy Synthes Products, Inc. | Expandable intervertebral implant and associated method of manufacturing the same |
US11737881B2 (en) | 2008-01-17 | 2023-08-29 | DePuy Synthes Products, Inc. | Expandable intervertebral implant and associated method of manufacturing the same |
US11712341B2 (en) | 2008-04-05 | 2023-08-01 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
US11707359B2 (en) | 2008-04-05 | 2023-07-25 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
US11602438B2 (en) | 2008-04-05 | 2023-03-14 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
US11712342B2 (en) | 2008-04-05 | 2023-08-01 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
US10449056B2 (en) | 2008-04-05 | 2019-10-22 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
US9993350B2 (en) | 2008-04-05 | 2018-06-12 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
US11701234B2 (en) | 2008-04-05 | 2023-07-18 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
US11617655B2 (en) | 2008-04-05 | 2023-04-04 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
US9931223B2 (en) | 2008-04-05 | 2018-04-03 | DePuy Synthes Products, Inc. | Expandable intervertebral implant |
WO2009147527A2 (en) | 2008-05-26 | 2009-12-10 | Rudolf Morgernstern Lopez | Intervertebral implant and installation tool |
US11612491B2 (en) | 2009-03-30 | 2023-03-28 | DePuy Synthes Products, Inc. | Zero profile spinal fusion cage |
US20110004222A1 (en) * | 2009-04-07 | 2011-01-06 | Lutz Biedermann | Tool for Use with a Bone Anchor, in Particular for Spinal Surgery |
US9149308B2 (en) * | 2009-04-07 | 2015-10-06 | Biedermann Technologies Gmbh & Co. Kg | Tool for use with a bone anchor, in particular for spinal surgery |
US9889284B2 (en) | 2009-08-27 | 2018-02-13 | Silver Bullet Therapeutics, Inc. | Bone implant and systems that controllably releases silver |
US11925723B2 (en) | 2009-08-27 | 2024-03-12 | Silver Bullet Therapeutics, Inc. | Bone implant and systems and coatings for the controllable release of antimicrobial metal ions |
US10368929B2 (en) | 2009-08-27 | 2019-08-06 | Silver Bullet Therapeutics, Inc. | Bone implants for the treatment of infection |
US10265435B2 (en) | 2009-08-27 | 2019-04-23 | Silver Bullet Therapeutics, Inc. | Bone implant and systems and coatings for the controllable release of antimicrobial metal ions |
US8221396B2 (en) | 2009-08-27 | 2012-07-17 | Silver Bullet Therapeutics, Inc. | Bone implants for the treatment of infection |
US10004548B2 (en) | 2009-08-27 | 2018-06-26 | Silver Bullet Therapeutics, Inc. | Bone implants for the treatment of infection |
US11224471B2 (en) | 2009-08-27 | 2022-01-18 | Silver Bullet Therapeutics, Inc. | Bone implants for the treatment of infection |
US9248254B2 (en) | 2009-08-27 | 2016-02-02 | Silver Bullet Therapeutics, Inc. | Bone implants for the treatment of infection |
US11020508B2 (en) | 2009-08-27 | 2021-06-01 | Silver Bullet Therapeutics, Inc. | Bone implant and systems and coatings for the controllable release of antimicrobial metal ions |
US10500062B2 (en) | 2009-12-10 | 2019-12-10 | DePuy Synthes Products, Inc. | Bellows-like expandable interbody fusion cage |
US20110144687A1 (en) * | 2009-12-10 | 2011-06-16 | Kleiner Jeffrey | Lateral Based Retractor System |
US11607321B2 (en) | 2009-12-10 | 2023-03-21 | DePuy Synthes Products, Inc. | Bellows-like expandable interbody fusion cage |
US10966840B2 (en) | 2010-06-24 | 2021-04-06 | DePuy Synthes Products, Inc. | Enhanced cage insertion assembly |
US9895236B2 (en) | 2010-06-24 | 2018-02-20 | DePuy Synthes Products, Inc. | Enhanced cage insertion assembly |
US11872139B2 (en) | 2010-06-24 | 2024-01-16 | DePuy Synthes Products, Inc. | Enhanced cage insertion assembly |
US11911287B2 (en) | 2010-06-24 | 2024-02-27 | DePuy Synthes Products, Inc. | Lateral spondylolisthesis reduction cage |
US11654033B2 (en) | 2010-06-29 | 2023-05-23 | DePuy Synthes Products, Inc. | Distractible intervertebral implant |
US10548741B2 (en) | 2010-06-29 | 2020-02-04 | DePuy Synthes Products, Inc. | Distractible intervertebral implant |
US11452607B2 (en) | 2010-10-11 | 2022-09-27 | DePuy Synthes Products, Inc. | Expandable interspinous process spacer implant |
US9108051B2 (en) | 2010-11-12 | 2015-08-18 | Silver Bullet Therapeutics, Inc. | Bone implant and systems that controllably releases silver |
US9789298B2 (en) | 2010-11-12 | 2017-10-17 | Silver Bullet Therapeutics, Inc. | Bone implant and systems that controllably releases silver |
US8771323B2 (en) | 2010-11-12 | 2014-07-08 | Silver Bullet Therapeutics, Inc. | Bone implant and systems that controllably releases silver |
WO2012102842A1 (en) * | 2011-01-28 | 2012-08-02 | Laser Spine Surgical Center, LLC | Foraminoplasty device |
US9486149B2 (en) * | 2011-03-10 | 2016-11-08 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10736661B2 (en) | 2011-03-10 | 2020-08-11 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US11484418B2 (en) | 2011-03-10 | 2022-11-01 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10182842B2 (en) | 2011-03-10 | 2019-01-22 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10111759B2 (en) | 2011-03-10 | 2018-10-30 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US20150094610A1 (en) * | 2011-03-10 | 2015-04-02 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US20150112398A1 (en) * | 2011-03-10 | 2015-04-23 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US9492194B2 (en) * | 2011-03-10 | 2016-11-15 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10729462B2 (en) | 2011-03-10 | 2020-08-04 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US11484419B2 (en) | 2011-03-10 | 2022-11-01 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10743915B2 (en) | 2011-03-10 | 2020-08-18 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10743913B2 (en) | 2011-03-10 | 2020-08-18 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10743914B2 (en) | 2011-03-10 | 2020-08-18 | DePuy Snythes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10744004B2 (en) | 2011-03-10 | 2020-08-18 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
AU2012225473B2 (en) * | 2011-03-10 | 2016-07-21 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US11547443B2 (en) | 2011-03-10 | 2023-01-10 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US11547442B2 (en) * | 2011-03-10 | 2023-01-10 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
AU2016247198B2 (en) * | 2011-03-10 | 2019-04-04 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US11484420B2 (en) | 2011-03-10 | 2022-11-01 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US11234736B2 (en) | 2011-10-27 | 2022-02-01 | DePuy Synthes Products, Inc. | Method and devices for a sub-splenius/supra-levator scapulae surgical access technique |
US11911017B2 (en) | 2011-10-27 | 2024-02-27 | DePuy Synthes Products, Inc. | Method and devices for a sub-splenius/supra-levator scapulae surgical access technique |
US11134987B2 (en) | 2011-10-27 | 2021-10-05 | DePuy Synthes Products, Inc. | Method and devices for a sub-splenius/supra-levator scapulae surgical access technique |
US11937797B2 (en) | 2011-10-27 | 2024-03-26 | DePuy Synthes Products, Inc. | Method and devices for a sub-splenius/supra-levator scapulae surgical access technique |
US11241255B2 (en) | 2011-10-27 | 2022-02-08 | DePuy Synthes Products, Inc. | Method and devices for a sub-splenius/supra-levator scapulae surgical access technique |
US11278323B2 (en) | 2011-10-27 | 2022-03-22 | DePuy Synthes Products, Inc. | Method and devices for a sub-splenius/supra-levator scapulae surgical access technique |
US11660082B2 (en) | 2011-11-01 | 2023-05-30 | DePuy Synthes Products, Inc. | Dilation system |
USRE48534E1 (en) | 2012-04-16 | 2021-04-27 | DePuy Synthes Products, Inc. | Detachable dilator blade |
US10058433B2 (en) | 2012-07-26 | 2018-08-28 | DePuy Synthes Products, Inc. | Expandable implant |
US9883951B2 (en) | 2012-08-30 | 2018-02-06 | Interventional Spine, Inc. | Artificial disc |
US11559295B2 (en) | 2012-09-26 | 2023-01-24 | DePuy Synthes Products, Inc. | NIR/red light for lateral neuroprotection |
US11219439B2 (en) | 2012-09-26 | 2022-01-11 | DePuy Synthes Products, Inc. | NIR/RED light for lateral neuroprotection |
US9198674B2 (en) * | 2012-12-14 | 2015-12-01 | Warsaw Orthopedic, Inc. | Surgical instrument and method |
US20140171946A1 (en) * | 2012-12-14 | 2014-06-19 | Warsaw Orthopedic, Inc. | Surgical instrument and method |
US11850164B2 (en) | 2013-03-07 | 2023-12-26 | DePuy Synthes Products, Inc. | Intervertebral implant |
US9522070B2 (en) | 2013-03-07 | 2016-12-20 | Interventional Spine, Inc. | Intervertebral implant |
US11497619B2 (en) | 2013-03-07 | 2022-11-15 | DePuy Synthes Products, Inc. | Intervertebral implant |
US10413422B2 (en) | 2013-03-07 | 2019-09-17 | DePuy Synthes Products, Inc. | Intervertebral implant |
US9855058B2 (en) | 2013-03-11 | 2018-01-02 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10898341B2 (en) | 2013-03-11 | 2021-01-26 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US11759329B2 (en) | 2013-03-11 | 2023-09-19 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10813772B2 (en) | 2013-03-11 | 2020-10-27 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US9277928B2 (en) | 2013-03-11 | 2016-03-08 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10918495B2 (en) | 2013-03-11 | 2021-02-16 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10898342B2 (en) | 2013-03-11 | 2021-01-26 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US11590002B2 (en) | 2013-03-14 | 2023-02-28 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US10537443B2 (en) | 2013-03-14 | 2020-01-21 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US9993353B2 (en) | 2013-03-14 | 2018-06-12 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US11006991B2 (en) | 2013-07-03 | 2021-05-18 | DePuy Synthes Products, Inc. | Method and apparatus for sacroiliac joint fixation |
US9522028B2 (en) | 2013-07-03 | 2016-12-20 | Interventional Spine, Inc. | Method and apparatus for sacroiliac joint fixation |
US10166056B2 (en) | 2013-07-03 | 2019-01-01 | DePuy Synthes Products, Inc. | Method and apparatus for sacroiliac joint fixation |
US9821094B2 (en) | 2014-06-11 | 2017-11-21 | Silver Bullet Therapeutics, Inc. | Coatings for the controllable release of antimicrobial metal ions |
US8927004B1 (en) | 2014-06-11 | 2015-01-06 | Silver Bullet Therapeutics, Inc. | Bioabsorbable substrates and systems that controllably release antimicrobial metal ions |
US9114197B1 (en) | 2014-06-11 | 2015-08-25 | Silver Bullett Therapeutics, Inc. | Coatings for the controllable release of antimicrobial metal ions |
US8999367B1 (en) | 2014-06-11 | 2015-04-07 | Silver Bullet Therapeutics, Inc. | Bioabsorbable substrates and systems that controllably release antimicrobial metal ions |
US9452242B2 (en) | 2014-06-11 | 2016-09-27 | Silver Bullet Therapeutics, Inc. | Enhancement of antimicrobial silver, silver coatings, or silver platings |
US11224453B2 (en) | 2014-07-08 | 2022-01-18 | Spinal Elements, Inc. | Apparatus and methods for disrupting intervertebral disc tissue |
US10863994B2 (en) | 2014-08-04 | 2020-12-15 | Medos International Sàrl | Flexible transport auger |
US11712252B2 (en) | 2014-08-04 | 2023-08-01 | Medos International Sarl | Flexible transport auger |
US9980737B2 (en) | 2014-08-04 | 2018-05-29 | Medos International Sarl | Flexible transport auger |
US9924979B2 (en) | 2014-09-09 | 2018-03-27 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US10786330B2 (en) | 2014-09-09 | 2020-09-29 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US10264959B2 (en) | 2014-09-09 | 2019-04-23 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US10111712B2 (en) | 2014-09-09 | 2018-10-30 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US11213196B2 (en) | 2014-09-09 | 2022-01-04 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US11564811B2 (en) | 2015-02-06 | 2023-01-31 | Spinal Elements, Inc. | Graft material injector system and method |
US11426290B2 (en) | 2015-03-06 | 2022-08-30 | DePuy Synthes Products, Inc. | Expandable intervertebral implant, system, kit and method |
US11464523B2 (en) | 2015-03-31 | 2022-10-11 | Medos International Sarl | Percutaneous disc clearing device |
US10786264B2 (en) | 2015-03-31 | 2020-09-29 | Medos International Sarl | Percutaneous disc clearing device |
US20170000627A1 (en) * | 2015-06-30 | 2017-01-05 | Mark M Levy | Tool for intervertebral cage |
US9833338B2 (en) * | 2015-06-30 | 2017-12-05 | Expanding Orthopedics Inc. | Tool for intervertebral cage |
US9913727B2 (en) | 2015-07-02 | 2018-03-13 | Medos International Sarl | Expandable implant |
US11331090B2 (en) | 2015-09-04 | 2022-05-17 | Medos International Sarl | Surgical visualization systems and related methods |
US11672562B2 (en) | 2015-09-04 | 2023-06-13 | Medos International Sarl | Multi-shield spinal access system |
US10758220B2 (en) | 2015-09-04 | 2020-09-01 | Medos International Sarl | Devices and methods for providing surgical access |
US11744447B2 (en) | 2015-09-04 | 2023-09-05 | Medos International | Surgical visualization systems and related methods |
US10779810B2 (en) | 2015-09-04 | 2020-09-22 | Medos International Sarl | Devices and methods for surgical retraction |
US11950766B2 (en) | 2015-09-04 | 2024-04-09 | Medos International Sàrl | Surgical visualization systems and related methods |
US11793546B2 (en) | 2015-09-04 | 2023-10-24 | Medos International Sarl | Surgical visualization systems and related methods |
US10682130B2 (en) | 2015-09-04 | 2020-06-16 | Medos International Sarl | Surgical access port stabilization |
US10869659B2 (en) | 2015-09-04 | 2020-12-22 | Medos International Sarl | Surgical instrument connectors and related methods |
US11801070B2 (en) | 2015-09-04 | 2023-10-31 | Medos International Sarl | Surgical access port stabilization |
US10874425B2 (en) | 2015-09-04 | 2020-12-29 | Medos International Sarl | Multi-shield spinal access system |
US11000312B2 (en) | 2015-09-04 | 2021-05-11 | Medos International Sarl | Multi-shield spinal access system |
US11806043B2 (en) | 2015-09-04 | 2023-11-07 | Medos International Sarl | Devices and methods for providing surgical access |
US11439380B2 (en) | 2015-09-04 | 2022-09-13 | Medos International Sarl | Surgical instrument connectors and related methods |
US11883064B2 (en) | 2015-09-04 | 2024-01-30 | Medos International Sarl | Multi-shield spinal access system |
US11712264B2 (en) | 2015-09-04 | 2023-08-01 | Medos International Sarl | Multi-shield spinal access system |
US11559328B2 (en) | 2015-09-04 | 2023-01-24 | Medos International Sarl | Multi-shield spinal access system |
US11344190B2 (en) | 2015-09-04 | 2022-05-31 | Medos International Sarl | Surgical visualization systems and related methods |
US10987129B2 (en) | 2015-09-04 | 2021-04-27 | Medos International Sarl | Multi-shield spinal access system |
US10299838B2 (en) | 2016-02-05 | 2019-05-28 | Medos International Sarl | Method and instruments for interbody fusion and posterior fixation through a single incision |
US11020153B2 (en) | 2016-02-05 | 2021-06-01 | Medos International Sarl | Method and instruments for interbody fusion and posterior fixation through a single incision |
US11596522B2 (en) | 2016-06-28 | 2023-03-07 | Eit Emerging Implant Technologies Gmbh | Expandable and angularly adjustable intervertebral cages with articulating joint |
US11596523B2 (en) | 2016-06-28 | 2023-03-07 | Eit Emerging Implant Technologies Gmbh | Expandable and angularly adjustable articulating intervertebral cages |
US11510788B2 (en) | 2016-06-28 | 2022-11-29 | Eit Emerging Implant Technologies Gmbh | Expandable, angularly adjustable intervertebral cages |
US10537436B2 (en) | 2016-11-01 | 2020-01-21 | DePuy Synthes Products, Inc. | Curved expandable cage |
US10888433B2 (en) | 2016-12-14 | 2021-01-12 | DePuy Synthes Products, Inc. | Intervertebral implant inserter and related methods |
US20180271574A1 (en) * | 2017-03-22 | 2018-09-27 | Benvenue Medical, Inc. | Minimal Impact Access System To Disc Space |
US10758286B2 (en) * | 2017-03-22 | 2020-09-01 | Benvenue Medical, Inc. | Minimal impact access system to disc space |
US11771483B2 (en) | 2017-03-22 | 2023-10-03 | Spinal Elements, Inc. | Minimal impact access system to disc space |
US10398563B2 (en) | 2017-05-08 | 2019-09-03 | Medos International Sarl | Expandable cage |
US11446155B2 (en) | 2017-05-08 | 2022-09-20 | Medos International Sarl | Expandable cage |
US11344424B2 (en) | 2017-06-14 | 2022-05-31 | Medos International Sarl | Expandable intervertebral implant and related methods |
US10940016B2 (en) | 2017-07-05 | 2021-03-09 | Medos International Sarl | Expandable intervertebral fusion cage |
US11583327B2 (en) | 2018-01-29 | 2023-02-21 | Spinal Elements, Inc. | Minimally invasive interbody fusion |
US11471145B2 (en) | 2018-03-16 | 2022-10-18 | Spinal Elements, Inc. | Articulated instrumentation and methods of using the same |
US11446156B2 (en) | 2018-10-25 | 2022-09-20 | Medos International Sarl | Expandable intervertebral implant, inserter instrument, and related methods |
US11013530B2 (en) | 2019-03-08 | 2021-05-25 | Medos International Sarl | Surface features for device retention |
US11241252B2 (en) | 2019-03-22 | 2022-02-08 | Medos International Sarl | Skin foundation access portal |
US11129727B2 (en) | 2019-03-29 | 2021-09-28 | Medos International Sari | Inflatable non-distracting intervertebral implants and related methods |
US11813026B2 (en) | 2019-04-05 | 2023-11-14 | Medos International Sarl | Systems, devices, and methods for providing surgical trajectory guidance |
US11806245B2 (en) | 2020-03-06 | 2023-11-07 | Eit Emerging Implant Technologies Gmbh | Expandable intervertebral implant |
US11426286B2 (en) | 2020-03-06 | 2022-08-30 | Eit Emerging Implant Technologies Gmbh | Expandable intervertebral implant |
US11771517B2 (en) | 2021-03-12 | 2023-10-03 | Medos International Sarl | Camera position indication systems and methods |
US11850160B2 (en) | 2021-03-26 | 2023-12-26 | Medos International Sarl | Expandable lordotic intervertebral fusion cage |
US11752009B2 (en) | 2021-04-06 | 2023-09-12 | Medos International Sarl | Expandable intervertebral fusion cage |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050256525A1 (en) | Dilation introducer for orthopedic surgery | |
US10293147B2 (en) | Telescopic percutaneous tissue dilation systems and related methods | |
EP3205371B1 (en) | Telescopic percutaneous tissue dilation systems and related methods of producing | |
US20080287981A1 (en) | Dilation introducer and methods for orthopedic surgery | |
US7087058B2 (en) | Method and apparatus for providing posterior or anterior trans-sacral access to spinal vertebrae | |
US9168033B2 (en) | Interspinous implants and methods for implanting same | |
US8075593B2 (en) | Interspinous implants and methods for implanting same | |
US7641657B2 (en) | Method and apparatus for providing posterior or anterior trans-sacral access to spinal vertebrae | |
US8870760B2 (en) | Surgical dilator, retractor and mounting pad | |
JP3573461B2 (en) | Modular intramedullary nail inserted into cannula | |
CN101128158B (en) | Less invasive surgical system and methods | |
US20040133201A1 (en) | Methods and apparatuses for treating the spine through an access device | |
US20230000529A1 (en) | Stabilization System, Implant, And Methods For Preventing Relative Motion Between Sections Of Tissue | |
KR101469567B1 (en) | Interspinous implants and methods for implanting same | |
US20130012955A1 (en) | System and Method for Pedicle Screw Placement in Vertebral Alignment | |
US11191575B2 (en) | Systems and methods for off-axis augmentation of a vertebral body | |
JP6983204B2 (en) | Systems and methods for intramedullary nail implantation | |
WO2024081209A1 (en) | Lateral mass drill guide system | |
JP2021000440A (en) | Systems and methods for intramedullary nail implantation | |
WO2024081280A2 (en) | Spinal decortication and grafting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TRIAGE MEDICAL INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CULBERT, BRAD;OLMOS, FAUSTO;WARREN, CHRISTOPHER;REEL/FRAME:015719/0982 Effective date: 20050210 |
|
AS | Assignment |
Owner name: INTERVENTIONAL SPINE, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:TRIAGE MEDICAL, INC.;REEL/FRAME:020236/0722 Effective date: 20061128 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |